OA17933A - Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application - Google Patents
Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application Download PDFInfo
- Publication number
- OA17933A OA17933A OA1201200507 OA17933A OA 17933 A OA17933 A OA 17933A OA 1201200507 OA1201200507 OA 1201200507 OA 17933 A OA17933 A OA 17933A
- Authority
- OA
- OAPI
- Prior art keywords
- group
- ethyl
- trifluoromethyl
- trifluoro
- piperidine
- Prior art date
Links
- WFTDBNIIESVDAI-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl carbamate Chemical class NC(=O)OC(C(F)(F)F)C(F)(F)F WFTDBNIIESVDAI-UHFFFAOYSA-N 0.000 title abstract description 4
- 230000001225 therapeutic Effects 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 106
- 239000002253 acid Substances 0.000 claims abstract description 16
- 238000007792 addition Methods 0.000 claims abstract description 16
- -1 phenyloxy Chemical group 0.000 claims description 100
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 46
- 125000002947 alkylene group Chemical group 0.000 claims description 45
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 34
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 20
- 201000002674 obstructive nephropathy Diseases 0.000 claims description 20
- 125000000217 alkyl group Chemical group 0.000 claims description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
- 208000002193 Pain Diseases 0.000 claims description 11
- SIKJAQJRHWYJAI-UHFFFAOYSA-N indole Chemical group C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 11
- RCRCTBLIHCHWDZ-UHFFFAOYSA-N 5Z,8Z,11Z,14Z-eicosatetraenoic acid, 2-glyceryl ester Chemical compound CCCCCC=CCC=CCC=CCC=CCCCC(=O)OC(CO)CO RCRCTBLIHCHWDZ-UHFFFAOYSA-N 0.000 claims description 9
- 125000006360 carbonyl amino methylene group Chemical group [H]N(C([*:1])=O)C([H])([H])[*:2] 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 9
- 125000005843 halogen group Chemical group 0.000 claims description 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 7
- 125000000524 functional group Chemical group 0.000 claims description 7
- 125000001072 heteroaryl group Chemical group 0.000 claims description 7
- 125000004043 oxo group Chemical group O=* 0.000 claims description 6
- 125000004430 oxygen atoms Chemical group O* 0.000 claims description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 6
- FNQJDLTXOVEEFB-UHFFFAOYSA-N 1,2,3-benzothiadiazole Chemical compound C1=CC=C2SN=NC2=C1 FNQJDLTXOVEEFB-UHFFFAOYSA-N 0.000 claims description 5
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical group C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 claims description 5
- CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 5
- BGDOLELXXPTPFX-UHFFFAOYSA-N 3,4-dihydro-2H-1,2-benzoxazine Chemical compound C1=CC=C2ONCCC2=C1 BGDOLELXXPTPFX-UHFFFAOYSA-N 0.000 claims description 5
- 239000005964 Acibenzolar-S-methyl Substances 0.000 claims description 5
- JYZIHLWOWKMNNX-UHFFFAOYSA-N Benzimidazole Chemical group C1=C[CH]C2=NC=NC2=C1 JYZIHLWOWKMNNX-UHFFFAOYSA-N 0.000 claims description 5
- KTZQTRPPVKQPFO-UHFFFAOYSA-N Benzisoxazole Chemical group C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 claims description 5
- FCEHBMOGCRZNNI-UHFFFAOYSA-N Benzothiophene Chemical group C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims description 5
- BCMCBBGGLRIHSE-UHFFFAOYSA-N Benzoxazole Chemical group C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 claims description 5
- CTAPFRYPJLPFDF-UHFFFAOYSA-N Isoxazole Chemical group C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims description 5
- 150000001412 amines Chemical class 0.000 claims description 5
- 230000001684 chronic Effects 0.000 claims description 5
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims description 5
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 125000001624 naphthyl group Chemical group 0.000 claims description 5
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical group C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims description 5
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 5
- KYQCOXFCLRTKLS-UHFFFAOYSA-N pyrazine Chemical group C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 5
- WTKZEGDFNFYCGP-UHFFFAOYSA-N pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 5
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- 208000005298 Acute Pain Diseases 0.000 claims description 4
- 208000000094 Chronic Pain Diseases 0.000 claims description 4
- 206010020751 Hypersensitivity Diseases 0.000 claims description 4
- 206010061255 Ischaemia Diseases 0.000 claims description 4
- 230000001154 acute Effects 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical group C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 4
- 200000000018 inflammatory disease Diseases 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- FZWLAAWBMGSTSO-UHFFFAOYSA-N thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 claims description 3
- 206010004018 Bacterial infectious disease Diseases 0.000 claims description 3
- 208000008787 Cardiovascular Disease Diseases 0.000 claims description 3
- 206010063057 Cystitis noninfective Diseases 0.000 claims description 3
- 208000002173 Dizziness Diseases 0.000 claims description 3
- 206010058108 Dyslipidaemia Diseases 0.000 claims description 3
- 206010015037 Epilepsy Diseases 0.000 claims description 3
- 208000008665 Gastrointestinal Disease Diseases 0.000 claims description 3
- 210000000987 Immune System Anatomy 0.000 claims description 3
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 3
- 230000035633 Metabolized Effects 0.000 claims description 3
- 206010028813 Nausea Diseases 0.000 claims description 3
- 206010053643 Neurodegenerative disease Diseases 0.000 claims description 3
- 208000001132 Osteoporosis Diseases 0.000 claims description 3
- 208000006551 Parasitic Disease Diseases 0.000 claims description 3
- 206010040984 Sleep disease Diseases 0.000 claims description 3
- 206010046543 Urinary incontinence Diseases 0.000 claims description 3
- 208000001756 Virus Disease Diseases 0.000 claims description 3
- 206010047700 Vomiting Diseases 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 3
- 235000014632 disordered eating Nutrition 0.000 claims description 3
- 201000006180 eating disease Diseases 0.000 claims description 3
- 125000001188 haloalkyl group Chemical group 0.000 claims description 3
- 125000000623 heterocyclic group Chemical group 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 125000002883 imidazolyl group Chemical group 0.000 claims description 3
- 230000000926 neurological Effects 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 239000000546 pharmaceutic aid Substances 0.000 claims description 3
- 230000002685 pulmonary Effects 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims description 3
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 claims description 2
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 claims description 2
- 125000004414 alkyl thio group Chemical group 0.000 claims description 2
- 125000005418 aryl aryl group Chemical group 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 230000000875 corresponding Effects 0.000 claims 1
- 125000004995 haloalkylthio group Chemical group 0.000 claims 1
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 abstract description 22
- 102100007223 MGLL Human genes 0.000 abstract description 20
- 101700027140 MGLL Proteins 0.000 abstract description 20
- 230000002401 inhibitory effect Effects 0.000 abstract description 11
- 150000003839 salts Chemical class 0.000 abstract description 6
- 239000003112 inhibitor Substances 0.000 abstract description 5
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 120
- 239000000203 mixture Substances 0.000 description 90
- 239000000243 solution Substances 0.000 description 87
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 84
- 239000000047 product Substances 0.000 description 62
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 40
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 40
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 38
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 34
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 32
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 28
- 239000003921 oil Substances 0.000 description 28
- 235000019198 oils Nutrition 0.000 description 28
- 238000005160 1H NMR spectroscopy Methods 0.000 description 27
- 239000012074 organic phase Substances 0.000 description 27
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 26
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 24
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 24
- 238000002844 melting Methods 0.000 description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 22
- CRCTZWNJRMZUIO-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropane Chemical group FC(F)(F)[CH]C(F)(F)F CRCTZWNJRMZUIO-UHFFFAOYSA-N 0.000 description 21
- 238000004587 chromatography analysis Methods 0.000 description 20
- 239000000741 silica gel Substances 0.000 description 20
- 229910002027 silica gel Inorganic materials 0.000 description 20
- 238000010828 elution Methods 0.000 description 19
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 19
- 229910052938 sodium sulfate Inorganic materials 0.000 description 19
- 235000011152 sodium sulphate Nutrition 0.000 description 19
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Inorganic materials [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 18
- 239000007787 solid Substances 0.000 description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 16
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 15
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 14
- 239000000843 powder Substances 0.000 description 14
- 229910052786 argon Inorganic materials 0.000 description 12
- 238000003756 stirring Methods 0.000 description 11
- GXYPITRJSPDNLU-UHFFFAOYSA-M (4-nitrophenyl)chloranuidylformate Chemical compound [O-]C(=O)[Cl-]C1=CC=C([N+]([O-])=O)C=C1 GXYPITRJSPDNLU-UHFFFAOYSA-M 0.000 description 10
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 239000002585 base Substances 0.000 description 8
- KONIYTHNVWYBMP-UHFFFAOYSA-N ethylcyclohexane Chemical compound [CH2-]C[C+]1CCCCC1 KONIYTHNVWYBMP-UHFFFAOYSA-N 0.000 description 8
- 150000001793 charged compounds Chemical class 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Substances ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 7
- 239000001184 potassium carbonate Substances 0.000 description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 description 7
- CPBZARXQRZTYGI-UHFFFAOYSA-N 3-cyclopentylpropylcyclohexane Chemical compound C1CCCCC1CCCC1CCCC1 CPBZARXQRZTYGI-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 5
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 5
- UPWGQKDVAURUGE-KTKRTIGZSA-N 2-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC(CO)CO UPWGQKDVAURUGE-KTKRTIGZSA-N 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N 2-propanol Substances CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 125000004432 carbon atoms Chemical group C* 0.000 description 5
- OKKJLVBELUTLKV-MZCSYVLQSA-N cd3od Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 239000005695 Ammonium acetate Substances 0.000 description 4
- 206010053317 Hydrophobia Diseases 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 4
- USFZMSVCRYTOJT-UHFFFAOYSA-N ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 4
- 229940043376 ammonium acetate Drugs 0.000 description 4
- 235000019257 ammonium acetate Nutrition 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000002194 synthesizing Effects 0.000 description 4
- CNDZPLQYMSBISO-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 3-[(naphthalen-1-ylsulfonylamino)methyl]pyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1CNS(=O)(=O)C1=CC=CC2=CC=CC=C12 CNDZPLQYMSBISO-UHFFFAOYSA-N 0.000 description 3
- WIPYXQJZFCYVPR-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 3-[1-[(4-chlorophenyl)sulfonylamino]cyclopropyl]azetidine-1-carboxylate Chemical compound C1N(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1C1(NS(=O)(=O)C=2C=CC(Cl)=CC=2)CC1 WIPYXQJZFCYVPR-UHFFFAOYSA-N 0.000 description 3
- AQUGSNRKINOPNA-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 3-[2-[[methyl(phenyl)carbamoyl]amino]ethyl]azetidine-1-carboxylate Chemical compound C=1C=CC=CC=1N(C)C(=O)NCCC1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)C1 AQUGSNRKINOPNA-UHFFFAOYSA-N 0.000 description 3
- XMLHGCRTMCWWQR-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[(3-chlorophenyl)carbamoylamino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1NC(=O)NC1=CC=CC(Cl)=C1 XMLHGCRTMCWWQR-UHFFFAOYSA-N 0.000 description 3
- UBPAIBLGWMAHSZ-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[2-[(5-carbamoylpyrazin-2-yl)amino]ethyl]piperidine-1-carboxylate Chemical compound C1=NC(C(=O)N)=CN=C1NCCC1CCN(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1 UBPAIBLGWMAHSZ-UHFFFAOYSA-N 0.000 description 3
- KOVYCBLAOUWEPO-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[3-(3-cyanophenyl)phenoxy]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1OC1=CC=CC(C=2C=C(C=CC=2)C#N)=C1 KOVYCBLAOUWEPO-UHFFFAOYSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- 210000004556 Brain Anatomy 0.000 description 3
- 208000002551 Irritable Bowel Syndrome Diseases 0.000 description 3
- VXUYXOFXAQZZMF-UHFFFAOYSA-N Titanium isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 3
- UCPYLLCMEDAXFR-UHFFFAOYSA-N Triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 3
- RQBBFKINEJYDOB-UHFFFAOYSA-N acetic acid;acetonitrile Chemical compound CC#N.CC(O)=O RQBBFKINEJYDOB-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- KVVMXWRFYAGASO-UHFFFAOYSA-M azetidine-1-carboxylate Chemical compound [O-]C(=O)N1CCC1 KVVMXWRFYAGASO-UHFFFAOYSA-M 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000005712 crystallization Effects 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- KZMGYPLQYOPHEL-UHFFFAOYSA-N ethoxyethane;trifluoroborane Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 3
- 125000000593 indol-1-yl group Chemical group [H]C1=C([H])C([H])=C2N([*])C([H])=C([H])C2=C1[H] 0.000 description 3
- SECXISVLQFMRJM-UHFFFAOYSA-N n-methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 3
- YGYAWVDWMABLBF-UHFFFAOYSA-N phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 3
- 230000001681 protective Effects 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000001187 sodium carbonate Substances 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 201000002661 spondylitis Diseases 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000000699 topical Effects 0.000 description 3
- XKPUTYHULLBTHW-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 3-(aminomethyl)pyrrolidine-1-carboxylate;hydrochloride Chemical compound Cl.NCC1CCN(C(=O)OC(C(F)(F)F)C(F)(F)F)C1 XKPUTYHULLBTHW-UHFFFAOYSA-N 0.000 description 2
- VIJLMXNKSQKUKW-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(4-cyanophenyl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1C1=CC=C(C#N)C=C1 VIJLMXNKSQKUKW-UHFFFAOYSA-N 0.000 description 2
- KOFCIPQNSITVLN-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(aminomethyl)piperidine-1-carboxylate;hydrochloride Chemical compound Cl.NCC1CCN(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1 KOFCIPQNSITVLN-UHFFFAOYSA-N 0.000 description 2
- GEAGXPNIYFXHAF-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[(2-methylpropan-2-yl)oxycarbonylamino]piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)NC1CCN(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1 GEAGXPNIYFXHAF-UHFFFAOYSA-N 0.000 description 2
- XCXXUHUSUQLLHJ-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[(4-carbamoylpyrazol-1-yl)methyl]piperidine-1-carboxylate Chemical compound C1=C(C(=O)N)C=NN1CC1CCN(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1 XCXXUHUSUQLLHJ-UHFFFAOYSA-N 0.000 description 2
- QXXZLQIZSKWGLT-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[[2-(4-chlorophenoxy)-2-methylpropanoyl]amino]methyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1CNC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 QXXZLQIZSKWGLT-UHFFFAOYSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- CVDYQGBBBOOKLY-UHFFFAOYSA-N 1-(piperidin-4-ylmethyl)pyrazole-4-carboxamide;hydrochloride Chemical compound Cl.C1=C(C(=O)N)C=NN1CC1CCNCC1 CVDYQGBBBOOKLY-UHFFFAOYSA-N 0.000 description 2
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-Aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- FIYJTMMWNLHSCS-UHFFFAOYSA-N 3-(3-piperidin-4-yloxyphenyl)benzonitrile Chemical compound N#CC1=CC=CC(C=2C=C(OC3CCNCC3)C=CC=2)=C1 FIYJTMMWNLHSCS-UHFFFAOYSA-N 0.000 description 2
- ZLYBFBAHAQEEQQ-UHFFFAOYSA-N 4-chlorobenzenesulfonyl chloride Chemical compound ClC1=CC=C(S(Cl)(=O)=O)C=C1 ZLYBFBAHAQEEQQ-UHFFFAOYSA-N 0.000 description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 2
- CMFSSNCSYNOWKR-UHFFFAOYSA-N 5-(2-piperidin-4-ylethylamino)pyrazine-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1=NC(C(=O)N)=CN=C1NCCC1CCNCC1 CMFSSNCSYNOWKR-UHFFFAOYSA-N 0.000 description 2
- 125000004539 5-benzimidazolyl group Chemical group N1=CNC2=C1C=CC(=C2)* 0.000 description 2
- 206010001897 Alzheimer's disease Diseases 0.000 description 2
- 206010002027 Amyotrophy Diseases 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 206010003246 Arthritis Diseases 0.000 description 2
- 206010011401 Crohn's disease Diseases 0.000 description 2
- IMORNICQZVCHOP-UHFFFAOYSA-N N-[1-(azetidin-3-yl)cyclopropyl]-4-chlorobenzenesulfonamide;hydrochloride Chemical compound Cl.C1=CC(Cl)=CC=C1S(=O)(=O)NC1(C2CNC2)CC1 IMORNICQZVCHOP-UHFFFAOYSA-N 0.000 description 2
- SOMYHXRJSAEQBL-UHFFFAOYSA-N N-piperidin-4-yl-5-(trifluoromethyl)pyridin-2-amine Chemical compound N1=CC(C(F)(F)F)=CC=C1NC1CCNCC1 SOMYHXRJSAEQBL-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N Oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 235000019502 Orange oil Nutrition 0.000 description 2
- DLYUQMMRRRQYAE-UHFFFAOYSA-N Phosphorus pentoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N Trimethylsilyl chloride Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N Triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- TWQALNIUGRUFEQ-UHFFFAOYSA-N [1,2]oxazolo[3,4-d]oxadiazole Chemical compound N1=NOC2=CON=C21 TWQALNIUGRUFEQ-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- KHBQMWCZKVMBLN-UHFFFAOYSA-N benzenesulfonimidic acid Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- VRAVWQUXPCWGSU-UHFFFAOYSA-N bis(1H-1,2,4-triazol-5-yl)methanone Chemical compound N1=CNN=C1C(=O)C=1N=CNN=1 VRAVWQUXPCWGSU-UHFFFAOYSA-N 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- WDCDAAMJNUHOIY-UHFFFAOYSA-N ethyl acetate;2-propan-2-yloxypropane Chemical compound CCOC(C)=O.CC(C)OC(C)C WDCDAAMJNUHOIY-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 125000005842 heteroatoms Chemical group 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 230000002633 protecting Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- LZUYKOBTHSPKED-UHFFFAOYSA-N (4-chlorophenyl)-piperidin-4-ylmethanone;hydrochloride Chemical compound Cl.C1=CC(Cl)=CC=C1C(=O)C1CCNCC1 LZUYKOBTHSPKED-UHFFFAOYSA-N 0.000 description 1
- QBUPMCKEDKOMMV-UHFFFAOYSA-N (4-nitrophenyl) 4-[(4-carbamoylpyrazol-1-yl)methyl]piperidine-1-carboxylate Chemical compound C1=C(C(=O)N)C=NN1CC1CCN(C(=O)OC=2C=CC(=CC=2)[N+]([O-])=O)CC1 QBUPMCKEDKOMMV-UHFFFAOYSA-N 0.000 description 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 1
- IJBHSMUIIXTWHN-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 3-(1-benzothiophene-2-carbonylamino)azetidine-1-carboxylate Chemical compound C1N(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1NC(=O)C1=CC2=CC=CC=C2S1 IJBHSMUIIXTWHN-UHFFFAOYSA-N 0.000 description 1
- JBIAFVHUHZDWRN-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 3-(2,3-dihydro-1H-inden-5-ylsulfonylamino)azetidine-1-carboxylate Chemical compound C1N(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1NS(=O)(=O)C1=CC=C(CCC2)C2=C1 JBIAFVHUHZDWRN-UHFFFAOYSA-N 0.000 description 1
- YYLVPLMFZCDZHS-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 3-(2-aminoethyl)azetidine-1-carboxylate;hydrochloride Chemical compound Cl.NCCC1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)C1 YYLVPLMFZCDZHS-UHFFFAOYSA-N 0.000 description 1
- XFSZHJIQKKVCOZ-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 3-(benzylsulfonylamino)azetidine-1-carboxylate Chemical compound C1N(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1NS(=O)(=O)CC1=CC=CC=C1 XFSZHJIQKKVCOZ-UHFFFAOYSA-N 0.000 description 1
- OZZLAVWNFHQBGY-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 3-[(4-bromo-2-fluorophenyl)sulfonylamino]azetidine-1-carboxylate Chemical compound FC1=CC(Br)=CC=C1S(=O)(=O)NC1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)C1 OZZLAVWNFHQBGY-UHFFFAOYSA-N 0.000 description 1
- HURISUCJBXJSSR-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 3-[(4-methylnaphthalen-1-yl)sulfonylamino]azetidine-1-carboxylate Chemical compound C12=CC=CC=C2C(C)=CC=C1S(=O)(=O)NC1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)C1 HURISUCJBXJSSR-UHFFFAOYSA-N 0.000 description 1
- LIEORFSYDBRBAT-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 3-[(4-phenylphenyl)sulfonylamino]azetidine-1-carboxylate Chemical compound C1N(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1NS(=O)(=O)C1=CC=C(C=2C=CC=CC=2)C=C1 LIEORFSYDBRBAT-UHFFFAOYSA-N 0.000 description 1
- OGXIIVRZDOLPRB-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 3-[(5-bromo-2-methoxyphenyl)sulfonylamino]azetidine-1-carboxylate Chemical compound COC1=CC=C(Br)C=C1S(=O)(=O)NC1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)C1 OGXIIVRZDOLPRB-UHFFFAOYSA-N 0.000 description 1
- BGKDIESFZVCVMP-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 3-[(benzylcarbamoylamino)methyl]pyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1CNC(=O)NCC1=CC=CC=C1 BGKDIESFZVCVMP-UHFFFAOYSA-N 0.000 description 1
- XGSIPLFTQZHFCI-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 3-[(naphthalen-2-ylsulfonylamino)methyl]pyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1CNS(=O)(=O)C1=CC=C(C=CC=C2)C2=C1 XGSIPLFTQZHFCI-UHFFFAOYSA-N 0.000 description 1
- GMWJWMIZXHFITA-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 3-[1-(pyridin-3-ylsulfonylamino)cyclopropyl]azetidine-1-carboxylate Chemical compound C1N(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1C1(NS(=O)(=O)C=2C=NC=CC=2)CC1 GMWJWMIZXHFITA-UHFFFAOYSA-N 0.000 description 1
- CUGYGAZFGYYPGS-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 3-[1-[(2-methoxy-5-methylsulfonylphenyl)sulfonylamino]cyclopropyl]azetidine-1-carboxylate Chemical compound COC1=CC=C(S(C)(=O)=O)C=C1S(=O)(=O)NC1(C2CN(C2)C(=O)OC(C(F)(F)F)C(F)(F)F)CC1 CUGYGAZFGYYPGS-UHFFFAOYSA-N 0.000 description 1
- MAYNKKZUHYZVSM-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 3-[2-(benzylcarbamoylamino)ethyl]azetidine-1-carboxylate Chemical compound C1N(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1CCNC(=O)NCC1=CC=CC=C1 MAYNKKZUHYZVSM-UHFFFAOYSA-N 0.000 description 1
- OTGIPPKJTIFDLC-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 3-[2-(naphthalen-1-ylsulfonylamino)ethyl]azetidine-1-carboxylate Chemical compound C1N(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1CCNS(=O)(=O)C1=CC=CC2=CC=CC=C12 OTGIPPKJTIFDLC-UHFFFAOYSA-N 0.000 description 1
- VKHNPHVJLQGBOZ-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 3-[2-(naphthalen-2-ylsulfonylamino)ethyl]azetidine-1-carboxylate Chemical compound C1N(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1CCNS(=O)(=O)C1=CC=C(C=CC=C2)C2=C1 VKHNPHVJLQGBOZ-UHFFFAOYSA-N 0.000 description 1
- VVOVFEPCKZNZRJ-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 3-[2-[(2-phenylacetyl)amino]ethyl]azetidine-1-carboxylate Chemical compound C1N(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1CCNC(=O)CC1=CC=CC=C1 VVOVFEPCKZNZRJ-UHFFFAOYSA-N 0.000 description 1
- TYQBLFSVURHIBJ-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 3-[2-[(3-chlorophenyl)carbamoylamino]ethyl]azetidine-1-carboxylate Chemical compound C1N(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1CCNC(=O)NC1=CC=CC(Cl)=C1 TYQBLFSVURHIBJ-UHFFFAOYSA-N 0.000 description 1
- PDUCYCSNMIFZAJ-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 3-[2-[(4-cyanophenyl)carbamoylamino]ethyl]azetidine-1-carboxylate Chemical compound C1N(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1CCNC(=O)NC1=CC=C(C#N)C=C1 PDUCYCSNMIFZAJ-UHFFFAOYSA-N 0.000 description 1
- LLQICYOFPGZSQC-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 3-[2-[[2-(4-chlorophenoxy)acetyl]amino]ethyl]azetidine-1-carboxylate Chemical compound C1N(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1CCNC(=O)COC1=CC=C(Cl)C=C1 LLQICYOFPGZSQC-UHFFFAOYSA-N 0.000 description 1
- SUARWRNFLTWTMT-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 3-[3-(3-cyanophenyl)phenoxy]azetidine-1-carboxylate Chemical compound C1N(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1OC1=CC=CC(C=2C=C(C=CC=2)C#N)=C1 SUARWRNFLTWTMT-UHFFFAOYSA-N 0.000 description 1
- AKHMMUCWYSNETI-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 3-[3-(4-fluorophenyl)phenoxy]azetidine-1-carboxylate Chemical compound C1=CC(F)=CC=C1C1=CC=CC(OC2CN(C2)C(=O)OC(C(F)(F)F)C(F)(F)F)=C1 AKHMMUCWYSNETI-UHFFFAOYSA-N 0.000 description 1
- QPRDEJZBHXWAIN-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 3-[[(3-chlorophenyl)carbamoylamino]methyl]pyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1CNC(=O)NC1=CC=CC(Cl)=C1 QPRDEJZBHXWAIN-UHFFFAOYSA-N 0.000 description 1
- NIRBJCBNSODMJP-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 3-[[(3-chlorophenyl)sulfonylamino]methyl]pyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1CNS(=O)(=O)C1=CC=CC(Cl)=C1 NIRBJCBNSODMJP-UHFFFAOYSA-N 0.000 description 1
- CYFRZJFSETYGOW-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 3-[[(4-chlorophenyl)carbamoylamino]methyl]azetidine-1-carboxylate Chemical compound C1N(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1CNC(=O)NC1=CC=C(Cl)C=C1 CYFRZJFSETYGOW-UHFFFAOYSA-N 0.000 description 1
- POEQEGCODBVSFZ-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 3-[[(4-chlorophenyl)carbamoylamino]methyl]pyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1CNC(=O)NC1=CC=C(Cl)C=C1 POEQEGCODBVSFZ-UHFFFAOYSA-N 0.000 description 1
- KZFJIUGORWXRPL-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 3-[[(4-chlorophenyl)sulfonylamino]methyl]azetidine-1-carboxylate Chemical compound C1N(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1CNS(=O)(=O)C1=CC=C(Cl)C=C1 KZFJIUGORWXRPL-UHFFFAOYSA-N 0.000 description 1
- CKSHQLPJBNDDLU-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 3-[[(4-chlorophenyl)sulfonylamino]methyl]pyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1CNS(=O)(=O)C1=CC=C(Cl)C=C1 CKSHQLPJBNDDLU-UHFFFAOYSA-N 0.000 description 1
- HJQKFJRALIOZPW-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 3-[[(4-cyanophenyl)carbamoylamino]methyl]pyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1CNC(=O)NC1=CC=C(C#N)C=C1 HJQKFJRALIOZPW-UHFFFAOYSA-N 0.000 description 1
- XKSCZWFFHBETIM-VOTSOKGWSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 3-[[[(E)-3-phenylprop-2-enoyl]amino]methyl]pyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1CNC(=O)\C=C\C1=CC=CC=C1 XKSCZWFFHBETIM-VOTSOKGWSA-N 0.000 description 1
- DOAIULRFFNQEBL-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 3-[[[2-(4-chlorophenoxy)acetyl]amino]methyl]pyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1CNC(=O)COC1=CC=C(Cl)C=C1 DOAIULRFFNQEBL-UHFFFAOYSA-N 0.000 description 1
- ZNYIXTLHHXDNRB-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 3-[[[methyl(phenyl)carbamoyl]amino]methyl]pyrrolidine-1-carboxylate Chemical compound C=1C=CC=CC=1N(C)C(=O)NCC1CCN(C(=O)OC(C(F)(F)F)C(F)(F)F)C1 ZNYIXTLHHXDNRB-UHFFFAOYSA-N 0.000 description 1
- KWXSCVOWPCYDLW-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(1,3-benzoxazol-2-yl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1C1=NC2=CC=CC=C2O1 KWXSCVOWPCYDLW-UHFFFAOYSA-N 0.000 description 1
- CLSKCYQKHJWPNB-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2,3-dihydro-1,4-benzoxazine-4-carbonylamino)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1NC(=O)N1C2=CC=CC=C2OCC1 CLSKCYQKHJWPNB-UHFFFAOYSA-N 0.000 description 1
- QNMYHMIURYLHOH-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-methoxyphenyl)piperidine-1-carboxylate Chemical compound COC1=CC=CC=C1C1CCN(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1 QNMYHMIURYLHOH-UHFFFAOYSA-N 0.000 description 1
- IDZIQUQXMJXCFC-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-oxo-3H-benzimidazol-1-yl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1N1C(=O)NC2=CC=CC=C21 IDZIQUQXMJXCFC-UHFFFAOYSA-N 0.000 description 1
- XDSWBBVXPSXMDS-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(3-carbamoylphenoxy)piperidine-1-carboxylate Chemical compound NC(=O)C1=CC=CC(OC2CCN(CC2)C(=O)OC(C(F)(F)F)C(F)(F)F)=C1 XDSWBBVXPSXMDS-UHFFFAOYSA-N 0.000 description 1
- MXEGECKKTGPYJT-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(4-carbamoylphenoxy)piperidine-1-carboxylate Chemical compound C1=CC(C(=O)N)=CC=C1OC1CCN(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1 MXEGECKKTGPYJT-UHFFFAOYSA-N 0.000 description 1
- POEFSNCCULNZQL-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(4-chlorobenzoyl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1C(=O)C1=CC=C(Cl)C=C1 POEFSNCCULNZQL-UHFFFAOYSA-N 0.000 description 1
- LGABICMYSHJSHR-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(4-chloronaphthalen-1-yl)oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1OC1=CC=C(Cl)C2=CC=CC=C12 LGABICMYSHJSHR-UHFFFAOYSA-N 0.000 description 1
- IECSZCPFBZSNDA-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(4-chlorophenyl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1C1=CC=C(Cl)C=C1 IECSZCPFBZSNDA-UHFFFAOYSA-N 0.000 description 1
- GSHALYADUWQEOI-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(4-fluorobenzoyl)piperidine-1-carboxylate Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1 GSHALYADUWQEOI-UHFFFAOYSA-N 0.000 description 1
- PXRYGJZKKRAXNQ-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(4-fluorophenoxy)piperidine-1-carboxylate Chemical compound C1=CC(F)=CC=C1OC1CCN(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1 PXRYGJZKKRAXNQ-UHFFFAOYSA-N 0.000 description 1
- APWYNRJNYSZWCQ-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(5-fluoro-1,2-benzoxazol-3-yl)piperidine-1-carboxylate Chemical compound C12=CC(F)=CC=C2ON=C1C1CCN(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1 APWYNRJNYSZWCQ-UHFFFAOYSA-N 0.000 description 1
- WEIZXKWHOQBSEJ-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(6-cyanonaphthalen-2-yl)oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1OC1=CC=C(C=C(C=C2)C#N)C2=C1 WEIZXKWHOQBSEJ-UHFFFAOYSA-N 0.000 description 1
- RVPNIVYVKDVAAB-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(6-fluoro-1,2-benzoxazol-3-yl)piperidine-1-carboxylate Chemical compound N=1OC2=CC(F)=CC=C2C=1C1CCN(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1 RVPNIVYVKDVAAB-UHFFFAOYSA-N 0.000 description 1
- LWMRMDYCECTARF-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(6-fluoro-2H-indazol-3-yl)piperidine-1-carboxylate Chemical compound N=1NC2=CC(F)=CC=C2C=1C1CCN(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1 LWMRMDYCECTARF-UHFFFAOYSA-N 0.000 description 1
- VAXOSNZBLUAHOA-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(6-methoxynaphthalen-2-yl)oxypiperidine-1-carboxylate Chemical compound C1=CC2=CC(OC)=CC=C2C=C1OC1CCN(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1 VAXOSNZBLUAHOA-UHFFFAOYSA-N 0.000 description 1
- IOIAPGNJLBAWCN-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(7-methoxynaphthalen-2-yl)oxypiperidine-1-carboxylate Chemical compound C=1C2=CC(OC)=CC=C2C=CC=1OC1CCN(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1 IOIAPGNJLBAWCN-UHFFFAOYSA-N 0.000 description 1
- PTZVPXSJIZTYAZ-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(benzenesulfonamidomethyl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1CNS(=O)(=O)C1=CC=CC=C1 PTZVPXSJIZTYAZ-UHFFFAOYSA-N 0.000 description 1
- SSCIDFZKTMRSBX-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(benzenesulfonyl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1S(=O)(=O)C1=CC=CC=C1 SSCIDFZKTMRSBX-UHFFFAOYSA-N 0.000 description 1
- UPBIFUSVWTUQLG-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(benzylcarbamoylamino)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1NC(=O)NCC1=CC=CC=C1 UPBIFUSVWTUQLG-UHFFFAOYSA-N 0.000 description 1
- RFCYPPYOJYPALM-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(benzylsulfonylamino)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1NS(=O)(=O)CC1=CC=CC=C1 RFCYPPYOJYPALM-UHFFFAOYSA-N 0.000 description 1
- GBEVLAHMGLWFEA-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(naphthalen-1-ylsulfonylamino)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1NS(=O)(=O)C1=CC=CC2=CC=CC=C12 GBEVLAHMGLWFEA-UHFFFAOYSA-N 0.000 description 1
- MBUWXIMGVOAZLL-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(naphthalen-2-yloxymethyl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1COC1=CC=C(C=CC=C2)C2=C1 MBUWXIMGVOAZLL-UHFFFAOYSA-N 0.000 description 1
- VWFCIYHFKAUIBS-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(naphthalen-2-ylsulfonylamino)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1NS(=O)(=O)C1=CC=C(C=CC=C2)C2=C1 VWFCIYHFKAUIBS-UHFFFAOYSA-N 0.000 description 1
- WWQAKHAUONKDIJ-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(phenoxycarbonylamino)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1NC(=O)OC1=CC=CC=C1 WWQAKHAUONKDIJ-UHFFFAOYSA-N 0.000 description 1
- JBYFDEKJUJNBHP-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(phenylcarbamoylamino)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1NC(=O)NC1=CC=CC=C1 JBYFDEKJUJNBHP-UHFFFAOYSA-N 0.000 description 1
- KTGXZUBDCNLQRT-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(pyridin-3-ylsulfonylamino)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1NS(=O)(=O)C1=CC=CN=C1 KTGXZUBDCNLQRT-UHFFFAOYSA-N 0.000 description 1
- YHTXHCWUKTXEKA-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[(1-methylsulfonyl-2,3-dihydroindol-5-yl)carbamoylamino]piperidine-1-carboxylate Chemical compound C=1C=C2N(S(=O)(=O)C)CCC2=CC=1NC(=O)NC1CCN(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1 YHTXHCWUKTXEKA-UHFFFAOYSA-N 0.000 description 1
- WXXINOWVEUGHIR-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[(1H-indazol-6-ylcarbamoylamino)methyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1CNC(=O)NC1=CC=C(C=NN2)C2=C1 WXXINOWVEUGHIR-UHFFFAOYSA-N 0.000 description 1
- JXTWTJRDXMDGTD-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[(2,3-dihydro-1,4-benzodioxin-6-ylsulfonylamino)methyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1CNS(=O)(=O)C1=CC=C(OCCO2)C2=C1 JXTWTJRDXMDGTD-UHFFFAOYSA-N 0.000 description 1
- WXQVSOCBHYQADD-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[(2,3-dihydro-1,4-benzoxazine-4-carbonylamino)methyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1CNC(=O)N1C2=CC=CC=C2OCC1 WXQVSOCBHYQADD-UHFFFAOYSA-N 0.000 description 1
- SFYRDCHYTCPVEX-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[(3-carbamoylphenoxy)methyl]piperidine-1-carboxylate Chemical compound NC(=O)C1=CC=CC(OCC2CCN(CC2)C(=O)OC(C(F)(F)F)C(F)(F)F)=C1 SFYRDCHYTCPVEX-UHFFFAOYSA-N 0.000 description 1
- UUJWXHDGDKJAFS-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[(3-chloro-1-benzothiophene-2-carbonyl)amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1NC(=O)C1=C(Cl)C2=CC=CC=C2S1 UUJWXHDGDKJAFS-UHFFFAOYSA-N 0.000 description 1
- MWNGVMDBEKCHQB-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[(3-cyanophenyl)carbamoylamino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1NC(=O)NC1=CC=CC(C#N)=C1 MWNGVMDBEKCHQB-UHFFFAOYSA-N 0.000 description 1
- IVSBNMIEVAJYTC-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[(3-methylsulfonylphenyl)carbamoylamino]piperidine-1-carboxylate Chemical compound CS(=O)(=O)C1=CC=CC(NC(=O)NC2CCN(CC2)C(=O)OC(C(F)(F)F)C(F)(F)F)=C1 IVSBNMIEVAJYTC-UHFFFAOYSA-N 0.000 description 1
- MOFXUXPEPMNWGN-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[(3H-benzimidazol-5-ylcarbamoylamino)methyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1CNC(=O)NC1=CC=C(N=CN2)C2=C1 MOFXUXPEPMNWGN-UHFFFAOYSA-N 0.000 description 1
- IADZEXGBYZHZLB-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[(4-carbamoylphenoxy)methyl]piperidine-1-carboxylate Chemical compound C1=CC(C(=O)N)=CC=C1OCC1CCN(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1 IADZEXGBYZHZLB-UHFFFAOYSA-N 0.000 description 1
- WKSSEBWMYUYRQY-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[(4-chlorobenzoyl)amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1NC(=O)C1=CC=C(Cl)C=C1 WKSSEBWMYUYRQY-UHFFFAOYSA-N 0.000 description 1
- JEBWSEPNUXOSHH-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[(4-chlorophenyl)sulfonylamino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1NS(=O)(=O)C1=CC=C(Cl)C=C1 JEBWSEPNUXOSHH-UHFFFAOYSA-N 0.000 description 1
- KHWGOTCWKNCTPA-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[(4-chlorophenyl)sulfonylcarbamoylamino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1NC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 KHWGOTCWKNCTPA-UHFFFAOYSA-N 0.000 description 1
- PFNTWWNHFRAZPX-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[(4-cyanophenyl)carbamoylamino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1NC(=O)NC1=CC=C(C#N)C=C1 PFNTWWNHFRAZPX-UHFFFAOYSA-N 0.000 description 1
- HMNYHVXZVQNFIU-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[(4-methylsulfonylphenyl)sulfonylamino]piperidine-1-carboxylate Chemical compound C1=CC(S(=O)(=O)C)=CC=C1S(=O)(=O)NC1CCN(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1 HMNYHVXZVQNFIU-UHFFFAOYSA-N 0.000 description 1
- YGLKTWMSKHTYQH-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[(5-bromo-2-methoxyphenyl)sulfonylamino]piperidine-1-carboxylate Chemical compound COC1=CC=C(Br)C=C1S(=O)(=O)NC1CCN(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1 YGLKTWMSKHTYQH-UHFFFAOYSA-N 0.000 description 1
- OGJDYHQDBCQOCR-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[(5-carbamoylpyridin-2-yl)amino]piperidine-1-carboxylate Chemical compound N1=CC(C(=O)N)=CC=C1NC1CCN(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1 OGJDYHQDBCQOCR-UHFFFAOYSA-N 0.000 description 1
- NAECEVLOEDMDSQ-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[(5-cyanopyridin-2-yl)amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1NC1=CC=C(C#N)C=N1 NAECEVLOEDMDSQ-UHFFFAOYSA-N 0.000 description 1
- OMBBJCRDTXXANK-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[(6-bromopyridin-2-yl)amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1NC1=CC=CC(Br)=N1 OMBBJCRDTXXANK-UHFFFAOYSA-N 0.000 description 1
- LFIAWLUMLNHSIV-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[(6-cyanonaphthalen-2-yl)oxymethyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1COC1=CC=C(C=C(C=C2)C#N)C2=C1 LFIAWLUMLNHSIV-UHFFFAOYSA-N 0.000 description 1
- LACPRDLOQJKGTI-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[(6-methoxynaphthalen-2-yl)oxymethyl]piperidine-1-carboxylate Chemical compound C1=CC2=CC(OC)=CC=C2C=C1OCC1CCN(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1 LACPRDLOQJKGTI-UHFFFAOYSA-N 0.000 description 1
- VDBRRFYUNNRPJG-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[(7-methoxynaphthalen-2-yl)oxymethyl]piperidine-1-carboxylate Chemical compound C=1C2=CC(OC)=CC=C2C=CC=1OCC1CCN(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1 VDBRRFYUNNRPJG-UHFFFAOYSA-N 0.000 description 1
- WUVJAHRDXJKUEL-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[(benzylcarbamoylamino)methyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1CNC(=O)NCC1=CC=CC=C1 WUVJAHRDXJKUEL-UHFFFAOYSA-N 0.000 description 1
- UFXUHKCSBCOPTE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[(naphthalen-1-ylsulfonylamino)methyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1CNS(=O)(=O)C1=CC=CC2=CC=CC=C12 UFXUHKCSBCOPTE-UHFFFAOYSA-N 0.000 description 1
- VTROFTAGQRUJMM-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[(naphthalen-2-ylsulfonylamino)methyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1CNS(=O)(=O)C1=CC=C(C=CC=C2)C2=C1 VTROFTAGQRUJMM-UHFFFAOYSA-N 0.000 description 1
- NPQJYWJGBOWIBW-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[1-[(4-methoxyphenyl)sulfonylamino]cyclopropyl]piperidine-1-carboxylate Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)NC1(C2CCN(CC2)C(=O)OC(C(F)(F)F)C(F)(F)F)CC1 NPQJYWJGBOWIBW-UHFFFAOYSA-N 0.000 description 1
- RYIWKTGRFJVBIY-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[2-(2,3-dihydro-1,4-benzoxazine-4-carbonylamino)ethyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1CCNC(=O)N1C2=CC=CC=C2OCC1 RYIWKTGRFJVBIY-UHFFFAOYSA-N 0.000 description 1
- ZORUNESGKWBPSP-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[2-(3-carbamoylphenoxy)ethyl]piperidine-1-carboxylate Chemical compound NC(=O)C1=CC=CC(OCCC2CCN(CC2)C(=O)OC(C(F)(F)F)C(F)(F)F)=C1 ZORUNESGKWBPSP-UHFFFAOYSA-N 0.000 description 1
- GPDDXEPGWVGOLJ-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[2-(4-carbamoylphenoxy)ethyl]piperidine-1-carboxylate Chemical compound C1=CC(C(=O)N)=CC=C1OCCC1CCN(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1 GPDDXEPGWVGOLJ-UHFFFAOYSA-N 0.000 description 1
- FSYSZBDUDJRXDY-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[2-(4-phenylphenoxy)ethyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1CCOC1=CC=C(C=2C=CC=CC=2)C=C1 FSYSZBDUDJRXDY-UHFFFAOYSA-N 0.000 description 1
- DJVRHAUCOZFBOL-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[2-(trifluoromethyl)phenyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1C1=CC=CC=C1C(F)(F)F DJVRHAUCOZFBOL-UHFFFAOYSA-N 0.000 description 1
- WBGPGQWJQBSVBZ-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[2-[(3-methylsulfonylbenzoyl)amino]ethyl]piperidine-1-carboxylate Chemical compound CS(=O)(=O)C1=CC=CC(C(=O)NCCC2CCN(CC2)C(=O)OC(C(F)(F)F)C(F)(F)F)=C1 WBGPGQWJQBSVBZ-UHFFFAOYSA-N 0.000 description 1
- XGYGQFNMUAJATK-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[2-[(4-chlorophenyl)carbamoylamino]ethyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1CCNC(=O)NC1=CC=C(Cl)C=C1 XGYGQFNMUAJATK-UHFFFAOYSA-N 0.000 description 1
- QPOATSHJXXASOT-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[2-[(4-methylsulfonylbenzoyl)amino]ethyl]piperidine-1-carboxylate Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(=O)NCCC1CCN(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1 QPOATSHJXXASOT-UHFFFAOYSA-N 0.000 description 1
- BQFZRJLKBFHFCI-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[2-[(4-methylsulfonylphenyl)sulfonylamino]ethyl]piperidine-1-carboxylate Chemical compound C1=CC(S(=O)(=O)C)=CC=C1S(=O)(=O)NCCC1CCN(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1 BQFZRJLKBFHFCI-UHFFFAOYSA-N 0.000 description 1
- KLZYDCPPUHHNQA-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[2-[(4-sulfamoylbenzoyl)amino]ethyl]piperidine-1-carboxylate Chemical compound C1=CC(S(=O)(=O)N)=CC=C1C(=O)NCCC1CCN(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1 KLZYDCPPUHHNQA-UHFFFAOYSA-N 0.000 description 1
- CNHHEQFQVDGKFQ-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[2-[(5-carbamoylpyridin-2-yl)amino]ethyl]piperidine-1-carboxylate Chemical compound N1=CC(C(=O)N)=CC=C1NCCC1CCN(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1 CNHHEQFQVDGKFQ-UHFFFAOYSA-N 0.000 description 1
- HXZDBUYIFMIOOV-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[2-[(6-carbamoylpyrazin-2-yl)amino]ethyl]piperidine-1-carboxylate Chemical compound NC(=O)C1=CN=CC(NCCC2CCN(CC2)C(=O)OC(C(F)(F)F)C(F)(F)F)=N1 HXZDBUYIFMIOOV-UHFFFAOYSA-N 0.000 description 1
- LBHCGEWQSODOBD-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[3-(3-chlorophenyl)phenoxy]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1OC1=CC=CC(C=2C=C(Cl)C=CC=2)=C1 LBHCGEWQSODOBD-UHFFFAOYSA-N 0.000 description 1
- FJDYFCJQFQOKAS-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[3-(3-fluorophenyl)phenoxy]piperidine-1-carboxylate Chemical compound FC1=CC=CC(C=2C=C(OC3CCN(CC3)C(=O)OC(C(F)(F)F)C(F)(F)F)C=CC=2)=C1 FJDYFCJQFQOKAS-UHFFFAOYSA-N 0.000 description 1
- ODXXRRXNAVKEQT-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[3-(4-chlorophenyl)phenoxy]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1OC1=CC=CC(C=2C=CC(Cl)=CC=2)=C1 ODXXRRXNAVKEQT-UHFFFAOYSA-N 0.000 description 1
- RBSGLHAUMFWVFK-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[3-(4-cyanophenyl)phenoxy]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1OC1=CC=CC(C=2C=CC(=CC=2)C#N)=C1 RBSGLHAUMFWVFK-UHFFFAOYSA-N 0.000 description 1
- OWWCIHZXJKYVMR-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[3-(4-fluorophenyl)phenoxy]piperidine-1-carboxylate Chemical compound C1=CC(F)=CC=C1C1=CC=CC(OC2CCN(CC2)C(=O)OC(C(F)(F)F)C(F)(F)F)=C1 OWWCIHZXJKYVMR-UHFFFAOYSA-N 0.000 description 1
- VPCVRJMAMJUCEL-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[4-(4-cyanophenyl)phenoxy]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1OC1=CC=C(C=2C=CC(=CC=2)C#N)C=C1 VPCVRJMAMJUCEL-UHFFFAOYSA-N 0.000 description 1
- ZLQCTDBHWVJERZ-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[4-(methylcarbamoyl)phenyl]piperidine-1-carboxylate Chemical compound C1=CC(C(=O)NC)=CC=C1C1CCN(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1 ZLQCTDBHWVJERZ-UHFFFAOYSA-N 0.000 description 1
- KUTSUHTVJOBKAQ-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[5-(3-cyanophenyl)pyridin-3-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1OC1=CN=CC(C=2C=C(C=CC=2)C#N)=C1 KUTSUHTVJOBKAQ-UHFFFAOYSA-N 0.000 description 1
- KTCUHWDFAIJCNB-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[5-(4-fluorophenyl)-1,3,4-oxadiazol-2-yl]piperidine-1-carboxylate Chemical compound C1=CC(F)=CC=C1C1=NN=C(C2CCN(CC2)C(=O)OC(C(F)(F)F)C(F)(F)F)O1 KTCUHWDFAIJCNB-UHFFFAOYSA-N 0.000 description 1
- GLAAFENCGMUXBR-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[6-(3-cyanophenyl)pyrazin-2-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1OC1=CN=CC(C=2C=C(C=CC=2)C#N)=N1 GLAAFENCGMUXBR-UHFFFAOYSA-N 0.000 description 1
- PKJWJZJMRDTTQK-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[6-(3-cyanophenyl)pyridin-2-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1OC1=CC=CC(C=2C=C(C=CC=2)C#N)=N1 PKJWJZJMRDTTQK-UHFFFAOYSA-N 0.000 description 1
- ZAEJAIJWLTURKP-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[6-(4-fluorophenyl)pyrazin-2-yl]oxypiperidine-1-carboxylate Chemical compound C1=CC(F)=CC=C1C1=CN=CC(OC2CCN(CC2)C(=O)OC(C(F)(F)F)C(F)(F)F)=N1 ZAEJAIJWLTURKP-UHFFFAOYSA-N 0.000 description 1
- QQBJWUJJFPHSGP-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[(1-methylsulfonyl-2,3-dihydroindol-5-yl)carbamoylamino]methyl]piperidine-1-carboxylate Chemical compound C=1C=C2N(S(=O)(=O)C)CCC2=CC=1NC(=O)NCC1CCN(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1 QQBJWUJJFPHSGP-UHFFFAOYSA-N 0.000 description 1
- YCAPDDAXHBRMHG-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[(2,4-dimethoxyphenyl)sulfonylamino]methyl]piperidine-1-carboxylate Chemical compound COC1=CC(OC)=CC=C1S(=O)(=O)NCC1CCN(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1 YCAPDDAXHBRMHG-UHFFFAOYSA-N 0.000 description 1
- LRTLNSFVNRTAKL-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[(2,5-dimethoxyphenyl)sulfonylamino]methyl]piperidine-1-carboxylate Chemical compound COC1=CC=C(OC)C(S(=O)(=O)NCC2CCN(CC2)C(=O)OC(C(F)(F)F)C(F)(F)F)=C1 LRTLNSFVNRTAKL-UHFFFAOYSA-N 0.000 description 1
- CEFJDHFBAOWBAZ-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[(2-fluorophenyl)sulfonylamino]methyl]piperidine-1-carboxylate Chemical compound FC1=CC=CC=C1S(=O)(=O)NCC1CCN(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1 CEFJDHFBAOWBAZ-UHFFFAOYSA-N 0.000 description 1
- WHXDQYAMIZHGTN-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[(2-methoxy-5-methylsulfonylphenyl)carbamoylamino]methyl]piperidine-1-carboxylate Chemical compound COC1=CC=C(S(C)(=O)=O)C=C1NC(=O)NCC1CCN(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1 WHXDQYAMIZHGTN-UHFFFAOYSA-N 0.000 description 1
- BRDQLGNGMSVEQZ-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[(2-methoxy-5-methylsulfonylphenyl)sulfonylamino]methyl]piperidine-1-carboxylate Chemical compound COC1=CC=C(S(C)(=O)=O)C=C1S(=O)(=O)NCC1CCN(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1 BRDQLGNGMSVEQZ-UHFFFAOYSA-N 0.000 description 1
- AFLUNVVIGYWJLP-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[(3,4-difluorophenyl)sulfonylamino]methyl]piperidine-1-carboxylate Chemical compound C1=C(F)C(F)=CC=C1S(=O)(=O)NCC1CCN(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1 AFLUNVVIGYWJLP-UHFFFAOYSA-N 0.000 description 1
- POBWOHMWUJDICE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[(3-chloro-1-benzothiophene-2-carbonyl)amino]methyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1CNC(=O)C1=C(Cl)C2=CC=CC=C2S1 POBWOHMWUJDICE-UHFFFAOYSA-N 0.000 description 1
- KXCKEZSJMNFSNV-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[(3-chloro-4-fluorophenyl)sulfonylamino]methyl]piperidine-1-carboxylate Chemical compound C1=C(Cl)C(F)=CC=C1S(=O)(=O)NCC1CCN(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1 KXCKEZSJMNFSNV-UHFFFAOYSA-N 0.000 description 1
- LXGRLERXKPIKMK-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[(3-chlorophenyl)sulfonylamino]methyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1CNS(=O)(=O)C1=CC=CC(Cl)=C1 LXGRLERXKPIKMK-UHFFFAOYSA-N 0.000 description 1
- KBTHKYQSXWZCHM-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[(3-cyanophenyl)sulfonylamino]methyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1CNS(=O)(=O)C1=CC=CC(C#N)=C1 KBTHKYQSXWZCHM-UHFFFAOYSA-N 0.000 description 1
- YSVVEDMAGXHYDN-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[(3-fluoro-4-methoxyphenyl)sulfonylamino]methyl]piperidine-1-carboxylate Chemical compound C1=C(F)C(OC)=CC=C1S(=O)(=O)NCC1CCN(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1 YSVVEDMAGXHYDN-UHFFFAOYSA-N 0.000 description 1
- ANIMSQOXKQMNDE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[(3-fluoro-4-methylphenyl)sulfonylamino]methyl]piperidine-1-carboxylate Chemical compound C1=C(F)C(C)=CC=C1S(=O)(=O)NCC1CCN(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1 ANIMSQOXKQMNDE-UHFFFAOYSA-N 0.000 description 1
- LXFWFIWGIFDZEW-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[(3-methoxyphenyl)sulfonylamino]methyl]piperidine-1-carboxylate Chemical compound COC1=CC=CC(S(=O)(=O)NCC2CCN(CC2)C(=O)OC(C(F)(F)F)C(F)(F)F)=C1 LXFWFIWGIFDZEW-UHFFFAOYSA-N 0.000 description 1
- ZZNTZEYMCXMLFO-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[(3-methylphenyl)sulfonylamino]methyl]piperidine-1-carboxylate Chemical compound CC1=CC=CC(S(=O)(=O)NCC2CCN(CC2)C(=O)OC(C(F)(F)F)C(F)(F)F)=C1 ZZNTZEYMCXMLFO-UHFFFAOYSA-N 0.000 description 1
- GOGLYIPOTUTBDD-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[(4-carbamoylpyridin-2-yl)amino]methyl]piperidine-1-carboxylate Chemical compound NC(=O)C1=CC=NC(NCC2CCN(CC2)C(=O)OC(C(F)(F)F)C(F)(F)F)=C1 GOGLYIPOTUTBDD-UHFFFAOYSA-N 0.000 description 1
- ACAOJEHTQCNTCV-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[(4-chloro-2,5-dimethylphenyl)sulfonylamino]methyl]piperidine-1-carboxylate Chemical compound C1=C(Cl)C(C)=CC(S(=O)(=O)NCC2CCN(CC2)C(=O)OC(C(F)(F)F)C(F)(F)F)=C1C ACAOJEHTQCNTCV-UHFFFAOYSA-N 0.000 description 1
- OOOVHNNMYWMNKB-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[(4-chlorobenzoyl)amino]methyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1CNC(=O)C1=CC=C(Cl)C=C1 OOOVHNNMYWMNKB-UHFFFAOYSA-N 0.000 description 1
- MGEODTPYTLNNHP-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[(4-chlorophenyl)methylsulfonylamino]methyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1CNS(=O)(=O)CC1=CC=C(Cl)C=C1 MGEODTPYTLNNHP-UHFFFAOYSA-N 0.000 description 1
- RLYMQNQYCHGICP-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[(4-chlorophenyl)sulfonylamino]methyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1CNS(=O)(=O)C1=CC=C(Cl)C=C1 RLYMQNQYCHGICP-UHFFFAOYSA-N 0.000 description 1
- LMPKWAYGBHMQKE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[(4-chlorophenyl)sulfonylcarbamoylamino]methyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1CNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 LMPKWAYGBHMQKE-UHFFFAOYSA-N 0.000 description 1
- PRGMENYZRVHWDC-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[(4-cyanophenyl)sulfonylamino]methyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1CNS(=O)(=O)C1=CC=C(C#N)C=C1 PRGMENYZRVHWDC-UHFFFAOYSA-N 0.000 description 1
- INNJVOOCTILWKV-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[(4-fluoro-3-methoxyphenyl)sulfonylamino]methyl]piperidine-1-carboxylate Chemical compound C1=C(F)C(OC)=CC(S(=O)(=O)NCC2CCN(CC2)C(=O)OC(C(F)(F)F)C(F)(F)F)=C1 INNJVOOCTILWKV-UHFFFAOYSA-N 0.000 description 1
- UCFUUJWOYLLSRN-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[(4-methoxyphenyl)sulfonylamino]methyl]piperidine-1-carboxylate Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)NCC1CCN(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1 UCFUUJWOYLLSRN-UHFFFAOYSA-N 0.000 description 1
- HFDAPUDBCVSNDR-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[(4-methylphenyl)sulfonylamino]methyl]piperidine-1-carboxylate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NCC1CCN(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1 HFDAPUDBCVSNDR-UHFFFAOYSA-N 0.000 description 1
- UHDQSMBJUPVFJR-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[(4-phenylphenyl)sulfonylamino]methyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1CNS(=O)(=O)C1=CC=C(C=2C=CC=CC=2)C=C1 UHDQSMBJUPVFJR-UHFFFAOYSA-N 0.000 description 1
- RSZKOIMFMDJDKT-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[(4-pyrrolidin-1-ylsulfonylphenyl)sulfonylamino]methyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1CNS(=O)(=O)C1=CC=C(S(=O)(=O)N2CCCC2)C=C1 RSZKOIMFMDJDKT-UHFFFAOYSA-N 0.000 description 1
- YDIWRASYPXBTLQ-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[(5-carbamoylpyrazin-2-yl)amino]methyl]piperidine-1-carboxylate Chemical compound C1=NC(C(=O)N)=CN=C1NCC1CCN(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1 YDIWRASYPXBTLQ-UHFFFAOYSA-N 0.000 description 1
- OXMMNAOCBBGUPS-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[(5-carbamoylpyridin-2-yl)amino]methyl]piperidine-1-carboxylate Chemical compound N1=CC(C(=O)N)=CC=C1NCC1CCN(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1 OXMMNAOCBBGUPS-UHFFFAOYSA-N 0.000 description 1
- JIHZEXBDSSVCBZ-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[(5-chloro-1,3-dimethylpyrazol-4-yl)sulfonylamino]methyl]piperidine-1-carboxylate Chemical compound CC1=NN(C)C(Cl)=C1S(=O)(=O)NCC1CCN(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1 JIHZEXBDSSVCBZ-UHFFFAOYSA-N 0.000 description 1
- STMODGVJKGIBPO-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[(5-fluoro-2-methoxyphenyl)sulfonylamino]methyl]piperidine-1-carboxylate Chemical compound COC1=CC=C(F)C=C1S(=O)(=O)NCC1CCN(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1 STMODGVJKGIBPO-UHFFFAOYSA-N 0.000 description 1
- ICEMPZPDICUREK-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[(6-carbamoylpyridin-2-yl)amino]methyl]piperidine-1-carboxylate Chemical compound NC(=O)C1=CC=CC(NCC2CCN(CC2)C(=O)OC(C(F)(F)F)C(F)(F)F)=N1 ICEMPZPDICUREK-UHFFFAOYSA-N 0.000 description 1
- RTJCUNIZEXOXFS-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[(6-chloropyridin-2-yl)amino]methyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1CNC1=CC=CC(Cl)=N1 RTJCUNIZEXOXFS-UHFFFAOYSA-N 0.000 description 1
- BTDVKTFLBMWZAV-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[(6-chloropyridin-3-yl)sulfonylamino]methyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1CNS(=O)(=O)C1=CC=C(Cl)N=C1 BTDVKTFLBMWZAV-UHFFFAOYSA-N 0.000 description 1
- JSUCKQREGJXUBX-VOTSOKGWSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[(E)-3-phenylprop-2-enoyl]amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1NC(=O)\C=C\C1=CC=CC=C1 JSUCKQREGJXUBX-VOTSOKGWSA-N 0.000 description 1
- LLXKAUSOBRBTIU-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[2-(4-chlorophenoxy)acetyl]amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1NC(=O)COC1=CC=C(Cl)C=C1 LLXKAUSOBRBTIU-UHFFFAOYSA-N 0.000 description 1
- SLIYSIXFDDKRIW-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[3-(3-cyanophenyl)phenoxy]methyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1COC1=CC=CC(C=2C=C(C=CC=2)C#N)=C1 SLIYSIXFDDKRIW-UHFFFAOYSA-N 0.000 description 1
- NPWCBGXAXOISDB-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[3-(4-cyanophenyl)phenoxy]methyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1COC1=CC=CC(C=2C=CC(=CC=2)C#N)=C1 NPWCBGXAXOISDB-UHFFFAOYSA-N 0.000 description 1
- KHSRSQVZOOKOQN-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[4-(4-cyanophenyl)phenoxy]methyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1COC1=CC=C(C=2C=CC(=CC=2)C#N)C=C1 KHSRSQVZOOKOQN-UHFFFAOYSA-N 0.000 description 1
- MKLNLBHFEQPXAM-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[5-(trifluoromethyl)pyridin-2-yl]amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1NC1=CC=C(C(F)(F)F)C=N1 MKLNLBHFEQPXAM-UHFFFAOYSA-N 0.000 description 1
- DWSMPUOFINXTRU-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[5-(trifluoromethyl)pyridin-2-yl]amino]piperidine-1-carboxylate;hydrochloride Chemical compound Cl.C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1NC1=CC=C(C(F)(F)F)C=N1 DWSMPUOFINXTRU-UHFFFAOYSA-N 0.000 description 1
- MPYYWCHYGUZZOV-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[[2-(4-chlorophenoxy)acetyl]amino]methyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1CNC(=O)COC1=CC=C(Cl)C=C1 MPYYWCHYGUZZOV-UHFFFAOYSA-N 0.000 description 1
- VFEROZGSDIZADQ-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[[2-(trifluoromethoxy)phenyl]sulfonylamino]methyl]piperidine-1-carboxylate Chemical compound FC(F)(F)OC1=CC=CC=C1S(=O)(=O)NCC1CCN(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1 VFEROZGSDIZADQ-UHFFFAOYSA-N 0.000 description 1
- CTDYEEOTJAKIOE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[[2-(trifluoromethyl)phenyl]sulfonylamino]methyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1CNS(=O)(=O)C1=CC=CC=C1C(F)(F)F CTDYEEOTJAKIOE-UHFFFAOYSA-N 0.000 description 1
- RYONHRYTFHXPBP-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[[3-(2-methylpyrimidin-4-yl)phenyl]sulfonylamino]methyl]piperidine-1-carboxylate Chemical compound CC1=NC=CC(C=2C=C(C=CC=2)S(=O)(=O)NCC2CCN(CC2)C(=O)OC(C(F)(F)F)C(F)(F)F)=N1 RYONHRYTFHXPBP-UHFFFAOYSA-N 0.000 description 1
- SJIIBDHFEJMNMB-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[[3-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl]sulfonylamino]methyl]piperidine-1-carboxylate Chemical compound O1C(C)=NN=C1C1=CC=CC(S(=O)(=O)NCC2CCN(CC2)C(=O)OC(C(F)(F)F)C(F)(F)F)=C1 SJIIBDHFEJMNMB-UHFFFAOYSA-N 0.000 description 1
- WXMFEUXPVLCNLH-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[[3-(trifluoromethoxy)phenyl]sulfonylamino]methyl]piperidine-1-carboxylate Chemical compound FC(F)(F)OC1=CC=CC(S(=O)(=O)NCC2CCN(CC2)C(=O)OC(C(F)(F)F)C(F)(F)F)=C1 WXMFEUXPVLCNLH-UHFFFAOYSA-N 0.000 description 1
- IEYNIMJLEUYHDI-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[[3-(trifluoromethyl)phenyl]sulfonylamino]methyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1CNS(=O)(=O)C1=CC=CC(C(F)(F)F)=C1 IEYNIMJLEUYHDI-UHFFFAOYSA-N 0.000 description 1
- VCAAKLJHSBHNLG-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[[4-(1,3-oxazol-5-yl)phenyl]sulfonylamino]methyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1CNS(=O)(=O)C1=CC=C(C=2OC=NC=2)C=C1 VCAAKLJHSBHNLG-UHFFFAOYSA-N 0.000 description 1
- ZAYCVVSEYUYEBC-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[[4-(trifluoromethoxy)phenyl]sulfonylamino]methyl]piperidine-1-carboxylate Chemical compound C1=CC(OC(F)(F)F)=CC=C1S(=O)(=O)NCC1CCN(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1 ZAYCVVSEYUYEBC-UHFFFAOYSA-N 0.000 description 1
- NOAFVSGLNVJMII-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[[4-(trifluoromethyl)phenyl]sulfonylamino]methyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1CNS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 NOAFVSGLNVJMII-UHFFFAOYSA-N 0.000 description 1
- IRFXTJIQAVZAJG-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[[4-chloro-3-(trifluoromethyl)phenyl]sulfonylamino]methyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1CNS(=O)(=O)C1=CC=C(Cl)C(C(F)(F)F)=C1 IRFXTJIQAVZAJG-UHFFFAOYSA-N 0.000 description 1
- AXTDHPODQZYFNY-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[[4-fluoro-2-(trifluoromethyl)phenyl]sulfonylamino]methyl]piperidine-1-carboxylate Chemical compound FC(F)(F)C1=CC(F)=CC=C1S(=O)(=O)NCC1CCN(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1 AXTDHPODQZYFNY-UHFFFAOYSA-N 0.000 description 1
- SCSPGJDWKWJBCC-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[[4-fluoro-3-(trifluoromethyl)phenyl]sulfonylamino]methyl]piperidine-1-carboxylate Chemical compound C1=C(C(F)(F)F)C(F)=CC=C1S(=O)(=O)NCC1CCN(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1 SCSPGJDWKWJBCC-UHFFFAOYSA-N 0.000 description 1
- ZFJCIOHEOYMXOR-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-aminopiperidine-1-carboxylate;hydrochloride Chemical compound Cl.NC1CCN(C(=O)OC(C(F)(F)F)C(F)(F)F)CC1 ZFJCIOHEOYMXOR-UHFFFAOYSA-N 0.000 description 1
- MWWNGOGZSYMETP-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-benzylpiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1CC1=CC=CC=C1 MWWNGOGZSYMETP-UHFFFAOYSA-N 0.000 description 1
- OREVEBMHKNWXGQ-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-naphthalen-1-ylpiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1C1=CC=CC2=CC=CC=C12 OREVEBMHKNWXGQ-UHFFFAOYSA-N 0.000 description 1
- QVIILYJQMMWOJN-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-naphthalen-2-yloxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1OC1=CC=C(C=CC=C2)C2=C1 QVIILYJQMMWOJN-UHFFFAOYSA-N 0.000 description 1
- PRQZFKVIFJVRIA-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-pyridin-4-yloxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1OC1=CC=NC=C1 PRQZFKVIFJVRIA-UHFFFAOYSA-N 0.000 description 1
- ZQZUBCWJCPKMMZ-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-pyridin-4-ylsulfanylpiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C(F)(F)F)C(F)(F)F)CCC1SC1=CC=NC=C1 ZQZUBCWJCPKMMZ-UHFFFAOYSA-N 0.000 description 1
- TXEFKIHXCABCDQ-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl azetidine-1-carboxylate Chemical compound FC(F)(F)C(C(F)(F)F)OC(=O)N1CCC1 TXEFKIHXCABCDQ-UHFFFAOYSA-N 0.000 description 1
- HOWNGVDIGBTCLX-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl piperidine-1-carboxylate Chemical compound FC(F)(F)C(C(F)(F)F)OC(=O)N1CCCCC1 HOWNGVDIGBTCLX-UHFFFAOYSA-N 0.000 description 1
- DCFZZSCDPHKZPV-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl pyrrolidine-1-carboxylate Chemical compound FC(F)(F)C(C(F)(F)F)OC(=O)N1CCCC1 DCFZZSCDPHKZPV-UHFFFAOYSA-N 0.000 description 1
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 1
- OWQPOVKKUWUEKE-UHFFFAOYSA-N 1,2,3-benzotriazine Chemical compound N1=NN=CC2=CC=CC=C21 OWQPOVKKUWUEKE-UHFFFAOYSA-N 0.000 description 1
- SLLFVLKNXABYGI-UHFFFAOYSA-N 1,2,3-benzoxadiazole Chemical compound C1=CC=C2ON=NC2=C1 SLLFVLKNXABYGI-UHFFFAOYSA-N 0.000 description 1
- UGUHFDPGDQDVGX-UHFFFAOYSA-N 1,2,3-thiadiazole Chemical compound C1=CSN=N1 UGUHFDPGDQDVGX-UHFFFAOYSA-N 0.000 description 1
- IXAZIGSJNTYTGJ-UHFFFAOYSA-N 1,2,5-thiadiazinane 1,1-dioxide Chemical compound O=S1(=O)CNCCN1 IXAZIGSJNTYTGJ-UHFFFAOYSA-N 0.000 description 1
- ADBZIZGMAVRJPN-UHFFFAOYSA-N 1,2,5-thiadiazolidine 1,1-dioxide Chemical compound O=S1(=O)NCCN1 ADBZIZGMAVRJPN-UHFFFAOYSA-N 0.000 description 1
- VODZRKXBWJKZLE-UHFFFAOYSA-N 1,2,6-thiadiazinane 1,1-dioxide Chemical compound O=S1(=O)NCCCN1 VODZRKXBWJKZLE-UHFFFAOYSA-N 0.000 description 1
- CSNIZNHTOVFARY-UHFFFAOYSA-N 1,2-benzothiazole Chemical compound C1=CC=C2C=NSC2=C1 CSNIZNHTOVFARY-UHFFFAOYSA-N 0.000 description 1
- CFRCZLVPCCLZFG-UHFFFAOYSA-N 1,3,4-oxathiazinane 3,3-dioxide Chemical group O=S1(=O)COCCN1 CFRCZLVPCCLZFG-UHFFFAOYSA-N 0.000 description 1
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-Benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 1
- NQPJDJVGBDHCAD-UHFFFAOYSA-N 1,3-diazinan-2-one Chemical compound OC1=NCCCN1 NQPJDJVGBDHCAD-UHFFFAOYSA-N 0.000 description 1
- OYELEBBISJGNHJ-UHFFFAOYSA-N 1,3-oxazinan-2-one Chemical compound O=C1NCCCO1 OYELEBBISJGNHJ-UHFFFAOYSA-N 0.000 description 1
- HPARLNRMYDSBNO-UHFFFAOYSA-N 1,4-Benzodioxine Chemical compound C1=CC=C2OC=COC2=C1 HPARLNRMYDSBNO-UHFFFAOYSA-N 0.000 description 1
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- NZRLCYJRHKUVCV-UHFFFAOYSA-N 1-chloro-2-(trifluoromethoxy)benzene Chemical compound FC(F)(F)OC1=CC=CC=C1Cl NZRLCYJRHKUVCV-UHFFFAOYSA-N 0.000 description 1
- HHIRBXHEYVDUAM-UHFFFAOYSA-N 1-chloro-3-isocyanatobenzene Chemical compound ClC1=CC=CC(N=C=O)=C1 HHIRBXHEYVDUAM-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- ZKAMEFMDQNTDFK-UHFFFAOYSA-N 1H-imidazo[4,5-b]pyrazine Chemical compound C1=CN=C2NC=NC2=N1 ZKAMEFMDQNTDFK-UHFFFAOYSA-N 0.000 description 1
- ZVXKYWHJBYIYNI-UHFFFAOYSA-N 1H-pyrazole-4-carboxamide Chemical compound NC(=O)C=1C=NNC=1 ZVXKYWHJBYIYNI-UHFFFAOYSA-N 0.000 description 1
- DDZGQYREBDXECY-UHFFFAOYSA-N 1H-pyrazolo[3,4-b]pyrazine Chemical compound C1=CN=C2C=NNC2=N1 DDZGQYREBDXECY-UHFFFAOYSA-N 0.000 description 1
- AMFYRKOUWBAGHV-UHFFFAOYSA-N 1H-pyrazolo[4,3-b]pyridine Chemical compound C1=CN=C2C=NNC2=C1 AMFYRKOUWBAGHV-UHFFFAOYSA-N 0.000 description 1
- NMEPLWZDUIIAAC-UHFFFAOYSA-N 1H-pyrazolo[4,3-c]pyridazine Chemical compound C1=NN=C2C=NNC2=C1 NMEPLWZDUIIAAC-UHFFFAOYSA-N 0.000 description 1
- APXRHPDHORGIEB-UHFFFAOYSA-N 1H-pyrazolo[4,3-d]pyrimidine Chemical compound N1=CN=C2C=NNC2=C1 APXRHPDHORGIEB-UHFFFAOYSA-N 0.000 description 1
- XWIYUCRMWCHYJR-UHFFFAOYSA-N 1H-pyrrolo[3,2-b]pyridine Chemical compound C1=CC=C2NC=CC2=N1 XWIYUCRMWCHYJR-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- YJUFGFXVASPYFQ-UHFFFAOYSA-N 2,3-dihydro-1-benzothiophene Chemical compound C1=CC=C2SCCC2=C1 YJUFGFXVASPYFQ-UHFFFAOYSA-N 0.000 description 1
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 description 1
- BVDRUCCQKHGCRX-UHFFFAOYSA-N 2,3-dihydroxypropyl formate Chemical class OCC(O)COC=O BVDRUCCQKHGCRX-UHFFFAOYSA-N 0.000 description 1
- XUWHAWMETYGRKB-UHFFFAOYSA-N 2-Piperidinone Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N 2-Pyrrolidone Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 1
- GSKMWMFOQQBVMI-UHFFFAOYSA-N 2-bromo-5-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=C(Br)N=C1 GSKMWMFOQQBVMI-UHFFFAOYSA-N 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- CMLFRMDBDNHMRA-UHFFFAOYSA-N 2H-1,2-benzoxazine Chemical compound C1=CC=C2C=CNOC2=C1 CMLFRMDBDNHMRA-UHFFFAOYSA-N 0.000 description 1
- VPIISTLIZXHVOC-UHFFFAOYSA-N 2H-imidazo[4,5-d][1,2]oxazole Chemical compound N1OC2=NC=NC2=C1 VPIISTLIZXHVOC-UHFFFAOYSA-N 0.000 description 1
- KWLMVXGOHGQFPL-UHFFFAOYSA-N 2H-imidazo[4,5-d][1,2]thiazole Chemical compound N1SC2=NC=NC2=C1 KWLMVXGOHGQFPL-UHFFFAOYSA-N 0.000 description 1
- NQFKGOQVVYYPJL-UHFFFAOYSA-N 2H-imidazo[4,5-d][1,3]oxazole Chemical compound C1=NC2=NCOC2=N1 NQFKGOQVVYYPJL-UHFFFAOYSA-N 0.000 description 1
- UMZCLZPXPCNKML-UHFFFAOYSA-N 2H-imidazo[4,5-d][1,3]thiazole Chemical compound C1=NC2=NCSC2=N1 UMZCLZPXPCNKML-UHFFFAOYSA-N 0.000 description 1
- BOXRDDIXJOUZLV-UHFFFAOYSA-N 2H-imidazo[4,5-d]thiadiazole Chemical compound N1SC2=NC=NC2=N1 BOXRDDIXJOUZLV-UHFFFAOYSA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- XNHQSBQAZFTNNU-UHFFFAOYSA-N 2H-pyrrolo[2,3-d][1,2]oxazole Chemical compound O1NC=C2N=CC=C21 XNHQSBQAZFTNNU-UHFFFAOYSA-N 0.000 description 1
- IYCIKRLAHGFBAC-UHFFFAOYSA-N 2H-pyrrolo[2,3-d][1,2]thiazole Chemical compound S1NC=C2N=CC=C21 IYCIKRLAHGFBAC-UHFFFAOYSA-N 0.000 description 1
- AJYRHXDJIOJMGS-UHFFFAOYSA-N 2H-pyrrolo[2,3-d][1,3]oxazole Chemical compound C1=NC2=NCOC2=C1 AJYRHXDJIOJMGS-UHFFFAOYSA-N 0.000 description 1
- GBJCWBWQIQXFLH-UHFFFAOYSA-N 2H-pyrrolo[2,3-d][1,3]thiazole Chemical compound C1=NC2=NCSC2=C1 GBJCWBWQIQXFLH-UHFFFAOYSA-N 0.000 description 1
- BQIAUWZKAHYGNU-UHFFFAOYSA-N 2H-pyrrolo[2,3-d]oxadiazole Chemical compound O1NN=C2N=CC=C21 BQIAUWZKAHYGNU-UHFFFAOYSA-N 0.000 description 1
- RZZFVKWGGPNTIW-UHFFFAOYSA-N 2H-pyrrolo[2,3-d]thiadiazole Chemical compound S1NN=C2N=CC=C21 RZZFVKWGGPNTIW-UHFFFAOYSA-N 0.000 description 1
- IYDCWWPOHIRIQG-UHFFFAOYSA-N 3-(3-hydroxyphenyl)benzonitrile Chemical compound OC1=CC=CC(C=2C=C(C=CC=2)C#N)=C1 IYDCWWPOHIRIQG-UHFFFAOYSA-N 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- WITJHZRCLVXYCA-UHFFFAOYSA-N 3H-1,2-benzodioxepine Chemical compound C1=CCOOC2=CC=CC=C21 WITJHZRCLVXYCA-UHFFFAOYSA-N 0.000 description 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
- WIAZPDPJRACUDP-UHFFFAOYSA-N 4-piperidin-4-ylbenzonitrile Chemical compound C1=CC(C#N)=CC=C1C1CCNCC1 WIAZPDPJRACUDP-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- DOAYWDKFDPSTSV-UHFFFAOYSA-N 5-Chloro-1,3-dihydro-1-(4-piperidinyl)-2H-benzimidazol-2-one Chemical compound O=C1NC2=CC(Cl)=CC=C2N1C1CCNCC1 DOAYWDKFDPSTSV-UHFFFAOYSA-N 0.000 description 1
- GFEFMHWOSWUJSO-UHFFFAOYSA-N 5-chloropyrazine-2-carboxamide Chemical compound NC(=O)C1=CN=C(Cl)C=N1 GFEFMHWOSWUJSO-UHFFFAOYSA-N 0.000 description 1
- MJQSRSOTRPMVKB-UHFFFAOYSA-N 5H-imidazo[4,5-c]pyridazine Chemical compound C1=NNC2=NC=NC2=C1 MJQSRSOTRPMVKB-UHFFFAOYSA-N 0.000 description 1
- IXXAYKKRCMMEBY-UHFFFAOYSA-N 5H-pyrazolo[3,4-d][1,3]oxazole Chemical compound N1=NC2=NCOC2=C1 IXXAYKKRCMMEBY-UHFFFAOYSA-N 0.000 description 1
- VHHWHDFVZGPKRT-UHFFFAOYSA-N 5H-pyrazolo[3,4-d][1,3]thiazole Chemical compound N1=NC2=NCSC2=C1 VHHWHDFVZGPKRT-UHFFFAOYSA-N 0.000 description 1
- MRMGJMGHPJZSAE-UHFFFAOYSA-N 6-fluoro-3-piperidin-4-yl-1,2-benzoxazole Chemical compound N=1OC2=CC(F)=CC=C2C=1C1CCNCC1 MRMGJMGHPJZSAE-UHFFFAOYSA-N 0.000 description 1
- 108060000400 ANGPTL8 Proteins 0.000 description 1
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 206010002023 Amyloidosis Diseases 0.000 description 1
- 206010002022 Amyloidosis Diseases 0.000 description 1
- 206010002556 Ankylosing spondylitis Diseases 0.000 description 1
- 206010002855 Anxiety Diseases 0.000 description 1
- 206010057666 Anxiety disease Diseases 0.000 description 1
- 206010059512 Apoptosis Diseases 0.000 description 1
- 208000006673 Asthma Diseases 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 206010003816 Autoimmune disease Diseases 0.000 description 1
- XYOVOXDWRFGKEX-UHFFFAOYSA-N Azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N Azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 208000009137 Behcet Syndrome Diseases 0.000 description 1
- 201000008335 Behcet's disease Diseases 0.000 description 1
- IANQTJSKSUMEQM-UHFFFAOYSA-N Benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 1
- IOJUPLGTWVMSFF-UHFFFAOYSA-N Benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 206010064913 Bronchial disease Diseases 0.000 description 1
- 206010006451 Bronchitis Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- VRJSRZDQTSVYIK-INIZCTEOSA-N C1=CC(F)=CC=C1C1=CC=CC(O[C@@H]2CN(CC2)C(=O)OC(C(F)(F)F)C(F)(F)F)=C1 Chemical compound C1=CC(F)=CC=C1C1=CC=CC(O[C@@H]2CN(CC2)C(=O)OC(C(F)(F)F)C(F)(F)F)=C1 VRJSRZDQTSVYIK-INIZCTEOSA-N 0.000 description 1
- VRJSRZDQTSVYIK-MRXNPFEDSA-N C1=CC(F)=CC=C1C1=CC=CC(O[C@H]2CN(CC2)C(=O)OC(C(F)(F)F)C(F)(F)F)=C1 Chemical compound C1=CC(F)=CC=C1C1=CC=CC(O[C@H]2CN(CC2)C(=O)OC(C(F)(F)F)C(F)(F)F)=C1 VRJSRZDQTSVYIK-MRXNPFEDSA-N 0.000 description 1
- KIGKPVYHOGOXME-KRWDZBQOSA-N C1N(C(=O)OC(C(F)(F)F)C(F)(F)F)CC[C@@H]1OC1=CC=CC(C=2C=C(C=CC=2)C#N)=C1 Chemical compound C1N(C(=O)OC(C(F)(F)F)C(F)(F)F)CC[C@@H]1OC1=CC=CC(C=2C=C(C=CC=2)C#N)=C1 KIGKPVYHOGOXME-KRWDZBQOSA-N 0.000 description 1
- KIGKPVYHOGOXME-QGZVFWFLSA-N C1N(C(=O)OC(C(F)(F)F)C(F)(F)F)CC[C@H]1OC1=CC=CC(C=2C=C(C=CC=2)C#N)=C1 Chemical compound C1N(C(=O)OC(C(F)(F)F)C(F)(F)F)CC[C@H]1OC1=CC=CC(C=2C=C(C=CC=2)C#N)=C1 KIGKPVYHOGOXME-QGZVFWFLSA-N 0.000 description 1
- ARYPKWFKYHTWAJ-UHFFFAOYSA-N COC1=C(C=CC=C1)S(=O)(=O)NCC1CCN(CC1)C(=O)OC(C(F)(F)F)C(F)(F)F Chemical compound COC1=C(C=CC=C1)S(=O)(=O)NCC1CCN(CC1)C(=O)OC(C(F)(F)F)C(F)(F)F ARYPKWFKYHTWAJ-UHFFFAOYSA-N 0.000 description 1
- KHZUKYIZGPSERM-UHFFFAOYSA-N CS(=O)(=O)C1=CC=C(C=C1)NCC1CCN(CC1)C(=O)OC(C(F)(F)F)C(F)(F)F Chemical compound CS(=O)(=O)C1=CC=C(C=C1)NCC1CCN(CC1)C(=O)OC(C(F)(F)F)C(F)(F)F KHZUKYIZGPSERM-UHFFFAOYSA-N 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 102000018208 Cannabinoid receptor family Human genes 0.000 description 1
- 108050007331 Cannabinoid receptor family Proteins 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N Carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 206010007521 Cardiac arrhythmias Diseases 0.000 description 1
- 210000001638 Cerebellum Anatomy 0.000 description 1
- 208000007451 Chronic Bronchitis Diseases 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N Cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- CIBKOTLZZIWKRC-UHFFFAOYSA-N ClC1=C(C=CC=C1)S(=O)(=O)NCC1CCN(CC1)C(=O)OC(C(F)(F)F)C(F)(F)F Chemical compound ClC1=C(C=CC=C1)S(=O)(=O)NCC1CCN(CC1)C(=O)OC(C(F)(F)F)C(F)(F)F CIBKOTLZZIWKRC-UHFFFAOYSA-N 0.000 description 1
- SKKQPEVWKGZMBJ-UHFFFAOYSA-M ClC1=CC=C(OC(C(=O)NCC2CCN(CC2)C(=O)[O-])(C)C)C=C1 Chemical compound ClC1=CC=C(OC(C(=O)NCC2CCN(CC2)C(=O)[O-])(C)C)C=C1 SKKQPEVWKGZMBJ-UHFFFAOYSA-M 0.000 description 1
- KRMKCVRAXYIIEH-UHFFFAOYSA-N ClC=1C(=C(C=CC1)S(=O)(=O)NCC1CCN(CC1)C(=O)OC(C(F)(F)F)C(F)(F)F)F Chemical compound ClC=1C(=C(C=CC1)S(=O)(=O)NCC1CCN(CC1)C(=O)OC(C(F)(F)F)C(F)(F)F)F KRMKCVRAXYIIEH-UHFFFAOYSA-N 0.000 description 1
- 208000008006 Collagen Disease Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 208000002573 Connective Tissue Disease Diseases 0.000 description 1
- 208000010247 Contact Dermatitis Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000004981 Coronary Disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 229960001681 Croscarmellose Sodium Drugs 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- 206010061428 Decreased appetite Diseases 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000001187 Dyskinesias Diseases 0.000 description 1
- 208000010118 Dystonia Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 206010014968 Ependymoma malignant Diseases 0.000 description 1
- VULTVGKEBUVXEM-UHFFFAOYSA-N FC(F)(F)C(OC(=O)N1CCCCC1CNS(=O)(=O)c1ccc(Cl)c(Cl)c1)C(F)(F)F Chemical compound FC(F)(F)C(OC(=O)N1CCCCC1CNS(=O)(=O)c1ccc(Cl)c(Cl)c1)C(F)(F)F VULTVGKEBUVXEM-UHFFFAOYSA-N 0.000 description 1
- WDFXJTJGYJCKEE-UHFFFAOYSA-M FC1=CC2=C(C(=NO2)C2CCN(CC2)C(=O)[O-])C=C1 Chemical compound FC1=CC2=C(C(=NO2)C2CCN(CC2)C(=O)[O-])C=C1 WDFXJTJGYJCKEE-UHFFFAOYSA-M 0.000 description 1
- HFVZRXWFXLPVHH-UHFFFAOYSA-N FC1=CC=C(C=C1)S(=O)(=O)NCC1CCN(CC1)C(=O)OC(C(F)(F)F)C(F)(F)F Chemical compound FC1=CC=C(C=C1)S(=O)(=O)NCC1CCN(CC1)C(=O)OC(C(F)(F)F)C(F)(F)F HFVZRXWFXLPVHH-UHFFFAOYSA-N 0.000 description 1
- 102100004504 GPR119 Human genes 0.000 description 1
- 101710030426 GPR119 Proteins 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 208000005017 Glioblastoma Diseases 0.000 description 1
- 201000001971 Huntington's disease Diseases 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N Indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
- 206010022114 Injury Diseases 0.000 description 1
- UXGVMFHEKMGWMA-UHFFFAOYSA-N Isobenzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
- AWJUIBRHMBBTKR-UHFFFAOYSA-N Isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N Isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 208000009883 Joint Disease Diseases 0.000 description 1
- 206010025135 Lupus erythematosus Diseases 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 210000001767 Medulla Oblongata Anatomy 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 206010027193 Meningioma malignant Diseases 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N Methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 206010027599 Migraine Diseases 0.000 description 1
- 208000008085 Migraine Disorders Diseases 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 208000010125 Myocardial Infarction Diseases 0.000 description 1
- 208000003067 Myocardial Ischemia Diseases 0.000 description 1
- GYRMPDLIHUXUIG-UHFFFAOYSA-N N-[4-(5-Nitro-2-furyl)-2-thiazolyl]acetamide Chemical compound S1C(NC(=O)C)=NC(C=2OC(=CC=2)[N+]([O-])=O)=C1 GYRMPDLIHUXUIG-UHFFFAOYSA-N 0.000 description 1
- CPGWSLFYXMRNDV-UHFFFAOYSA-N N-methyl-N-phenylcarbamoyl chloride Chemical compound ClC(=O)N(C)C1=CC=CC=C1 CPGWSLFYXMRNDV-UHFFFAOYSA-N 0.000 description 1
- LJWZSXDLNMOUIP-UHFFFAOYSA-N N1C=CN=C2N=CC=C21 Chemical compound N1C=CN=C2N=CC=C21 LJWZSXDLNMOUIP-UHFFFAOYSA-N 0.000 description 1
- KCTZOTUQSGYWLV-UHFFFAOYSA-N N1C=NC=C2N=CC=C21 Chemical compound N1C=NC=C2N=CC=C21 KCTZOTUQSGYWLV-UHFFFAOYSA-N 0.000 description 1
- YTJAMOLQXDNLJC-UHFFFAOYSA-N N1N=CC=C2N=CC=C21 Chemical compound N1N=CC=C2N=CC=C21 YTJAMOLQXDNLJC-UHFFFAOYSA-N 0.000 description 1
- SHCRKMNTWSCEBT-UHFFFAOYSA-N N1N=NC=C2N=CC=C21 Chemical compound N1N=NC=C2N=CC=C21 SHCRKMNTWSCEBT-UHFFFAOYSA-N 0.000 description 1
- DNYFBUNUHRCABQ-UHFFFAOYSA-N N1OC2=CN=NC2=C1 Chemical compound N1OC2=CN=NC2=C1 DNYFBUNUHRCABQ-UHFFFAOYSA-N 0.000 description 1
- NIQIXYTVAJNCRB-UHFFFAOYSA-N N1SC2=CN=NC2=C1 Chemical compound N1SC2=CN=NC2=C1 NIQIXYTVAJNCRB-UHFFFAOYSA-N 0.000 description 1
- 206010029098 Neoplasm skin Diseases 0.000 description 1
- 208000007538 Neurilemmoma Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010029331 Neuropathy peripheral Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030043 Ocular hypertension Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 208000003154 Papilloma Diseases 0.000 description 1
- 206010061536 Parkinson's disease Diseases 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N Phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 210000002307 Prostate Anatomy 0.000 description 1
- 206010061920 Psychotic disease Diseases 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N Pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N Pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N Quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- XSCHRSMBECNVNS-UHFFFAOYSA-N Quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 1
- 101710030983 RNF138 Proteins 0.000 description 1
- 210000003994 Retinal Ganglion Cells Anatomy 0.000 description 1
- 206010039083 Rhinitis Diseases 0.000 description 1
- VASSYPAICMPZTK-UHFFFAOYSA-M S(N)(=O)(=O)C1=CC=C(C=C1)NCC1CCN(CC1)C(=O)[O-] Chemical compound S(N)(=O)(=O)C1=CC=C(C=C1)NCC1CCN(CC1)C(=O)[O-] VASSYPAICMPZTK-UHFFFAOYSA-M 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 206010040767 Sjogren's syndrome Diseases 0.000 description 1
- 206010040979 Sleep apnoea syndrome Diseases 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N Sulfuryl chloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 101710029702 TICAM1 Proteins 0.000 description 1
- 101710021425 TRIM69 Proteins 0.000 description 1
- 102100003447 TRIM69 Human genes 0.000 description 1
- UWYZHKAOTLEWKK-UHFFFAOYSA-N Tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N Thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 206010044126 Tourette's disease Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- OVCXRBARSPBVMC-UHFFFAOYSA-N Triazolopyridine Chemical compound C=1N2C(C(C)C)=NN=C2C=CC=1C=1OC=NC=1C1=CC=C(F)C=C1 OVCXRBARSPBVMC-UHFFFAOYSA-N 0.000 description 1
- 206010068760 Ulcers Diseases 0.000 description 1
- JIUVDHALDWHJGU-UHFFFAOYSA-N [1,2]oxazolo[3,4-b]pyrazine Chemical compound N1=CC=NC2=CON=C21 JIUVDHALDWHJGU-UHFFFAOYSA-N 0.000 description 1
- BEQNKKAVZBNTRA-UHFFFAOYSA-N [1,2]oxazolo[3,4-d][1,2]oxazole Chemical compound O1N=C2C=NOC2=C1 BEQNKKAVZBNTRA-UHFFFAOYSA-N 0.000 description 1
- JOSPSPSUEXCXQA-UHFFFAOYSA-N [1,2]oxazolo[3,4-d]thiadiazole Chemical compound N1=NSC2=CON=C21 JOSPSPSUEXCXQA-UHFFFAOYSA-N 0.000 description 1
- NABZXASCLFSKLF-UHFFFAOYSA-N [1,2]oxazolo[4,3-b]pyridine Chemical compound C1=CC=NC2=CON=C21 NABZXASCLFSKLF-UHFFFAOYSA-N 0.000 description 1
- LUNHCIBEAIKLQJ-UHFFFAOYSA-N [1,2]oxazolo[4,3-c]pyridazine Chemical compound C1=CN=NC2=CON=C21 LUNHCIBEAIKLQJ-UHFFFAOYSA-N 0.000 description 1
- COGLFIODYRINPZ-UHFFFAOYSA-N [1,2]oxazolo[4,3-d]pyrimidine Chemical compound C1=NC=NC2=CON=C21 COGLFIODYRINPZ-UHFFFAOYSA-N 0.000 description 1
- MBKUOPNOYAVQPZ-UHFFFAOYSA-N [1,2]thiazolo[3,4-b]pyrazine Chemical compound N1=CC=NC2=CSN=C21 MBKUOPNOYAVQPZ-UHFFFAOYSA-N 0.000 description 1
- ISEFIGBTZQDSPY-UHFFFAOYSA-N [1,2]thiazolo[3,4-d]thiadiazole Chemical compound N1=NSC2=CSN=C21 ISEFIGBTZQDSPY-UHFFFAOYSA-N 0.000 description 1
- YJMPFOXUBAJFFA-UHFFFAOYSA-N [1,2]thiazolo[4,3-b]pyridine Chemical compound C1=CC=NC2=CSN=C21 YJMPFOXUBAJFFA-UHFFFAOYSA-N 0.000 description 1
- NXAFKXVMNVWYOF-UHFFFAOYSA-N [1,2]thiazolo[4,3-c]pyridazine Chemical compound C1=CN=NC2=CSN=C21 NXAFKXVMNVWYOF-UHFFFAOYSA-N 0.000 description 1
- MHIJLPSBYNTMDQ-UHFFFAOYSA-N [1,2]thiazolo[4,3-d]pyrimidine Chemical compound C1=NC=NC2=CSN=C21 MHIJLPSBYNTMDQ-UHFFFAOYSA-N 0.000 description 1
- AUTFWYBPTBBTOI-UHFFFAOYSA-N [1,2]thiazolo[4,5-c][1,2]oxazole Chemical compound O1N=C2C=NSC2=C1 AUTFWYBPTBBTOI-UHFFFAOYSA-N 0.000 description 1
- TWCSETUPLNCXFA-UHFFFAOYSA-N [1,2]thiazolo[4,5-d][1,3]oxazole Chemical compound C1=NSC2=C1N=CO2 TWCSETUPLNCXFA-UHFFFAOYSA-N 0.000 description 1
- PUZFXDRHCPIYCB-UHFFFAOYSA-N [1,3]oxazolo[4,5-b]pyrazine Chemical compound C1=CN=C2OC=NC2=N1 PUZFXDRHCPIYCB-UHFFFAOYSA-N 0.000 description 1
- UCHFVNUOUXPCEQ-UHFFFAOYSA-N [1,3]oxazolo[4,5-d][1,2]oxazole Chemical compound C1=NOC2=C1N=CO2 UCHFVNUOUXPCEQ-UHFFFAOYSA-N 0.000 description 1
- DJDHQDKIRMXSMW-UHFFFAOYSA-N [1,3]oxazolo[4,5-d][1,3]oxazole Chemical compound N1=COC2=C1N=CO2 DJDHQDKIRMXSMW-UHFFFAOYSA-N 0.000 description 1
- JYIZRDSHRYOVGE-UHFFFAOYSA-N [1,3]oxazolo[4,5-d]thiadiazole Chemical compound N1=NSC2=C1N=CO2 JYIZRDSHRYOVGE-UHFFFAOYSA-N 0.000 description 1
- BFPLMTPHDFFMTG-UHFFFAOYSA-N [1,3]oxazolo[5,4-b]pyridine Chemical compound C1=CN=C2OC=NC2=C1 BFPLMTPHDFFMTG-UHFFFAOYSA-N 0.000 description 1
- FVFBQHPTVOZLNI-UHFFFAOYSA-N [1,3]oxazolo[5,4-c]pyridazine Chemical compound C1=NN=C2OC=NC2=C1 FVFBQHPTVOZLNI-UHFFFAOYSA-N 0.000 description 1
- BRIOKNPDCPJCOD-UHFFFAOYSA-N [1,3]oxazolo[5,4-d]pyrimidine Chemical compound N1=CN=C2OC=NC2=C1 BRIOKNPDCPJCOD-UHFFFAOYSA-N 0.000 description 1
- OJADJQCOHXOBDN-UHFFFAOYSA-N [1,3]thiazolo[4,5-d][1,3]oxazole Chemical compound N1=CSC2=C1N=CO2 OJADJQCOHXOBDN-UHFFFAOYSA-N 0.000 description 1
- WFIHKLWVLPBMIQ-UHFFFAOYSA-N [1,3]thiazolo[5,4-b]pyridine Chemical compound C1=CN=C2SC=NC2=C1 WFIHKLWVLPBMIQ-UHFFFAOYSA-N 0.000 description 1
- IQPQWNKOIGAROB-UHFFFAOYSA-N [N-]=C=O Chemical compound [N-]=C=O IQPQWNKOIGAROB-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 201000005476 astroblastoma Diseases 0.000 description 1
- 201000001320 atherosclerosis Diseases 0.000 description 1
- 125000004429 atoms Chemical group 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- CKDWPUIZGOQOOM-UHFFFAOYSA-N carbamoyl chloride Chemical compound NC(Cl)=O CKDWPUIZGOQOOM-UHFFFAOYSA-N 0.000 description 1
- AOGYCOYQMAVAFD-UHFFFAOYSA-M carbonochloridate Chemical compound [O-]C(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-M 0.000 description 1
- 210000004027 cells Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 231100000080 dermatitis contact Toxicity 0.000 description 1
- 201000008286 diarrhea Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000002621 endocannabinoid Substances 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- 201000008228 ependymoblastoma Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 125000005469 ethylenyl group Chemical group 0.000 description 1
- 230000001747 exhibiting Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N furane Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- YRTCKZIKGWZNCU-UHFFFAOYSA-N furo[3,2-b]pyridine Chemical compound C1=CC=C2OC=CC2=N1 YRTCKZIKGWZNCU-UHFFFAOYSA-N 0.000 description 1
- JUQAECQBUNODQP-UHFFFAOYSA-N furo[3,2-d]pyrimidine Chemical compound C1=NC=C2OC=CC2=N1 JUQAECQBUNODQP-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- CYCBAKHQLAYYHQ-UHFFFAOYSA-N imidazo[4,5-c]pyrazole Chemical compound N1=NC2=NC=NC2=C1 CYCBAKHQLAYYHQ-UHFFFAOYSA-N 0.000 description 1
- CQQJSOXDEFZGFG-UHFFFAOYSA-N imidazo[4,5-d]imidazole Chemical compound C1=NC2=NC=NC2=N1 CQQJSOXDEFZGFG-UHFFFAOYSA-N 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- YAMHXTCMCPHKLN-UHFFFAOYSA-N imidazolidin-2-one Chemical compound O=C1NCCN1 YAMHXTCMCPHKLN-UHFFFAOYSA-N 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000002757 inflammatory Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000000968 intestinal Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 201000008203 medulloepithelioma Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 201000009906 meningitis Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 125000006431 methyl cyclopropyl group Chemical group 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 201000008895 mood disease Diseases 0.000 description 1
- VSEAAEQOQBMPQF-UHFFFAOYSA-N morpholin-3-one Chemical compound O=C1COCCN1 VSEAAEQOQBMPQF-UHFFFAOYSA-N 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- 229940113083 morpholine Drugs 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- DASJFYAPNPUBGG-UHFFFAOYSA-N naphthalene-1-sulfonyl chloride Chemical compound C1=CC=C2C(S(=O)(=O)Cl)=CC=CC2=C1 DASJFYAPNPUBGG-UHFFFAOYSA-N 0.000 description 1
- 230000001272 neurogenic Effects 0.000 description 1
- 150000002829 nitrogen Chemical group 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000000414 obstructive Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 201000010133 oligodendroglioma Diseases 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- RWXCVESEMJNNMF-UHFFFAOYSA-N oxadiazolo[5,4-b]pyridine Chemical compound C1=CN=C2ON=NC2=C1 RWXCVESEMJNNMF-UHFFFAOYSA-N 0.000 description 1
- HIYBICWLLTWQND-UHFFFAOYSA-N oxathiazinane 2,2-dioxide Chemical compound O=S1(=O)NCCCO1 HIYBICWLLTWQND-UHFFFAOYSA-N 0.000 description 1
- MBACRDZWRXWNMY-UHFFFAOYSA-N oxathiazolidine 2,2-dioxide Chemical compound O=S1(=O)NCCO1 MBACRDZWRXWNMY-UHFFFAOYSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- CWPIBZMCMRNFHK-UHFFFAOYSA-N piperazin-1-ium;carbamate Chemical class NC(O)=O.C1CNCCN1 CWPIBZMCMRNFHK-UHFFFAOYSA-N 0.000 description 1
- IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical compound O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- AAZYNPCMLRQUHI-UHFFFAOYSA-N propan-2-one;2-propan-2-yloxypropane Chemical compound CC(C)=O.CC(C)OC(C)C AAZYNPCMLRQUHI-UHFFFAOYSA-N 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (NE)-N-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- 230000000069 prophylaxis Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005470 propylenyl group Chemical group 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 201000004681 psoriasis Diseases 0.000 description 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- FQOBINBWTPHVEO-UHFFFAOYSA-N pyrazino[2,3-b]pyrazine Chemical compound N1=CC=NC2=NC=CN=C21 FQOBINBWTPHVEO-UHFFFAOYSA-N 0.000 description 1
- OUFHXMSGJIYFPW-UHFFFAOYSA-N pyrazino[2,3-c]pyridazine Chemical compound N1=NC=CC2=NC=CN=C21 OUFHXMSGJIYFPW-UHFFFAOYSA-N 0.000 description 1
- ARYJURLFRJCKLP-UHFFFAOYSA-N pyrazino[2,3-d]triazine Chemical compound N1=NN=CC2=NC=CN=C21 ARYJURLFRJCKLP-UHFFFAOYSA-N 0.000 description 1
- CEBCCVFQNCQQBO-UHFFFAOYSA-N pyridazino[4,3-c]pyridazine Chemical compound N1=CC=C2N=NC=CC2=N1 CEBCCVFQNCQQBO-UHFFFAOYSA-N 0.000 description 1
- YEYHFKBVNARCNE-UHFFFAOYSA-N pyrido[2,3-b]pyrazine Chemical compound N1=CC=NC2=CC=CN=C21 YEYHFKBVNARCNE-UHFFFAOYSA-N 0.000 description 1
- OHZYAOYVLLHTGW-UHFFFAOYSA-N pyrido[3,2-c]pyridazine Chemical compound C1=CN=NC2=CC=CN=C21 OHZYAOYVLLHTGW-UHFFFAOYSA-N 0.000 description 1
- BWESROVQGZSBRX-UHFFFAOYSA-N pyrido[3,2-d]pyrimidine Chemical compound C1=NC=NC2=CC=CN=C21 BWESROVQGZSBRX-UHFFFAOYSA-N 0.000 description 1
- HHQDNOXLJMIISM-UHFFFAOYSA-N pyrido[3,2-d]triazine Chemical compound C1=NN=NC2=CC=CN=C21 HHQDNOXLJMIISM-UHFFFAOYSA-N 0.000 description 1
- ATVQBGCKUAGPDN-UHFFFAOYSA-N pyrimido[5,4-c]pyridazine Chemical compound C1=NC=C2N=NC=CC2=N1 ATVQBGCKUAGPDN-UHFFFAOYSA-N 0.000 description 1
- JOZPEVMCAKXSEY-UHFFFAOYSA-N pyrimido[5,4-d]pyrimidine Chemical compound N1=CN=CC2=NC=NC=C21 JOZPEVMCAKXSEY-UHFFFAOYSA-N 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- MHOZZUICEDXVGD-UHFFFAOYSA-N pyrrolo[2,3-d]imidazole Chemical compound C1=NC2=CC=NC2=N1 MHOZZUICEDXVGD-UHFFFAOYSA-N 0.000 description 1
- QEIQICVPDMCDHG-UHFFFAOYSA-N pyrrolo[2,3-d]triazole Chemical compound N1=NC2=CC=NC2=N1 QEIQICVPDMCDHG-UHFFFAOYSA-N 0.000 description 1
- RQGPLDBZHMVWCH-UHFFFAOYSA-N pyrrolo[3,2-b]pyrrole Chemical compound C1=NC2=CC=NC2=C1 RQGPLDBZHMVWCH-UHFFFAOYSA-N 0.000 description 1
- GZTPJDLYPMPRDF-UHFFFAOYSA-N pyrrolo[3,2-c]pyrazole Chemical compound N1=NC2=CC=NC2=C1 GZTPJDLYPMPRDF-UHFFFAOYSA-N 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 230000000717 retained Effects 0.000 description 1
- 201000003774 sarcomatosis Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- FJCJSDUSBBJXJK-UHFFFAOYSA-N tert-butyl 3-[1-[(4-chlorophenyl)sulfonylamino]cyclopropyl]azetidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC1C1(NS(=O)(=O)C=2C=CC(Cl)=CC=2)CC1 FJCJSDUSBBJXJK-UHFFFAOYSA-N 0.000 description 1
- LBQDLHPFISVBRU-UHFFFAOYSA-N tert-butyl 4-(2-aminoethyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CCN)CC1 LBQDLHPFISVBRU-UHFFFAOYSA-N 0.000 description 1
- KLKBCNDBOVRQIJ-UHFFFAOYSA-N tert-butyl 4-(aminomethyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CN)CC1 KLKBCNDBOVRQIJ-UHFFFAOYSA-N 0.000 description 1
- CQIMWWOVGCOHBI-UHFFFAOYSA-N tert-butyl 4-[(4-carbamoylpyrazol-1-yl)methyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1CN1N=CC(C(N)=O)=C1 CQIMWWOVGCOHBI-UHFFFAOYSA-N 0.000 description 1
- ICTGFNSVOOQLIO-UHFFFAOYSA-N tert-butyl 4-[2-[(5-carbamoylpyrazin-2-yl)amino]ethyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1CCNC1=CN=C(C(N)=O)C=N1 ICTGFNSVOOQLIO-UHFFFAOYSA-N 0.000 description 1
- GCEWRKATIPFVGW-UHFFFAOYSA-N tert-butyl 4-[3-(3-cyanophenyl)phenoxy]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=CC=CC(C=2C=C(C=CC=2)C#N)=C1 GCEWRKATIPFVGW-UHFFFAOYSA-N 0.000 description 1
- XQNSBUGVNNBXJV-UHFFFAOYSA-N tert-butyl 4-[[(4-chlorophenyl)sulfonylamino]methyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1CNS(=O)(=O)C1=CC=C(Cl)C=C1 XQNSBUGVNNBXJV-UHFFFAOYSA-N 0.000 description 1
- DJQLEEANCWENKG-UHFFFAOYSA-N tert-butyl 4-[[4-(4-bromo-2-fluoroanilino)-6-methoxyquinazolin-7-yl]oxymethyl]piperidine-1-carboxylate Chemical compound N1=CN=C2C=C(OCC3CCN(CC3)C(=O)OC(C)(C)C)C(OC)=CC2=C1NC1=CC=C(Br)C=C1F DJQLEEANCWENKG-UHFFFAOYSA-N 0.000 description 1
- WIEJVMZWPIUWHO-UHFFFAOYSA-N tert-butyl N-(pyrrolidin-3-ylmethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCC1CCNC1 WIEJVMZWPIUWHO-UHFFFAOYSA-N 0.000 description 1
- CSPJUZSNJFANNU-UHFFFAOYSA-N tert-butyl N-[2-(azetidin-3-yl)ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCC1CNC1 CSPJUZSNJFANNU-UHFFFAOYSA-N 0.000 description 1
- CKXZPVPIDOJLLM-UHFFFAOYSA-N tert-butyl N-piperidin-4-ylcarbamate Chemical compound CC(C)(C)OC(=O)NC1CCNCC1 CKXZPVPIDOJLLM-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- QKTRRACPJVYJNU-UHFFFAOYSA-N thiadiazolo[5,4-b]pyridine Chemical compound C1=CN=C2SN=NC2=C1 QKTRRACPJVYJNU-UHFFFAOYSA-N 0.000 description 1
- PWVGMQFTWJTCNG-UHFFFAOYSA-N thiadiazolo[5,4-d]pyrimidine Chemical compound C1=NC=C2N=NSC2=N1 PWVGMQFTWJTCNG-UHFFFAOYSA-N 0.000 description 1
- GNPXXOFTVXIOLF-UHFFFAOYSA-N thiazetidine 1,1-dioxide Chemical compound O=S1(=O)CCN1 GNPXXOFTVXIOLF-UHFFFAOYSA-N 0.000 description 1
- DNGMYXZLJGHHOM-UHFFFAOYSA-N thiazinane 1,1-dioxide Chemical compound O=S1(=O)CCCCN1 DNGMYXZLJGHHOM-UHFFFAOYSA-N 0.000 description 1
- 125000004495 thiazol-4-yl group Chemical group S1C=NC(=C1)* 0.000 description 1
- 150000008634 thiazolopyrimidines Chemical class 0.000 description 1
- VJYJJHQEVLEOFL-UHFFFAOYSA-N thieno[3,2-b]thiophene Chemical compound S1C=CC2=C1C=CS2 VJYJJHQEVLEOFL-UHFFFAOYSA-N 0.000 description 1
- RBNBDIMXFJYDLQ-UHFFFAOYSA-N thieno[3,2-d]pyrimidine Chemical compound C1=NC=C2SC=CC2=N1 RBNBDIMXFJYDLQ-UHFFFAOYSA-N 0.000 description 1
- 239000002175 thienopyridine Substances 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- BSUNTQCMCCQSQH-UHFFFAOYSA-N triazine Chemical compound C1=CN=NN=C1.C1=CN=NN=C1 BSUNTQCMCCQSQH-UHFFFAOYSA-N 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 238000004450 types of analysis Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- MNFORVFSTILPAW-UHFFFAOYSA-N Β-Lactam Chemical compound O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 description 1
Abstract
The invention relates to hexafluoroisopropyl
carbamate derivatives of general formula (I):
Description
The présent invention relates to hexafluoroisopropyl carbamate dérivatives, to their préparation and to their therapeutic application. These compounds hâve an inhibitory activity with regard to the enzyme MGL (monoacyl glycerol lipase).
WO 2009141238 and WO 2010009207 disclose GPR119 receptor agonists which can comprise a hexafluoroisopropyl carbamate.
« Characterization of the Tunable Piperidine and Piperazine Carbamates as Inhibitors of Endocannabinoid Hydrolases » (J.Z. Long, X Jin, A. Adibekian, W.Li et al.) describes inhibitors of the enzyme MGL exhibiting an N-piperidine ring carrying a carbamate.
WO 2009/052319 discloses other types of compounds which are inhibitors of the enzyme MGL
A subject-matter of the invention is the compounds of formula (I):
(') R-Zin which:
R représente an R1 group optionally substituted by one or more R2 and/or R3 groups;
R1 représente an aryl or heteroaryl group;
R2 represents a halogen atom or a cyano, nitro, oxo, (Ci-C6)alkyl, (Ci-C6)alkoxy, hydroxyl, (C1-C6)alkylthio, (CrC6)haloalkyl, (Ci-C6)haloalkoxy, (CrCe^aloalkylthio, NR4R5, NR4COR5, NR4SO2R5, COR4, CO2R4, CONR4R5, SO2R4, SO2NR4R5, phenyloxy or benzyloxy group;
R3 represents a monocyclic aryl or heteroaryl group which can be substituted by one or more R2 groups which are identical to or different from one another;
R4 and R5 represent, independently of one another, a hydrogen atom or a (Ci-C6)alkyl group or form, with the nitrogen atom or the N-CO or N-SO2 fragment which
Λ J.
carries them, a heterocycle optionally substituted by a (C-|-C6)alkyl or benzyl group;
Z représente a bond, a (CrC6)alkylene group, a (C2-C6)alkenylene group, a (C2-C6)alkynylene group, an O-(Ci-C6)alkylene group or an N(RA)-(Ci-C6)alkylene group;
A représente a bond, an oxygen atom, a sulphur atom, an N(RA) group, an N(RA)(CrC6)alkylene group, a CON(RA) group, a CON(RA)-(CrC6)alkylene group, an SO2N(RA) group, an SO2N(RA)-(C-|-C6)alkylene group, an OCON(RA) group, an OCON(RA)-(Cr C6)alkylene group, an N(RB)CON(RA) group, an N(RB)CON(RA)-(CrC6)alkylene group, an N(Rb)SO2N(Ra) group, an N(RB)SO2N(RA)-(CrC6)alkylene group, an O-(Ci-C6)alkylene group, an N(RB)CO2 group, an N(RB)CO2-(C-i-C6)alkylene group, an S-(CrC6)alkylene group, an SO2 group, an SO2-(C1-C6)alkylene group, an N(RB)SO2 group, an N(RB)SO2(C-i-C6)alkylene group, a CO group, a CO-(C-i-C6)alkylene group, an N(RB)CO group, an N(RB)CO-(Ci-C6)alkylene group, an SO2N(RB)CO group, an SO2N(RB)CO(CrC6)alkylene group, an SO2N(RB)CON(RA) group or an SO2N(RB)CON(RA)~ (C-i-C6)alkylene group;
Ra and Rb represent, independently of one another, a hydrogen atom or a (Ci-C6)alkyl group;
m and n represent, independently of one another, an integer equal to 0 or 1, in the form of the base or of an addition sait with an acid.
The compounds of formula (I) can comprise one or more asymmetric carbon atoms. They can thus exist in the form of enantiomers or diastereoisomers. These enantiomers, diastereoisomers and their mixtures, including racemic mixtures, corne within the invention.
The compounds of formula (I) can exist in the form of bases or of addition salts with acids. Such addition salts corne within the invention.
These salts can be prepared with pharmaceutically acceptable acids but the salts of other acids, for example of use in the purification or the isolation of the compounds of formula (I), also corne within the invention.
In the context of the présent invention:
- CrCz, where t and z can take their values from 1 to 7, is understood to mean a
Λ J carbon chain or ring which can hâve from t to z carbon atoms; for example, C1-C3 can characterize a carbon chain having from 1 to 3 carbon atoms;
- a halogen is understood to mean a fluorine, a chlorine, a bromine or an iodine;
- an alkyl group is understood to mean a saturated, linear, branched or cyclized, aliphatic group optionally substituted by a saturated, linear, branched or cyclized, alkyl group. Mention may be made, by way of examples, of the methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, methylcyclopropyl and cyclopropylmethyl groups, and the like;
- an alkylene group is understood to mean a saturated, linear, branched or cyclized, divalent aliphatic group. By way of example, a (Ci-C6)alkylene group représente a linear, branched or cyclized divalent carbon chain of 1 to 6 carbon atoms, such as a methylenyl (-CH2-), an ethylenyl (-CH2CH2-), θ 1-methylethylenyl (-CH(CH3)CH2-), a propylenyl (-CH2CH2CH2-), a cyclopropylenyl (-(c-prop)), and the like;
- an alkenyl group is understood to mean a mono- or polyunsaturated, linear or branched, aliphatic group comprising, for example, one ortwo ethylenical unsaturations;
- an alkynyl group is understood to mean a mono- or polyunsaturated, linear or branched, aliphatic group comprising, for example, one ortwo ethynylic unsaturations;
- an alkoxy group is understood to mean an -O-alkyl radical where the alkyl group is as defined above;
- an alkylthio group is understood to mean an -S-alkyl radical where the alkyl group is as defined above;
- a haloalkyl group is understood to mean an alkyl group, one or more hydrogen atoms of which hâve been replaced by one or more identical or different halogen atoms. Mention may be made, by way of examples, of the CF3, CH2CF3, CHF2 and CCI3 groups;
- a halo(C-i-C6)alkoxy is understood to mean an -O-alkyl radical where the alkyl group is as defined above and which is substituted by one or more identical or different halogen atoms. Mention may be made, by way of examples, of the -OCF3, -OCHF2 and -OCCI3 groups;
- an aryl group is understood to mean an aromatic cyclic group comprising between 6 and 10 carbon atoms. Mention may be made, as examples of the aryl groups, of phenyl or naphthyl; this aryl group can also exist in the partially unsaturated form; mention may be made, as examples, of an indenyl, indanyl ortetralinyl group;
- a heteroaryl group is understood to mean a mono- or bicyclic group comprising from 5 to 10 atoms, including from 1 to 5 heteroatoms chosen from N, O and S, this group being aromatic, unsaturated or partially unsaturated or partially oxidized. Mention may be made, as examples of monocyclic heteroaryl groups, of: pyrrole, furan, thiophene, pyrazole, imidazoie, triazole, tetrazole, oxazole, isoxazole, oxadiazole, > } thiazole, isothiazole, thiadiazole, pyridine, pyrimidine, pyrazine, pyridazine or triazine. Mention may be made, as examples of bicyclic heteroaryl groups, of furofuran, thienothiophene, pyrrolopyrrole, pyrroloimidazole, pyrrolopyrazole, pyrrolotriazole, imidazoimidazole, imidazopyrazole, furopyrrole, furoimidazole, furopyrazole, furotriazole, pyrrolooxazole, imidazooxazole, pyrazolooxazole, furooxazole, oxazolooxazole, oxazoloisoxazole, pyrroloisoxazole, imidazoisoxazole, pyrazoloisoxazole, isoxazoloisoxazole, furoisoxazole, isoxazolooxadiazole, pyrrolooxadiazole, furooxadiazole, isoxazolooxadiazole, thienopyrrole, thienoimidazole, thienopyrazole, thienotriazole, pyrrolothiazole, imidazothiazole, pyrazolothiazole, triazolothiazole, furothiazole, oxazolothiazole, oxazoloisothiazole, pyrroloisothiazole, imidazoisothiazole, pyrazoloisothiazole, isoxazoloisothiazole, furoisothiazole, pyrrolothiadiazole, imidazothiadiazole, furothiadiazole, isoxazolothiadiazole, oxazolothiadiazole, isothiazolothiadiazole, indole, isoindole, benzimidazole, indazole, indolizine, benzofuran, isobenzofuran, benzothiophene, pyrrolopyridine, imidazopyridine, pyrazolopyridine, triazolopyridine, pyrazolopyrimidine, pyrrolopyridazine, tetrazolopyridine, pyrrolopyrazine, imidazopyridazine, pyrrolopyrimidine, imidazopyrazine, pyrazolopyridazine, imidazopyrimidine, pyrazolopyrazine, triazolopyridazine, pyrrolotriazine, furopyridine, furopyrimidine, furopyrazine, furopyridazine, furotriazine, oxazolopyridine, oxazolopyrimidine, oxazolopyrazine, oxazolopyridazine, isoxazolopyridine, isoxazolopyrimidine, isoxazolopyrazine, isoxazolopyridazine, oxadiazolopyridine, benzoxazole, benzisoxazole, benzoxadiazole, benzoxazine, benzodioxole, benzodioxine, benzodioxepine, thienopyridine, thienopyrimidine, thienopyrazine, thienopyridazine, thienotriazine, thiazolopyridine, thiazolopyrimidine, thiazolopyrazine, thiazolopyridazine, isothiazolopyridine, isothiazolopyrimidine, isothiazolopyrazine, isothiazolopyridazine, thiadiazolopyridine, thiadiazolopyrimidine, benzothiazole, benzisothiazole, benzothiadiazole, quinoline, isoquinoline, cinnoline, phthalazine, quinoxaline, quinazoline, naphthyridine, benzotriazine, pyridopyrimidine, pyridopyrazine, pyridopyridazine, pyridotriazine, pyrimidopyrimidine, pyrimidopyrazine, pyrimidopyridazine, pyrazinopyrazine, pyrazinopyridazine, pyrazinotriazine or pyridazinopyridazine.
These groups can exist in the unsaturated or partially unsaturated form; mention may be made, by way of examples, of: dihydrobenzofuran, dihydrobenzothiophene, tetrahydroquinoline, tetrahydroisoquinoline, indoline, dihydrobenzoxazine or dihydrobenzodioxane.
- a heterocycle group is understood to mean a saturated 3- to 7-membered cyclic group comprising from 1 to 4 heteroatoms chosen from N, O and S. Mention may be made, by way of examples, of the pyrrolidine, piperidine, morpholine, piperazine,
J. J aziridine, azetidine, azepine, thiomorpholine, N-methylpiperazine, homopiperazine, azetidin-2-one, 1,2-thiazetidine 1,1-dioxide, pyrrolidin-2-one, 1,2-isothiazolidine 1,1dioxide, piperidin-2-one, 1,2-thiazinane 1,1-dioxide, imidazolidin-2-one, oxazolidin-2-one, 1,2,5-thiadiazolidine 1,1-dioxide, 1,2,3-oxathiazolidine 2,2-dioxide, tetrahydropyrimidin-2one, 1,3-oxazinan-2-one, 1,2,6-thiadiazinane 1,1-dioxide, 1,2,3-oxathiazinane 2,2dioxide, piperazin-2-one, morpholin-3-one, 1,2,5-thiadiazinane 1,1-dioxide or 1,3,4oxathiazinane 3,3-dioxide groups.
In the context of the présent invention, the R, Z and A groups are read from left to right; the left part of the Z group is connected to the R group and the right part of Z is connected to the A group; likewise, the left part of the A group is connected to the Z group and the right part of A is connected to the ring System:
In the various groups as defined below, the A, Z, R, RA, RB, R1, R2 or R3 groups, when they are not defined, hâve the same définitions as those mentioned above.
Among the compounds of formula (I) which are subject-matters of the invention, a first group of compounds is composed of the compounds for which:
R1 represents a phenyl, naphthyl, indanyl, benzoxazole, benzisoxazole, benzimidazole, benzotriazole, oxadiazole, indazole, isoxazole, pyridine, pyrazine, pyrimidine, thienyl, thiazole, benzothiophene, indole, dihydrobenzodioxane, benzothiadiazole, pyrazole, dihydrobenzoxazine or indoline group;
R2 represents one or more groups chosen from a halogen atom or a methyl, trifluoromethyl, methoxy, trifluoromethoxy, cyano, oxo, CH3NHCO, CH3SO2, NH2CO, NH2SO2 or pyrrolidine-SO2 group;
R3 represents a group chosen from a phenyl or an oxazole;
and also the compound 2,2,2-trifluoro-1-(trifluoromethyl)ethyl 4-{[3-(2-methylpyrimidin-4yl)benzenesulphonylamino]methyl}piperidine-1-carboxylate.
Among the compounds of formula (I) which are subject-matter of the invention, a second group of compounds is composed of the compounds of formula (l)for which:
Z represents a bond or a CH2, (CH2)2, CH=CH, OC, OCH2 orOC(CH3)2 group.
J» X
Among the compouns of formula (I) which are subject-matter of the invention, a third group of compounds is composed of the compounds of formula (I) for which:
A represents a bond, an oxygen atom, a sulphur atom, an OCH2 group, an O(CH2)2 group, an NH, NHCH2 or NH(CH2)2 group, an SO2or CO group, a CONH group, a CONHCH2 or CONH(CH2)2 group, an SO2NH group, an SO2NHCH2 or SO2NH(CH2)2 group, an SO2NHCO, SO2NHCONH or SO2NHCONHCH2 group, an OCONH group, an NHCONH group, an NHCONHCH2 group, an N(CH3)CONHCH2, NHCONH(CH2)2 or N(CH3)CONH(CH2)2 group or an SO2N(CH3)CH2 group.
Among the compounds of formula (I) which are subject-matter of the invention, a fourth group of compounds is composed of the compounds of formula (I) for which:
m and n represent 1.
Among the compounds of formula (I) which are subject-matters of the invention, a fifth group of compounds is composed of the compounds of formula (I) for which:
m represents 1 and n represents 0.
Among the compounds of formula (I) which are subject-matters of the invention, a sixth group of compounds is composed of the compounds of formula (I) for which:
m and n represent 0.
Among the compounds of formula (I) which are subject-matters of the invention, a seventh group of compounds is composed of the compounds of formula (I) for which:
R1 represents a phenyl, naphthyl, indanyl, benzoxazole, benzisoxazole, benzimidazole, benzotriazole, oxadiazole, indazole, isoxazole, pyridine, pyrazine, pyrimidine, thienyl, thiazole, benzothiophene, indole, dihydrobenzodioxane, benzothiadiazole, pyrazole, dihydrobenzoxazine or indoline group;
R2 represents one or more groups chosen from a halogen atom or a methyl, trifluoromethyl, methoxy, trifluoromethoxy, cyano, oxo, CH3NHCO, CH3SO2, NH2CO, NH2SO2 or pyrrolidine-SO2 group;
R3 represents a group chosen from a phenyl or an oxazole;
Z represents a bond or a CH2, (CH2)2, CH=CH, CsC, OCH2 or OC(CH3)2 group;
A represents a bond, an oxygen atom, a sulphur atom, an OCH2 group, an O(CH2)2 group, an NH, NHCH2 or NH(CH2)2 group, an SO2or CO group, a CONH group, a CONHCH2 or CONH(CH2)2 group, an SO2NH group, an SO2NHCH2, SO2NH(CH2)2 or SO2NHC[CH2]2 group, an SO2NHCO, SO2NHCONH or SO2NHCONHCH2 group, an f 4L
OCONH group, an NHCONH group, an NHCONHCH2 group, an N(CH3)CONHCH2, NHCONH(CH2)2 or N(CH3)CONH(CH2)2 group or an SO2N(CH3)CH2 group;
m and n represent, independently of one another, an integer equal to 0 or 1, in the form of the base or of an addition sait with an acid.
The conbinations of the groups one to seven as defined above also corne within the invention.
Mention may in particular be made, among the compounds of formula (I) which are subject-matters of the invention, of thefollowing compounds:
• 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-(4-chlorophenyl)piperidine-1-carboxylate • 2,2,2-T rif I uoro-1 -(trifluoromethyl)ethyl 4-(m-tolyl)piperidine-1 -carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-(2-(trifluoromethyl)phenyl)piperidine-1carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-(2-methoxyphenyl)piperidine-1 -carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-(4-cyanophenyl)piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-(4-(methylcarbamoyl)phenyl)piperidine-1carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-(naphth-1-yl)piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-(benzoxazol-2-yl)piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-(5-fluorobenz[d]isoxazol-3-yl)piperidine-1carboxylate • 2,2,2-Trifluoro-1 -(trifluoromethyl)ethyl 4-(6-fluorobenz[d]isoxazol-3-yl)piperidine-1 carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-(2-oxo-2,3-dihydrobenzoimidazol-1-yl)piperid i ne-1 -carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-(5-chloro-2-oxo-2,3-dihydrobenzoimidazol-1- yl )pi peridine-1 -carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-(5-(trifluoromethyl)benzotriazol-1-yl)piperidine-
1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[5-(4-fluorophenyl)-1,3,4-oxadiazol-2yl]piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-(6-fluoro-1 H-indazol-3-yl)piperidine-1carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-(benzyl)piperidine-1-carboxylate *
• 2,2,2-T rifluoro-1 -(trif I u orometh y l)ethy 14-[3-(4-chlorophenyl)isoxazol-5ylmethyl]piperidine-1-carboxylate • 2,2l2-Trifluoro-1-(trifluoromethyl)ethyl 4-[2-(4-chlorophenyl)ethyl]piperidine-1carboxylate • 2,2,2-T rifluoro-1 -(trifluoromethyl)ethyl 4-(4-chlorophenylethynyl)piperidine-1 -carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 3-(4'-fluorobiphenyl-3-yloxy)azetidine-1carboxylate • 2,2,2-Trifluoro-1 -(trifluoromethyl)ethyl 3-(3'-cyanobiphenyl-3-yloxy)azetidine-1 carboxylate • 2,2,2-Trifluoro-1 -(trifluoromethyl)ethyl (S)-3-(4'-fluorobiphenyl-3-yloxy)pyrrolidine-1 carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl (R)-3-(4'-fluorobiphenyl-3-yloxy)pyrrolidine-1carboxylate • 2,2,2-Trifluoro-1 -(trifluoromethyl)ethyl (S)-3-(3'-cyanobiphenyl-3-yloxy)pyrrolidine-1 carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl (R)-3-(3'-cyanobiphenyl-3-yloxy)pyrrolidine-1carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-(4-fluorophenoxy)piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-(4-carbamoylphenoxy)piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-(3'-fluorobiphenyl-3-yloxy)piperidine-1carboxylate • 2,2,2-Trifluoro-1 -(trifluoromethyl)ethyl 4-(4'-fluorobiphenyl-3-yloxy)piperidine-1 carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-(3'-chlorobiphenyl-3-yloxy)piperidine-1carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-(4'-chlorobiphenyl-3-yloxy)piperidine-1carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-(3'-cyanobiphenyl-3-yloxy)piperidine-1carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-(4'-cyanobiphenyl-3-yloxy)piperidine-1carboxylate • 2,2,2-T rifluoro-1 -(trifluoromethyl)ethyl 4-(3'-cyanobiphenyl-4-yloxy)piperidine-1 carboxylate • 2,2,2-Trifluoro-1 -(trifluoromethyl)ethyl 4-(4'-cyanobiphenyl-4-yloxy)piperidine-1 carboxylate • 2,2,2-T rif I uoro-1 -(trifluoromethyl)ethyl 4-(3,-methoxybiphenyl-3-yloxy)piperidine-1 carboxylate • 2J2J2-Trifluoro-1-(trifluoromethyl)ethyl 4-(4'-methoxybiphenyl-3-yloxy)piperidine-1carboxylate • 2,2,2-Trifluoro-l -(trifluoromethyl)ethyl 4-(4-chloronaphth-1 -yloxy)piperidine-1 carboxylate • 2,2,2-Trifluoro-l-(trifluoromethyl)ethyl 4-(naphth-2-yloxy)piperidine-1 -carboxylate • 2,2,2-Trifluoro-l-(trifluoromethyl)ethyl 4-(6-cyanonaphth-2-yloxy)piperidine-1carboxylate • 2,2,2-Trifluoro-l-(trifluoromethyl)ethyl 4-(6-methoxynaphth-2-yloxy)piperidine-1carboxylate • 2,2,2-Trifluoro-l-(trifluoromethyl)ethyl 4-(7-methoxynaphth-2-yloxy)piperidine-1carboxylate • 2,2,2-Trifluoro-l-(trifluoromethyl)ethyl 4-(pyridin-4-yloxy)piperidine-1-carboxylate • 2,2,2-Trifluoro-l-(trifluoromethyl)ethyl 4-[6-(3-cyanophenyl)pyridin-2-yloxy]piperidine-1carboxylate • 2,2,2-Trifluoro-l-(trifluoromethyl)ethyl 4-[5-(3-cyanophenyl)pyridin-3-yloxy]piperidine-1carboxylate • 2,2,2-Trifluoro-l-(trifluoromethyl)ethyl 4-[6-(3-cyanophenyl)pyrimidin-4-yloxy]piperidine-
1-carboxylate • 2,2,2-Trifluoro-l-(trifluoromethyl)ethyl 4-[6-(4-fluorophenyl)pyrazin-2-yloxy]piperidine-1carboxylate • 2,2,2-Trifluoro-l-(trifluoromethyl)ethyl 4-[6-(3-cyanophenyl)pyrazin-2-yloxy]piperidine-1carboxylate • 2,2,2-T rif I uoro-1 -(trifluoromethyl)ethyl 4-(4-chloronaphth-1 -yloxymethyl)piperidine-1 carboxylate • 2,2,2-Trifluoro-l-(trifluoromethyl)ethyl 4-(3'-cyanobiphenyl-3-yloxymethyl)piperidine-1carboxylate • 2,2,2-Trifluoro-l-(trifluoromethyl)ethyl 4-(4'-cyanobiphenyl-3-yloxymethyl)piperidine-1carboxylate • 2,2,2-Trifluoro-l-(trifluoromethyl)ethyl 4-(3,-cyanobiphenyl-4-yloxymethyl)piperidine-1carboxylate • 2,2,2-Trifluoro-l-(trifluoromethyl)ethyl 4-(4'-cyanobiphenyl-4-yloxymethyl)piperidine-1carboxylate • 2,2,2-Trifluoro-l-(trifluoromethyl)ethyl 4-(naphth-2-yloxymethyl)piperidine-1-carboxylate
Λ ί • 2,2,2-Trifluoro-l -(trifluoromethyl)ethyl 4-(6-methoxynaphth-2-yloxymethyl)piperidine-1carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-(7-methoxynaphth-2-yloxymethyl)piperidine-1- carboxylate • 2,2,2-Trifluoro-1 -(trifluoromethyl)ethyl 4-(6-cyanonaphth-2-yloxymethyl)piperidine-1 - carboxylate • 2,2,2-Trifluoro-l-(trifluoromethyl)ethyl 4-[2-(biphenyl-4-yloxy)ethyl]-piperidine-1- carboxylate • 2,2,2-T rifluoro-1 -(trifluoromethyl)ethyl 4-[2-(4-chloronaphth-1 -yloxy)ethyl]piperidine-1 - carboxylate • 2,2,2-Trifluoro-l-(trifluoromethyl)ethyl 4-(6-bromopyridin-2-ylamino)piperidine-1- carboxylate • 2,2,2-Trifluoro-l-(trifluoromethyl)ethyl 4-(5-cyanopyridin-2-ylamino)piperidine-1carboxylate • 2,2,2-Trifluoro-l-(trifluoromethyl)ethyl 4-(5-carbamoylpyridin-2-ylamino)piperidine-1- carboxylate • 2,2,2-Trifluoro-l-(trifluoromethyl)ethyl 4-(5-(trifluoromethyl)pyridin-2-ylamino)piperidine-
1-carboxylate • 2,2,2-Trifluoro-1 -(trifluoromethyl)ethyl 4-(4-trifluoromethylpyrimidin-2-ylamino)piperidine-
1-carboxylate • 2,2,2-T rifluoro-1 -(trifluoromethyl)ethyl 4-(2-bromopyrimidin-4-ylamino)piperidine-1 carboxylate • 2,2,2-Trifluoro-l-(trifluoromethyl)ethyl 4-[6-(4-fluorophenyl)pyridin-2-ylamino]piperidine-
1-carboxylate • 2,2,2-T rifluoro-1 -(trifluoromethyl)ethyl 4-[6-(3-cyanophenyl)pyridin-2-ylamino]piperidine-
1-carboxylate • 2,2,2-T rifluoro-1 -(trifluoromethyl)ethyl 4-[2-(3-cyanophenyl)pyrimidin-4- ylamino]piperidine-1 -carboxylate • 2,2,2-Trifluoro-l-(trifluoromethyl)ethyl 4-[(6-chloropyridin-2-ylamino)methyl]piperidine-1carboxylate • 2,2,2-Trifluoro-l-(trifluoromethyl)ethyl 4-(pyridin-4-ylsulphanyl)piperidine-1-carboxylate • 2,2,2-Trifluoro-l-(trifluoromethyl)ethyl 4-(benzenesulphonyl)piperidine-1 -carboxylate • 2,2,2-Trifluoro-l-(trifluoromethyl)ethyl 4-(4-fluorobenzoyl)piperidine-1-carboxylate • 2,2,2-T rifluoro-1 -(trifluoromethyl)ethyl 4-(4-chlorobenzoyl)piperidine-1 -carboxylate • 2,2,2-Trifluoro-l-(trifluoromethyl)ethyl 4-(4-chlorobenzoylamino)piperidine-1-carboxylate r » • 2,2,2-T rif luoro-1 -(trifluoromethyl)ethyl 4-(4-methylbenzoylamino)piperidine-1 carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[(3-chlorobenzo[b]thiophene-2carbonyl)amino]piperidine-1 -carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[2-(4-chlorophenoxy)acetylamino]piperidine-1carboxylate • 2J2,2-Trifluoro-1-(trifluoromethyl)ethyl 3-[(E)-(3-phenylacryloyl)amino]azetidine-1carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[(E)-(3-phenylacryloyl)amino]piperidine-1carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[(4-chlorobenzoylamino)methyl]piperidine-1carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-{[(3-chlorobenzo[b]thiophene-2carbonyl)amino]methyl}piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-{[2-(4chlorophenoxy)acetylamino]methyl}piperidine-1 -carboxylate • 2,2,2-Trifluoro-1 -(trifluoromethyl)ethyl 4-{[2-(4-chlorophenoxy)-2methylpropionylamino]methyl}piperidine-1-carboxylate • 2,2,2-Trifluoro-l-(trifluoromethyl)ethyl 3-{[(E)-(3- phenylacryloyl)amino]methyl}pyrrolidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-{[(E)-(3-phenylacryloyl)amino]methyl}piperidine-
-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 3-{[2-(4chlorophenoxy)acetylamino]methyl}pyrrolidine-1-carboxylate • 2,2,2-Trifluoro-1 -(trifluoromethyl)ethyl 3-(2-(phenylacetylamino)ethyl)azetidine-1 carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 3-{2-[2-(4chlorophenoxy)acetylamino]ethyl}azetidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 3-{2-[(E)-(3-phenylacryloyl)amino]ethyl}azetidine-
1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 3-(5-bromo-2methoxybenzenesulphonylamino)azetidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 3-(4-bromo-2- fluorobenzenesulphonylamino)azetidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 3-(indane-5-sulphonylamino)azetidine-1carboxylate ; » • 2,2,2-Trifluoro-1 -(trifluoromethyl)ethyl 3-(biphenyl-4-sulphonylamino)azetidine-1carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 3-(4-methylnaphthalene-1sulphonylamino)azetidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 3-(5-chlorothiophene-2-sulphonylamino)azetidine-
1-carboxylate • 2,2,2-T rifluoro-1 -(trifluoromethyl)ethyl 3-(5-bromothiophene-2sulphonylamino)azetidine-1-carboxylate • 2,2,2-Trifluoro-1 -(trifluoromethyl)ethyl 3-[(benzo[b]thiophene-2carbonyl)amino]azetidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyi)ethyl 4-(3-chlorobenzenesulphonylamino)piperidine-1carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-(4-chlorobenzenesulphonylamino)piperidine-1carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-(5-bromo-2- methoxybenzenesulphonylamino)piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-(naphthalene-1-sulphonylamino)piperidine-1carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-(naphthalene-2-sulphonylamino)piperidine-1carboxylate • 2,2,2-Trifluoro-1 -(trifluoromethyl)ethyl 3-(phenylmethanesulphonylamino)azetidine-1 carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-(phenylmethanesulphonylamino)piperidine-1carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 3-[(4- chlorobenzenesulphonylamino)methyl]azetidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 3-[(3- chlorobenzenesulphonylamino)methyl]pyrrolidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 3-[(4- chlorobenzenesulphonylamino)methyl]pyrrolidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 3-[(naphthalene-1- sulphonylamino)methyl]pyrrolidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 3-[(naphthalene-2- sulphonylamino)methyl]pyrrolidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-((benzenesulphonylamino)methyl)piperidine-1carboxylate ι * • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[(4fluorobenzenesulphonylamino)methyl]piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[(2- chlorobenzenesulphonylamino)methyl]piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[(3- chlorobenzenesulphonylamino)methyl]piperidine-1-carboxylate • 2,2,2-T rifluoro-1 -(trifluoromethyl)ethyl 4-[(4-chlorobenzenesulphonylamino)-methyl]piperid i ne-1 -carboxylate • 2,2,2-T rifluoro-1 -(trifluoromethyl)ethyl 4-[(toluene-2-sulphonylamino)methyl]piperidine-1 carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[(toluene-3-sulphonylamino)methyl]piperidine-1carboxylate • 2,2,2-Trifluoro-1 -(trifluoromethyl)ethyl 4-[(toluene-4-sulphonylamino)methyl]piperidine-1 carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[(3-(trifluoromethyl)benzenesulphonylamino)methyl]piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[(4- (trifluoromethyl)benzenesulphonylamino)methyl]piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[(3methoxybenzenesulphonylamino)methyl]piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[(4-methoxybenzenesulphonylamino)methyl]piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[(3- {trifluoromethoxy}benzenesulphonylamino)methyl]piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[(4- {trifluoromethoxy}benzenesulphonylamino)methyl]piperidine-1-carboxylate • 2,2,2-Trifluoro-1 -(trifluoromethyl)ethyl 4-[(4-fluoro-2-{trifluoromethyl}benzenesulphonylamino)methyl]piperidine-1 -carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[(4cyanobenzenesulphonylamino)methyl]piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[(3-fluoro-4-methylbenzenesulphonyl- amino)methyl]piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[(3,4-difluorobenzenesulphonylamino)methyl]piperidine-1-carboxylate • 2,2,2-Trifluoro-1 -(trifluoromethyl)ethyl [(3,4-dichlorobenzenesulphonyl- amino)methyl]piperidine-1-carboxylate
J » • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl amino)methyl]piperidine-1-carboxylate • 2,2,2-T rifluoro-1 -(trifluoromethyl)ethyl
4-[(3-chloro-4-methylbenzenesulphonyl·
4-[(3-chloro-4-{trifluoromethoxy}benzene· sulphonylamino)methyl]piperidïne-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-((3,4dimethylbenzenesulphonylamino)methyl]piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[(3-fluoro-4methoxybenzenesulphonylamino)methyl]piperidine-1-carboxylate • 2,2,2-T rifluoro-1 -(trifluoromethyl)ethyl 4-[(4-fluoro-3-methylbenzenesulphonylamino)methyl]piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[(3-chloro-4fluorobenzenesulphonylamino)methyl]piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[(4-fluoro-3methoxybenzenesulphonylamino)methyl]piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[(4-fluoro-3- {trifluoromethyl}benzenesulphonylamino)methyl]piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[(4-chloro-3- {trifluoromethyl}benzenesulphonylamino)methyl]piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-((4{methanesulphonyl}benzenesulphonylamino)methyl]piperidine-1-carboxylate • 2,2,2-Trifluoro-1 -(trifluoromethyl)ethyl 4-{[4-(pyrrolidine-1 sulphonyl)benzenesulphonylamino]methyl}piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[(biphenyl-4-sulphonylamino)methyl]piperidine1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[(naphthalene-1sulphonylamino)methyl]piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[(naphthalene-2- sulphonylamino)methyl]piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-((3,5-dimethylisoxazole-4- sulphonylamino)methyl]piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[(4-{oxazol-5- yl}benzenesulphonylamino)methyl]piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[(4-chlorophenylmethanesulphonylamino)methyl]piperidine-1 -carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-(1-(4chlorobenzenesulphonylamino)cyclopropyl]piperidine-1-carboxylate • 2,2,2-Trifluoro-1 -(trifluoromethyl)ethyl 3-(2-(3- chlorobenzenesulphonylamino)ethyl]azetidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 3-(2-(4chlorobenzenesulphonylamino)ethyl]azetidine-1-carboxylate · 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 3-[2-(naphthalene-1sulphonylamino)ethyl]azetidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 3-[2-(naphthalene-2- sulphonylamino)ethyl]azetidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-(phenoxycarbonylamino)piperidine-1- carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-(3-phenylureido)piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[3-(3-chlorophenyl)ureido]piperidine-1carboxylate • 2,2,2-T rif luoro-1 -(trifluoromethyl)ethyl 4-[3-(4-chlorophenyl)ureido]piperidine-1 - carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[3-(3-cyanophenyl)ureido]piperidine-1carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[3-(4-cyanophenyl)ureido]piperidine-1carboxylate · 2,2,2-Trifluoro-1 -(trifluoromethyl)ethyl 4-(3-(2,4-difluorophenyl)ureido]piperidine-1 carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-(3-(2,4-dichlorophenyl)ureido]piperidine-1carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-(3-(2,5-dichlorophenyl)ureido]piperidine-1- carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[3-(5-chloro-2-methoxyphenyl)ureido]piperidine-
1-carboxylate • 2,2,2-T rifluoro-1 -(trifluoromethyl)ethyl 4-[3-(3-carbamoylphenyl)ureido]piperidine-1 carboxylate · 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-(3-benzylureido)piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 3-[3-(4-chlorophenyl)ureidomethyl]azetidine-1carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 3-[3-(3-chlorophenyl)ureidomethyl]pyrrolidine-1carboxylate · 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 3-[3-(4-chlorophenyl)ureidomethyl]pyrrolidine-1carboxylate r Μ.
• 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 3-[3-(4-cyanophenyl)ureidomethyl]pyrrolidine-1carboxylate • 2J2J2-Trifluoro-1-(trifluoromethyl)ethyl 4-[3-(4-chlorophenyl)ureidomethyl]piperidine-1carboxylate • 2,2,2-T rifluoro-1 -(trifluoromethyl)ethyl 4-{3-[2-(4-{trifluoromethyl}phenyl)thiazol-4-yl]ureidomethyl}piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 3-(3-benzylureidomethyl)pyrrolidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-(3-benzylureidomethyl)piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 3-(3-methyl-3-phenylureidomethyl)pyrrolidine-1carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 3-{2-[3-(3-chlorophenyl)ureido]ethyl}azetidine-1- carboxylate • 2,2,2-T rifluoro-1 -(trifluoromethyl)ethyl 3-{2-[3-(4-chlorophenyl)ureido]ethyl}azetidine-1 carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 3-{2-[3-(4-cyanophenyl)ureido]ethyl}azetidine-1- carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 3-[2-(3-methyl-3-phenylureido)ethyl]azetidine-1carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-{2-[3-(4-chlorophenyl)ureido]ethyl}piperidine-1- carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 3-[2-(3-benzylureido)ethyl]azetidine-1-carboxylate • 2,2,2-T rifluoro-1 -(trifluoromethyl)ethyl 4-(4-chlorobenzenesulphonylamino- carbonyl)piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-({[(4- chlorophenyl)sulphonyl]carbamoyl}amino)piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[({[(4- chlorophenyl)sulphonyl]carbamoyl}amino)methyl]piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-(3-carbamoylphenoxy)piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-(3-carbamoylphenoxymethyl)piperidine-1carboxylate • 2,2,2-T rifluoro-1 -(trifluoromethyl)ethyl 4-[(indole-1 -carbonyl)amino]piperidine-1 - carboxylate • 2,2,2-T rifluoro-1 -(trifluoromethyl)ethyl 4-{[(ind ole-1 -carbonyl)amino]methyl}piperidine-1 carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[(2fluorobenzenesulphonylamino)methyl]piperidine-1-carboxylate • 2,2,2-Trifluoro-1 -(trifluoromethyl)ethyl 4-[(2{trifluoromethyl}benzenesulphonylamino)methyl]piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[(2methoxybenzenesulphonylamino)methyl]piperidine-1-carboxylate · 2,2,2-Trifluoro-1 -(trifluoromethyl)ethyl 4-[(3cyanobenzenesulphonylamino)methyl]piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[(3-chloro-2fluorobenzenesulphonylamino)methyl]piperidine-1-carboxylate • 2,2,2-T rifluoro-1 -(trifluoromethyl)ethyl 4-[(benzo[b]thiophene-3- sulphonylamino)methyl]piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[1-(4methoxybenzenesulphonylamino)cyclopropyl]piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-{2-[(1/7-indol-1ylcarbonyl)amino]ethyl}piperidine-1-carboxylate · 2,2,2-Trifluoro-1 -(trifluoromethyl)ethyl 4-({[3(methylsulphonyl)phenyl]carbamoyl}amino)piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-{[(1 H-benzimidazol-5ylcarbamoyl)amino]methyl}piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-{[(1H-indazol-6- ylcarbamoyl)amino]methyl}piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-(4-carbamoylphenoxymethyl)piperidine-1carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[2-(3-carbamoylphenoxy)ethyl]piperidine-1carboxylate · 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[2-(4-carbamoylphenoxy)ethyl]piperidine-1carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-(4(methanesulphonyl)benzenesulphonylamino)piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-(pyridine-3-sulphonylamino)piperidine-1- carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[(2{trifluoromethoxy}benzenesulphonylamino)methyl]piperidine-1-carboxylate • 2,2,2-T rifluoro-1 -(trifluoromethyl)ethyl 4-[(2-methoxy-4methylbenzenesulphonylamino)methyl]piperidine-1-carboxylate · 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[(2,4dimethoxybenzenesulphonylamino)methyl]piperidine-1-carboxylate • 2,2,2-Trifluoro-1 -(trifluoromethyl)ethyl 4-[(2,5dimethoxybenzenesulphonylamino)methyl]piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[(5-fluoro-2methoxybenzenesulphonylamino)methyl]piperidine-1-carboxylate · 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[(5-methanesulphonyl-2methoxybenzenesulphonylamino)methyl]piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[(4-chloro-2,5- dimethylbenzenesulphonylamino)methyl]piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-{[3-(5-methyl-1,3,4-oxadiazol-2- yl)benzenesulphonylamino]methyl}piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[(2,3-dihydrobenzo[1,4]dioxine-6sulphonylamino)methyl]piperidine-1-carboxylate • 2J2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[(benzo[1,2,5]thiadiazole-4- sulphonylamino)methyl]piperidine-1-carboxylate · 2,2,2-Trifluoro-1 -(trifluoromethyl)ethyl 4-[(4-methyl-3J4-dihydro-2H-benz[1,4]oxazine-7sulphonylamino)methyl]piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-{[3-(2-methylpyrimidin-4- yl)benzenesulphonylamino]methyl}piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[(5-chloro-1,3-dimethyl-1 H-pyrazole-4- sulphonylamino)methyl]piperidine-1 -carboxylate • 2,2,2-Trifluoro-1 -(trifluoromethyl)ethyl 4-[(pyridine-3-sulphonylamino)methyl]piperidine-
1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[(6-chloropyridine-3sulphonylamino)methyl]piperidine-1-carboxylate · 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-{[/V-4-(chlorobenzenesulphonyl)-/\/methylamino]methyl}pîperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[2-(4(methanesulphonyl)benzenesulphonylamino)ethyl]piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[2-(pyridine-3-sulphonylamino)ethyl]piperidine-
1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 3-[1-(4chlorobenzenesulphonylamino)cyclopropyl]azetidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 3-[1-(5-methanesulphonyl-2- methoxybenzenesulphonylamino)cyclopropyl]azetidine-1-carboxylate · 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 3-[1-(pyridine-3sulphonylamino)cyclopropyl]azetidine-1 -carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 3-(1-(4- {methanesulphonyl}benzenesulphonylamino)cyclopropyl]azetidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[(4- {methanesulphonyl}phenylamino)methyl]piperidine-1-carboxylate · 2,2,2-Trifluoro-1-(trifluoromethyl)ethy! 4-[(4-sulfamoylphenylamino)methyl]piperidine-1carboxylate • 2,2,2-T rif I uoro-1 -(trifluoromethyl)ethyl 4-[(2-carbamoylpyridin-4ylamino)methyl]piperidine-1-carboxylate • 2,2,2-Trifluoro-1 -(trifluoromethyl)ethyl 4-[(4-carbamoylpyridin-2- ylamino)methyl]piperidine-1 -carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[(5-carbamoylpyridin-2- ylamino)methyl]piperidine-1 -carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[(6-carbamoylpyridin-2ylamino)methyl]piperidine-1 -carboxylate · 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[(5-carbamoylpyrazin-2ylamino)methyl]piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-(4-carbamoylpyrazol-1-ylmethyl)piperidine-1carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[2-(5-carbamoylpyridin-2- ylamino)ethyl]piperidine-1 -carboxylate • 2,2,2-T rifluoro-1 -(trifluoromethyl)ethyl 4-[2-(4-carbamoylpyrimidin-2ylamino)ethyl]piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[2-(5-carbamoylpyrazin-2ylamino)ethyl]piperidine-1-carboxylate · 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[2-(6-carbamoylpyrazin-2ylamino)ethyl]piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[(2,3-dihydrobenz[1,4]oxazine-4carbonyl)amino]piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-{[(2,3-dihydrobenz[1,4]oxazine-4- carbonyl)amino]methyl}piperidine-1 -carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[2-(3- {methanesulphonyl}benzoylamino)ethyl]piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[2-(4- {methanesulphonyl}benzoylamino)ethyl]piperidine-1-carboxylate · 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[2-(4-sulfamoylbenzoylamino)ethyl]piperidine-1carboxylate • 2,2,2-Trifluoro-1 -(trifluoromethyl)ethyl 4-{2-[(2,3-dihydrobenz[1,4]oxazine-4carbonyl)amino]ethyl}piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-(3-(1 H-benzimidazol-5-yl)ureido]piperidine-1carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[3-(1-methanesulphonyl-2,3-dihydro-1 H-indol-5yl)ureido]piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-(3-(1 H-indazol-6-yl)ureido]piperidine-1carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[3-(5-methanesulphonyl-2methoxyphenyl)ureidomethyl]piperidine-1-carboxylate • 2,2,2-T rifluoro-1 -(trifluoromethyl)ethyl 4-{3-[2-methoxy-5-(pyrrolidine-1 sulphonyl)phenyl]ureidomethyl}piperidine-1-carboxylate • 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[3-(1-methanesulphonyl-2,3-dihydro-1 H-indol-5yl)ureidomethyl]piperidine-1-carboxylate
In that which follows, the term protective group Pg is understood to mean a group which makes it possible, on the one hand, to protect a reactive functional group, such as a hydroxyl or an amine, during a synthesis and, on the other hand, to regenerate the reactive functional group intact at the end of the synthesis. Examples of protective groups and of protecting and deprotecting methods are given in Protective Groups in Organic Synthesis, Green et al., 2nd Edition (John Wiley & Sons Inc., New York), 1991.
The term leaving group is understood to mean, in that which follows, a group which can be easily cleaved from a molécule by splitting a heterolytic bond, with departure of an électron pair. This group can thus be easily replaced by another group, for example during a substitution reaction.
In accordance with the invention, the compounds of general formula (I) can be prepared according to the process which follows:
A general method (scheme 1) for the préparation of the compounds according to the invention consists in reacting an amine of general formula (II), in the base or sait form, in which m, n, A, Z and R are as defined above, with a dérivative of general formula (III), in which X représente a leaving group, such as a chlorine atom, a 4-nitrophenoxy group, an imidazole group, a 1,2,4-triazole group or an N-oxysuccinimide group. The reaction is carried out in a solvent, such as dichloromethane, acetonitrile, N-methylpyrrolidinone, dimethyl sulphoxide, dimethylformamide or a mixture of these solvents, optionally in the presence of a base, such as pyridine or diisopropylethylamine, and of a catalyst, such as 4-dimethylaminopyridine, at a température of between 0 and 80°C.
(H) (HO (I)
Scheme 1
The compounds of general formula (II) are available commercially or are described in the literature or can be prepared according to methods which are described therein or which are known to a person skilled in the art, as illustrated in the examples which follow.
The compounds of general formula (III) are prepared by reaction of the alcohol 1,1,1,3,3,3-hexafluoro-2-propanol with triphosgene, 4-nitrophenyl chloroformate, carbonyldiimidazole, carbonyldi(1,2,4-triazole) or carbonyldi(N-oxysuccinimide), in a solvent, such as dichloromethane, acetonitrile or N-methylpyrrolidinone, optionally in the presence of a base, such as pyridine, and of a catalyst, such as 4-dimethylaminopyridine, at a température of between 0 and 80°C. The compounds (III) are generally prepared and used in situ. Some of the compounds of general formula (III) hâve already been reported in the literature (X = chlorine, Synthesis, 1993 (1), 103-106; X = imidazole, Tetrahedron Letters, 1982, 23 (20), 2113-2116; X = 1,2,4-triazole, Chem. Pharm. Bull., 1983, 31 (12), 4578-4581).
Alternatively, the compounds of general formula (la), in which A represents a CON(Ra), CON(RA)-(Ci-C6)alkylene, SO2N(RA), SO2N(RA)-(Ci-C6)alkylene, N(Rb)CON(Ra), N(RB)CON(RA)-(CrC6)alkylene, OCON(RA) or OCON(RA)-(CrC6)alkylene group and R, Z, m and n are as defined above, can be prepared (Scheme 2) by reacting a dérivative of general formula (IV), in which W represents a carbonyl chloride (COCI), sulphonyl chloride (SO2CI), isocyanate (NCO), carbamoyl chloride (N(RB)COCI) or chloroformate (OCOCI) functional group, with a dérivative of general formula (V), in which V represents an amine HN(RA) or HN(RA)-(CrC6)alkylene functional group. This dérivative of formula (V) can be:
- a hexafluoroisopropyl piperidine-1-carboxylate dérivative, when m and n represent1 ;
- a hexafluoroisopropyl pyrrolidine-1-carboxylate dérivative, when m represents 1 and n represents 0;
- a hexafluoroisopropyl azetidine-1-carboxylate dérivative, when m and n represent 0.
(iv) (V) (la)
Scheme 2
The reaction is carried out in a solvent, such as dichloromethane, acetonitrile or N-methylpyrrolidinone, optionally in the presence of a base, such as pyridine or diisopropylethylamine, and of a catalyst such as 4-dimethylaminopyridine, at a température between 0 and 80°C.
The compounds of general formula (IV) are commercially available or are described in the literature or can be prepared according to methods which are described therein or which are known to a person skilled in the art.
The compounds of general formula (V), in the base or sait form, are novel and corne within the invention. They are of use as intermediates in the synthesis of the compounds of formula (la) and can be prepared as described in the examples which follow.
The examples which follow illustrate the préparation of a few compounds of the invention. These examples are not limiting and serve only to illustrate the invention. The microanalyses, the IR and NMR spectra and/or the LC/MS analyses confirm the structures and the purifies of the compounds obtained. The numbers of the compounds in the examples refer to those given in the table below, in which the chemical structures and the physical properties of a few compounds according to the invention are illustrated.
The proton nuclear magnetic résonance (1H NMR) spectra were recorded at 200 MHz or 400 MHz (chemical shifts δ in ppm) in d3-chloroform (CDCI3), d6-(dimethyl sulphoxide) (DMSO) or d4-methanol (CD3OD). The abbreviations used to characterize the signais are as follows: s = singlet, m = multiplet, d = doublet, t = triplet, q = quartet, sept. = septet.
Examples of LC/MS analytical methods are described in detail below. The rétention times (Rt) are expressed in minutes.
Method A:
HPLC / Trap - 5 mM ammonium acetate / acetonitrile gradient
ΤΟ: 100%A- T13 to T16 min: 100%B - T16.5 to T20 min: 100%A
Route A: ammonium acetate + 3% acetonitrile; Route B: acetonitrile
Flow rate: 0.5 ml/min - T°=40°C
Column: Kromasil C18 (50*2.1 mm; 3.5 pm)
Method B:
HPLC / ZQ - water / acetonitrile /trifluoroacetic acid gradient
T0:100%A - T13 to T16 min: 100%B - T16.5 to T20 min: 100%A
Route A: water+0.05% trifluoroacetic acid+3% acetonitrile ; Route B: acetonitrile+0.035% trifluoroacetic acid
Flow rate: 0.5 ml/min - T°=40°C
Column: Kromasil C18 (50*2.1 mm; 3.5 pm)
Method C:
HPLC / ZQ - 5 mM ammonium acetate / acetonitrile gradient
T0:100%A - T5.5 to T7 min: 100%B - T7.1 to T10 min: 100%A
Route A: ammonium acetate + 3% acetonitrile ; Route B: acetonitrile
Flow rate: 0.8 ml/min - T°=40°C
Column: Kromasil C18 (50*2.1 mm; 3.5 pm)
Method D:
UPLC / TOF - water / acetonitrile / trifluoroacetic acid gradient
T0: 98%A - T1.6 to T2.1 min: 100%B - T2.5 to T3 min: 98%A
Route A: water + 0.05% trifluoroacetic acid; Route B: acetonitrile + 0.035% trifluoroacetic acid
Flow rate: 1.0 ml/min - T°=40°C
Column: Acquity BEH C18 (50*2.1 mm; 1.7 pm)
Method E:
HPLC / TOF - water / acetonitrile / trifluoroacetic acid gradient
T0: 95%A - T2.5 min: 95%B
Route A: water + 0.05% trifluoroacetic acid; Route B: acetonitrile + 0.05% trifluoroacetic acid
Flow rate: 1.3 ml/min - ambient température
Column: YMC-Pack Jsphere H80 (33*2.1 mm; 4 pm)
Example 1 (compound No. 5)
2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-(4-cyanophenyl)piperidine-1-carboxylate
A solution of 0.604 g (3.6 mmol) of 1,1,1,3,3,3-trifluoro-2-propanol, 0.32 ml (3.96 mmol) of pyridine and 0.014 g (0.12 mmol) of 4-dimethylaminopyridine in 9 ml of dichloromethane is added dropwise to a solution, cooled to 0°C, under an argon atmosphère, of 0.356 g (1.2 mmol) of triphosgene in 8 ml of dichloromethane. Stirring is continued at ambient température for 6 hours. 0.670 g (3.6 mmol) of 4-(piperidin-4-yl)benzonitrile and 1.31 ml (7.92 mmol) of diisopropylethylamine are subsequently added. The mixture is left stirring overnight. 23 ml of dichloromethane are added. The organic phase is washed 3 times with 40 ml of ice-cold water, dried over sodium sulphate and evaporated to dryness. The product is purified by chromatography on silica gel, elution being carried out with a 15:85 mixture of ethyl acetate and cyclohexane. Crystallization is carried out from n-hexane in order to obtain 0.32 g (0.84 mmol) of product in the form of a white powder.
Melting point (°C): 54-56
LC/MS (method A): Rt 9.7 min, m/z 398 (MNH4+)
IR (KBr, cm’1): 2226,1743 1H NMR (CDCI3, δ ppm, 200 MHz): 7.65 (d, 2H), 7.35 (d, 2H), 5.8 (sept., 1H), 4.35 (m, 2H), 3.05 (m, 2H), 2.8 (m, 1H), 1.95 (m, 2H), 1.8 (m, 2H).
Example 2 (compound No. 10)
2,2,2-T rifluoro-1 -(trifluoromethyl)ethyl
4-(6-fluorobenz[d]isoxazol-3-yl)piperidine-1carboxylate
A solution of 0.342 g (1.7 mmol) of 4-nitrophenyl chloroformate in 6 ml of dichloromethane is added dropwise to a solution, cooled to 0°C, under an argon atmosphère, of 0.571 g (3.4 mmol) of 1,1,1,3,3,3-trifluoro-2-propanoi, 0.28 ml (3.4 mmol) of pyridine and 0.011 g (0.1 mmol) of 4-dimethylaminopyridine in 5 ml of dichloromethane. The mixture is stirred at ambient température overnight. 0.374 g (1.7 mmol) of 6-fluoro-3-(piperidin-4-yl)benz[d]isoxazole and then 0.74 ml (4.25 mmol) of diisopropylethylamine are subsequently added. The mixture is stirred at ambient température for 5 hours. 4 g of silica are added and the mixture is evaporated to dryness. The product is purified by chromatography on silica gel, elution being carried out with a 10:90 mixture and then a 15:85 mixture of ethyl acetate and cyclohexane. Crystallization is carried out in n-hexane in order to obtain 0.45 g (1.09 mmol) of product in the form of white crystals.
Melting point (°C): 91-93
LC/MS (method B): Rt 10.6 min, m/z 415 (MH+)
IR (KBr, cm’1): 1741 1H NMR (DMSO, δ ppm, 200 MHz): 8.0 (d.d, 1H), 7.7 (d.d, 1H), 7.3 (d.t, 1H), 6.55 (sept., 1 H), 4.05 (m, 2H), 3.5 (m, 1 H), 3.2 (m, 2H), 2.1 (m, 2H), 1.75 (m, 2H).
Example 3 (compound No. 12)
2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-(5-chloro-2-oxo-2,3-dihydrobenzimidazol-1y I )pi perid ine-1 -carboxylate ci
0.328 g (2 mmol) of carbonyldi(1,2,4-triazole) is added to a solution of 0.6725 g (4 mmol) of 1,1,1,3,3,3-trifluoro-2-propanol and 0.012 g (0.1 mmol) of 4-dimethylaminopyridine in 10 ml of dichloromethane. The mixture is stirred at ambient température overnight and then 0.503 g (2 mmol) of 5-chloro-1-piperidin-4-yl-1,3-dihydrobenzimidazol-2-one is added. Stirring is continued at ambient température for 3 hours and the dichloromethane is evaporated under vacuum. The residue is taken up in a mixture of 50 ml of ethyl acetate and 20 ml of 1N aqueous hydrochloric acid. The organic phase is separated by settling and is then washed with 2 times 20 ml of water and then with 20 ml of a saturated aqueous sodium chloride solution. It is dried over sodium sulphate and evaporated under vacuum. The product is purified by chromatography on silica gel, elution being carried out with a 30:70, then 40:60 and 50:50 mixture of ethyl acetate and cyclohexane. Recrystallization is subsequently carried out under hot conditions for a mixture of ethyl acetate and cyclohexane in order to obtain 0.28 g (0.62 mmol) of product in the form of a white crystalline powder.
Melting point (°C): 231-233
LC/MS (method B): Rt 9.3 min, m/z 446 (MH+)
IR(KBr, cm'1): 1751,1697 1H NMR (CDCIa, δ ppm, 200 MHz): 8.6 (s, 1H), 7.15-6.95 (m, 3H), 5.85 (sept., 1H), 4.64.3 (m, 3H), 3.1 (m, 2H), 2.4 (m, 2H), 1.95 (m, 2H).
Example 4 (compound No. 75)
2,2,2-Trifluoro-l-(trifluoromethyl)ethyl 4-(4-chlorobenzoyl)piperidine-1-carboxylate
O CF,
CI
0.512 g (2 mmol) of carbonyldi(N-oxysuccinimide) and 0.012 g (0.1 mmol) of 4-dimethylaminopyridine are added to a solution of 0.504 g (3 mmol) of 1,1,1,3,3,3trifluoro-2-propanol in 7 ml of dichloromethane. The mixture is stirred at ambient température for 4 hours. It is cooled to 0°C and 0.520 g (2 mmol) of (4-chlorophenyl)(piperidin-4-yl)methanone hydrochloride and then 1.04 ml (6 mmol) of diisopropylethylamine are added. The mixture is stirred at ambient température overnight. 20 ml of ice-cold water and 50 ml of ice-cold dichloromethane are added. The organic phase is separated by settling. It is washed twice with ice-cold water and then with 20 ml of a saturated aqueous sodium chloride solution. It is dried over sodium sulphate and evaporated to dryness. The product is purified by chromatography on silica gel, elution being carried out with a 5:95 and then 10:90 mixture of ethyl acetate and cyclohexane, in order to obtain 0.175 g (0.42 mmol) of product in the form of a colourless oil.
LC/MS (method A): Rt 10.9 min, m/z 418 (MH+)
IR (film, cm’1): 1739,1684 1H NMR (CDCI3, δ ppm, 200 MHz): 7.8 (d, 2H), 7.4 (d, 2H), 5.7 (sept., 1H), 4.1 (d, 2H), 3.5 (m, 1H), 3.1 (m, 2H), 1.9-1.6 (m, 4H).
Example 5 (compound No. 33)
2,2,2-Trifluoro-l -(trifluoromethyl)ethyl 4-(3’-cyanobiphenyl-3-yloxy)piperidine-1- carboxylate
5.1. terf-Butyl 4-(3’-cyanobiphenyl-3-yloxy)piperidine-1-carboxylate
A solution of 1.210 g (5.99 mmol) of diisopropyl azodicarboxylate is added dropwise to a solution, cooled to 0°C, under an argon atmosphère, of 0.974 g (4.99 mmol) of 3’-hydroxybiphenyl-3-carbonitrile, 1.205 g (5.99 mmol) of fe/ï-butyl 4-hydroxypiperidine-1carboxylate and 1.570 g (5.99 mmol) of triphenylphosphine in 12 ml of tetrahydrofuran. The mixture is subsequently stirred at ambient température overnight. 15 g of silica are added and the mixture is evaporated to dryness. The product is purified by chromatography on silica gel, elution being carried out with a 10:90 and then 15:85 mixture of ethyl acetate and cyclohexane, in order to obtain 1.538 g (4.06 mmol) of product in the form of a colourless oil.
5.2. 3’-(Piperidin-4-yloxy)biphenyl-3-carbonitrile
1.508 g (3.98 mmol) of tert-butyl 4-(3’-cyanobiphenyl-3-yloxy)piperidine-1-carboxylate obtained in stage 5.1. are dissolved in 13 ml of dichloromethane. 3.07 ml (39.84 mmol) of trifluoroacetic acid are added and the mixture is stirred at ambient température for 4 hours. It is evaporated to dryness and then coevaporated twice with 12 ml of 1,2dichloroethane. The residue is taken up in a mixture of 18 ml of dichloromethane and 9 ml of a 1N aqueous sodium hydroxide solution. The organic phase is separated by settling and the aqueous phase is extracted with 12 ml of dichloromethane. The organic phases are washed with 18 ml of water and then 18 ml of a saturated aqueous sodium chloride solution. They are dried over sodium sulphate and evaporated to dryness in order to provide 1.026 g (3.68 mmol) of product in the form of an orange oil.
5.3. 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-(3’-cyanobiphenyl-3-yloxy)piperidine-1carboxylate
A solution of 0.504 g (3 mmol) of 1,1,1,3,3,3-hexafluoro-2-propanol, 0.27 ml (3 mmol) of pyridine and 0.012 g (0.1 mmol) of 4-dimethylaminopyridine in 6 ml of dichloromethane is added dropwise to a solution, cooled to 0°C, under an argon atmosphère, of 0.296 g (1 mmol) of triphosgene in 7 ml of dichloromethane. The mixture is stirred at ambient température for 5 hours. A solution of 0.835 g (3 mmol) of 3’-(piperidin-4-yloxy)biphenyl3-carbonitrile obtained in stage 5.2. in 4.9 ml of dichloromethane and then 1.09 ml (6.6 mmol) of diisopropylethylamine are subsequently added. The mixture is stirred at ambient température overnight. 11 ml of dichloromethane are added and the organic phase is washed with 3 times 25 ml of ice-cold water. The organic phase is dried over sodium sulphate and evaporated to dryness. The product is purified by chromatography on silica gel, elution being carried out with a 10:90 mixture of ethyl acetate and cyclohexane. Crystallization is subsequently carried out from n-hexane in order to obtain 0.635 g (1.34 mmol) of product in the form of a white solid.
Melting point (°C): 80-82
LC/MS (method A): Rt 11.8 min, m/z 473 (MH+)
IR(KBr, cm’1): 2235, 1730 1H NMR (CDCIs, δ ppm, 200 MHz): 7.85 (m, 2H), 7.7-7.5 (m, 2H), 7.4 (t, 1H), 7.15 (m,
2H), 7.0 (d.d, 1H), 5.8 (sept., 1H), 4.65 (m, 1H), 3.85-3.55 (m, 4H), 2.0 (m, 4H).
Example 6 (compound No. 65)
2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-(5-(trifluoromethyl)pyridin-2-ylamino)piperidine-1carboxylate hydrochloride (1:1)
CF.
H
6.1. fert-Butyl 4-(5-(trifluoromethyl)pyridin-2-ylamino)piperidine-1-carboxylate
A mixture of 0.678 g (3 mmol) of 2-bromo-5-(trifluoromethyl)pyridine, 0.901 g (4.5 mmol) of terf-butyl 4-aminopiperidine-1-carboxylate and 0.829 g (6 mmol) of potassium carbonate in 5 ml of dimethyl sulphoxide is heated at 100°C for 20 hours. The mixture is cooled to ambient température and then 50 ml of ethyl acetate and 15 ml of water are added. The organic phase is separated by settling and washed twice with 15 ml of water and then with 15 ml of a saturated aqueous sodium chloride solution. It is dried over sodium sulphate and evaporated under vacuum. The product is purified by chromatography on silica gel, elution being carried out with a 20:80 and then 30:70 mixture of ethyl acetate and cyclohexane in order to obtain 0.864 g (2.5 mmol) of product in the form of a white solid.
Melting point (°C): 152
6.2. (Piperidin-4-yl)(5-(trifluoromethyl)pyridin-2-yl)amine
0.860 g (2.49 mmol) of fe/ï-butyl 4-(5-(trifluoromethyl)(pyridin-2-ylamino)piperidine-1carboxylate obtained in stage 6.1. is dissolved in 8.5 ml of dichloromethane. 1.91 ml of trifluoroacetic acid are added and the mixture is stirred at ambient température for 4 hours. The dichloromethane is evaporated and then the residue is coevaporated twice with 10 ml of 1,2-dichloroethane. The residue is taken up in a mixture of 50 ml of ethyl acetate, 10 ml of a 1N aqueous sodium hydroxide solution and 5 ml of a 33% aqueous ammonia solution. The organic phase is separated by settling. It is washed with 2 times 10 ml of water and then with 10 ml of a saturated aqueous sodium chloride solution. It is dried over sodium sulphate and evaporated to dryness to produce 0.572 g (2.33 mmol) of product in the form of an off-white solid.
Melting point (°C): 128
6.3. 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-(5-(trifluoromethyl)(pyridin-2- ylamino)piperidine-1 -carboxylate
A solution of 0.467 g (2.32 mmol) of 4-nitrophenyl chloroformate in 3 ml of dichloromethane is added dropwise to a solution, cooled to 0°C, under an argon atmosphère, of 0.781 g (4.64 mmol) of 1,1,1,3,3,3-hexafluoro-2-propanol, 0.38 ml (4.64 mmol) of pyridine and 0.014 g (0.11 mmol) of 4-dimethylaminopyridine in 1.5 ml of dichloromethane. The mixture is left at ambient température overnight and then 0.569 g (2.32 mmol) of (piperidin-4-yl)(5-(trifluoromethyl)pyridin-2-yl)amine obtained in stage 6.2. and 1.22 ml (6.96 mmol) of diisopropylethylamine in 5 ml of dichloromethane are added. The mixture is stirred for 5 hours and then evaporated. The residue is taken up in a mixture of 10 ml of ethyl acetate, 50 ml of diethyl ether and 20 ml of water. The organic phase is separated by settling and then washed with 3 times 20 ml of a 1M aqueous potassium carbonate solution. The aqueous phases are reextracted with 20 ml of diethyl ether. The organic phases are washed with 20 ml of water and then 20 ml of a saturated aqueous sodium chloride solution. They are dried over sodium sulphate and evaporated to dryness. The product is purified by chromatography on silica gel, elution being carried out with a 15:85 and then 20:80 mixture of ethyl acetate and cyclohexane, in order to obtain 0.766 g (1.74 mmol) of product in the form of a white solid.
1H NMR (CDCIs, δ ppm, 200 MHz): 8.3 (s, 1H), 7.55 (d.d, 1H), 6.25 (d, 1H), 5.75 (sept., 1H), 4.7 (d, 1H), 4.1 (m, 3H), 3.15 (m, 2H), 2.15 (m, 2H), 1.45 (m, 2H).
6.4. 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-(5-(trifluoromethyl)(pyridin-2- ylamino)piperidine-1-carboxylate hydrochloride (1:1)
0.75 g (1.71 mmol) of 2,2,2-trifluoro-1-(trifluoromethyl)ethyl 4-(5-(trifluoromethyl)pyridin-2ylamino)piperidine-1-carboxylate, obtained in stage 6.3, is dissolved in 15 ml of diisopropyl ether. 0.68 ml of a 5N solution of hydrochloric acid in isopropanol is added. The mixture is evaporated to dryness. The residue is recrystallized under hot conditions from a mixture of acetone and diisopropyl ether in order to obtain 0.616 g (1.30 mmol) of product in the form of white crystals.
Melting point (°C): 225-235 (décomposition) LC/MS (method B): Rt 9 min, m/z 440 (MH+) IR (KBr, cm’1): 1740,1673, 1624 1H NMR (CD3OD, δ ppm, 400 MHz): 8.25 (s, 1H), 8.05 (d.d, 1H), 7.15 (d, 1H), 6.15 (sept., 1 H), 4.2 (m, 2H), 4.0 (m, 1 H), 3.2 (m, 2H), 2.1 (m, 2H), 1.6 (m, 2H).
Example 7 (compound No. 120)
2,2,2-T rifluoro-1 -(trifluoromethyl)ethyl
4-[(4-chlorobenzenesulphonylamino)methyl]17933 piperidine-1 -carboxylate
O O
7.1. tert-Butyl 4-[(4-chlorobenzenesulphonylamino)methyl]piperidine-1-carboxylate
A solution of 0.844 g (4 mmol) of 4-chlorobenzenesulphonyl chloride in 5 ml of dichloromethane is added dropwise to a solution of 0.857 g (4 mmol) of tert-butyl 4-(aminomethyl)piperidine-1-carboxylate, 0.99 ml (6 mmol) of diisopropylethylamine and 0.024 g (0.2 mmol) of 4-dimethylaminopyridine in 9 ml of dichloromethane. The mixture is stirred at ambient température overnight. The organic phase is washed with 10 ml of water and then 4 ml of a 1N aqueous hydrochloric acid solution, 2 times 14 ml of water, 2 times 14 ml of a 1N aqueous sodium hydroxide solution, 3 times 14 ml of water and 14 ml of a saturated aqueous sodium chloride solution. It is dried over sodium sulphate and evaporated to dryness in order to obtain 1.371 g (3.52 mmol) of product in the form of an orange paste used as is in the following stage.
7.2. 4-Chloro-A/-(piperidin-4-ylmethyl)benzenesulphonamide
1.364 g (3.51 mmol), terf-butyl 4-[(4-chlorobenzenesulphonylamino)methyl]piperidine-1carboxylate, obtained in stage 7.1., are dissolved in 11 ml of dichloromethane. 2.7 ml (35 mmol) of trifluoroacetic acid are added. The mixture is stirred for 4 hours and then evaporated to dryness. The residue is taken up in 11 ml of a 1N aqueous hydrochloric acid solution. The aqueous phase is washed with 3 times 11 ml of diethyl ether and then 1.6 ml of a 33% aqueous sodium hydroxide solution are added. Extraction is carried out with 3 times 11 ml of dichloromethane and then with 3 times 15 ml of chloroform. The organic phases are dried over sodium sulphate and evaporated to dryness in order to obtain 0.847 g (2.93 mmol) of product in the form of a white solid.
7.3. 2,2,2-Trifluoro-1 -(trifluoromethyl)ethyl 4-[(4-chlorobenzenesulphonylamino)methyl]piperidine-1 -carboxylate
A solution of 0.59 g (2.93 mmol) of 4-nitrophenyl chloroformate in 6 ml of dichloromethane is added dropwise to a solution, cooled to 0°C, under an argon atmosphère, of 0.984 g (5.86 mmol) of 1,1,1,3,3,3-hexafluoro-2-propanol, 0.48 ml (5.86 mmol) of pyridine and 0.015 g (0.17 mmol) of 4-dimethylaminopyridine in 6 ml of dichloromethane. The mixture is left at ambient température overnight and then a mixture of 0.846 g (2.93 mmol) of 4-chloro-/V-(piperidin-4-ylmethyl)benzenesulphonamide obtained in stage 7.2. and 1.21 ml (7.33 mmol) of diisopropylethylamine in 9 ml of * «>
dichloromethane is added. The mixture is stirred at ambient température for 5 hours and then evaporated to dryness. The residue is taken up in a mixture of 16 ml of ethyl acetate and 56 ml of diethyl ether. The organic phase is washed with 4 times 50 ml of water and then 70 ml of a 1M aqueous sodium carbonate solution, 70 ml of water and 70 ml of a saturated aqueous sodium chloride solution. It is dried over sodium sulphate and evaporated to dryness. The residue is purified by chromatography on silica gel, elution being carried out with a 25:75 mixture of ethyl acetate and cyclohexane. Crystaliization is carried out from n-hexane in order to obtain 0.849 g (1.75 mmol) of product in the form of a white solid.
Melting point (°C): 136-138
LC/MS (method C): Rt 6.4 min, m/z 483 (MH+)
IR(KBr, cm’1): 3272,1726 1H NMR (CDCIg, δ ppm, 400 MHz): 7.85 (d, 2H), 7.55 (d, 2H), 5.75 (sept., 1H), 4.50 (m, 1 H), 4.20 (m, 2H), 2.90 (m, 4H), 1.75 (m, 3H), 1.15 (m, 2H).
Example 8 (compound No.166)
2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[3-(3-chlorophenyl)ureido]piperidine-1- carboxylate
O CF.
Cl
8.1. 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-(tert-butoxycarbonylamino)piperidine-1carboxylate
A solution of 3.02 g (15 mmol) of 4-nitrophenyl chloroformate is added dropwise to a solution, cooled to 0°C, under an argon atmosphère, of 3.15 ml (30 mmol) of 1,1,1,3,3,3hexafluoro-2-propanol, 2.42 ml (30 mmol) of pyridine and 0.091 g (0.75 mmol) of 4dimethylaminopyridine in 10 ml of dichloromethane. The mixture is left to react at ambient température overnight. It is cooled to 0°C and 3.00 g (15 mmol) of tert-butyl (piperidin-4yl)carbamate are added portionwise and then 6.55 ml (37.5 mmol) of diisopropylethylamine are added dropwise. The mixture is stirred at ambient température for 5 hours and evaporated. The residue is taken up in a mixture of 20 ml of ethyl acetate, 30 ml of water and 60 ml of diethyl ether. The organic phase is separated by settling. It is washed with 30 ml of water and then with 4 times 30 ml of a 1M aqueous sodium carbonate solution, 2 times 30 ml of water and 30 ml of a saturated aqueous sodium chloride solution. It is dried over sodium sulphate and evaporated to dryness in order to obtain 5.18 g (13.1 mmol) of product in the form of an off-white solid.
Melting point (°C): 104-106
IR (KBr, cm-1): 1731, 1678 1H NMR (CDCIs, δ ppm, 200 MHz): 5.65 (sept., 1 H), 4.3 (m, 1 H), 4.0 (m, 2H), 3.6 (m, 1 H),
2.95 (m, 2H), 1.95 (m, 2H), 1.4-1.2 (m+s, 11 H).
8.2. 2,2,2-Trifluoro-l-(trifluoromethyl)ethyl 4-aminopiperidine-1-carboxylate hydrochloride
5.10 g (12.93 mmol) of 2,2,2-trifluoro-1-(trifluoromethyl)ethyl 4-(tertbutoxycarbonylamino)piperidine-1-carboxylate obtained in stage 8.1. are dissolved in 18 ml of dichloromethane, and 5.2 ml of a 5N solution of hydrochloric acid in isopropanol 10 are added with stirring. After 3 hours, a further 2.6 ml of the hydrochloric acid solution are added. Stirring is continued at ambient température overnight. The mixture is evaporated to dryness. 50 ml of diisopropyl ether are added. Stirring is continued for 3 hours. The solid is filtered off and then dried under vacuum in the presence of phosphorus pentoxide in order to obtain 4.27 g (12.9 mmol) of product in the form of an off-white powder.
Melting point (°C): 204-206
IR (KBr, cm’1): 1731 1H NMR (DMSO, δ ppm, 200 MHz): 8.2 (m, 3H), 6.6 (sept., 1H), 4.0 (m, 2H), 3.4-2.9 (m, 3H), 2.0 (m,2H), 1.45 (m, 2H).
8.3. 2,2,2-Trifluoro-l-(trifluoromethyl)ethyl 4-[3-(3-chlorophenyl)ureido]piperidine-1carboxylate
0.30 ml (1.72 mmol) of diisopropylethylamine and then 0.230 g (1.5 mmol) of 3chlorophenyl isocyanate in solution in 3 ml of dichloromethane are added to a suspension of 0.545 g (1.65 mmol) of of 2,2,2-trifluoro-1-(trifluoromethyl)ethyl 4-aminopiperidine-125 carboxylate hydrochloride, obtained in stage 8.2., in 3 ml of dichloromethane. The mixture is stirred at ambient température overnight. It is evaporated to dryness. The residue is taken up in a mixture of 40 ml of ethyl acetate and 10 ml of water. The organic phase is separated by settling. It is washed with 10 ml of water and then 10 ml of a 1N aqueous hydrochloric acid solution, 10 ml of water and 10 ml of a saturated aqueous sodium 30 chloride solution. It is dried over sodium sulphate and evaporated to dryness. The product is purifled by chromatography on silica gel, elution being carried out with a 30:70 and then 40:60 mixture of ethyl acetate and cyclohexane. Recrystallization is carried out under hot conditions from a mixture of ethyl acetate and n-hexane in order to obtain 0.51 g (1.14 mmol) of product in the form of a white crystalline powder.
Melting point (°C): 204-206
LC/MS (method D): Rt 1.27 min, m/z448 (MH+)
IR (KBr, cm’1): 1725, 1683 1H NMR (DMSO, δ ppm, 400 MHz): 8.55 (s, 1H), 7.65 (s, 1H), 7.25 (m, 2H), 6.95 (d.d, 1H), 6.55 (sept., 1H), 6.35 (d, 1H), 3.9 (m, 2H), 3.75 (m, 1H), 3.2 (m, 2H), 1.9 (m, 2H), 1.35 (m,2H).
Example 9 (compound No. 87)
2,2,2-T rifluoro-1 -(trifluoromethyl)ethyl
4-{[2-(4-chlorophenoxy)-2-methylpropionylamino]methyl}piperidine-1 -carboxylate
9.1. 2,2,2-Trifluoro-l-(trifluoromethyl)ethyl 4-(aminomethyl)piperidine-1-carboxylate hydrochloride
As described in the preceding Examples 2, 6.3. and 7.3., a mixture of 0.41 ml (3.91 mmol) of 1,1,1,3,3,3-hexafluoro-2-propanol, 0.32 ml (3.91 mmol) of pyridine, 0.023 g (0.19 mmol) of 4-dimethylaminopyridine and 0.75 g (3.72 mmol) of 4-nitrophenyl chloroformate in solution in 13 ml of dichloromethane is left to react at ambient température overnight. 0.84 g (3.90 mmol) of terf-butyl (piperidin-4-yl)methylcarbamate and 2.1 ml (11.7 mmol) of diisopropylethylamine are added. The mixture is stirred at ambient température for 4 hours. The organic phase is washed with 5 times 25 ml of a 1N aqueous sodium hydroxide solution and then with 2 times 25 ml of a 1N aqueous hydrochloric acid solution. It is dried over magnésium sulphate in order to obtain 1.6 g of product in the form of an oil.
The product is taken up in 9.7 ml (39 mmol) of a 4N solution of hydrochloric acid in dioxane. The mixture is stirred at ambient température overnight and then evaporated to dryness. The residue is taken up in diethyl ether and the product is filtered off and dried under vacuum in order to obtain 0.91 g (2.64 mmol) of product in the form of an off-white powder.
Melting point (°C): 177-178
IR (KBr, cm'1): 1716 1H NMR (DMSO, δ ppm, 200 MHz): 7.95 (m, 3H), 6.55 (sept., 1H), 4.0 (m, 2H), 3.0 (m, 2H), 2.75 (m, 2H), 1.85 (m, 3H), 1.15 (m, 2H).
9.2. 2,2,2-Trifluoro-l -(trifluoromethyl)ethyl 4-{[2-(4-chlorophenoxy)-2-methylpropionylamino]methyl}piperidine-1-carboxylate
0.10 g (0.29 mmol) of 2,2,2-trifluoro-1-(trifluoromethyl)ethyl 4-(aminomethyl)piperidine-1carboxylate hydrochloride, obtained in stage 9.1., and 0.071 g (0.29 mmol) of 2-(4J chlorophenoxy)-2-methylpropionyl chloride are dissolved in 1.5 ml of dichloromethane. 0.13 ml (0.73 mmol) of diisopropylethylamine is added. The mixture is stirred at ambient température overnight. 1.5 ml of dichloromethane are added. The organic phase is washed with 2 ml of a 1N aqueous hydrochloric acid solution, then filtered through a hydrophobie cartridge and evaporated to dryness. The product is purified by chromatography on silica gel, elution being carried out with a gradient of 10:90 to 40:60 of ethyl acetate and cyclohexane, in 15 min, in order to obtain 0.089 g (0.176 mmol) of product in the form of a white powder.
Melting point (°C): 77-78
LC/MS (method D): Rt 1.44 min, m/z 505 (MH+)
IR(KBr, cm’1): 1749, 1655 1H NMR (DMSO, δ ppm, 400 MHz): 8.2 (t, 1H), 7.35 (d, 2H), 6.9 (d, 2H), 6.55 (sept., 1H),
3.9 (m, 2H), 3.0-2.85 (m, 4H), 1.7 (m, 1H), 1.55 (d, 2H), 1.45 (s, 6H), 1.0 (m, 2H).
Example 10 (compound No. 191)
2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 3-[2-(3-methyl-3-phenylureido)ethyl]azetidine-1carboxylate
10.1. 2,2,2-T rifl uoro-1 -(trifluoromethyl)ethyl 3-(2-aminoethyl)azetidine-1 -carboxylate hydrochloride
As described in the preceding Example 9.1., a mixture of 1.65 ml (15.63 mmol) of 1,1,1,3,3,3-hexafluoro-2-propanol, 1.27 ml (15.63 mmol) of pyridine, 0.090 g (0.74 mmol) of 4-dimethylaminopyridine and 3.0 g (14.88 mmol) of 4-nitrophenyl chloroformate in solution in 50 ml of dichloromethane is left to react at ambient température overnight.
Half the solution is withdrawn. 1.853 g (7.83 mmol) of fert-butyl (2-(azetidin-3yl)ethyl)carbamate, 4.19 ml (23.49 mmol) of diisopropylethylamine and 20 ml of dichloromethane are added. The mixture is stirred at ambient température overnight. The organic phase is subsequently washed with 3 times 50 ml of a 1N aqueous sodium hydroxide solution and then with 50 ml of a 1N aqueous hydrochloric acid solution. It is dried over magnésium sulphate and evaporated to dryness in order to obtain 3.00 g of product.
The product is taken up in 19 ml (76 mmol) of a 4N solution of hydrochloric acid in dioxane. A further 20 ml of dioxane are added. The mixture is stirred at ambient température for 5 hours. It is evaporated to dryness in order to obtain 2.50 g (7.56 mmol) » » of product in the form of an oil which solidifies.
Melting point (°C): 116-117
IR(KBr, cm’1): 1731 1H NMR (DMSO, δ ppm, 200 MHz): 8.0 (m, 3H), 6.5 (sept., 1H), 4.15 (m, 2H), 3.75 (m, 2H), 2.75 (m, 3H), 1.9 (m, 2H).
10.2. 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 3-[2-(3-methyl-3-phenylureido)ethyl]azetidine1-carboxylate
0.112 g (0.34 mmol) of 2,2,2-trifluoro-1-(trifluoromethyl)ethyl 3-(2-aminoethyl)azetidine-1carboxylate hydrochloride, obtained in stage 10.1., is dissolved in 2 ml of dichloromethane. 0.054 g (0.32 mmol) of N-methyl-N-phenylcarbamoyl chloride and 0.15 ml (0.85 mmol) of diisopropylethylamine are added. The mixture is stirred at ambient température overnight. The organic phase is washed with 3 times 2 ml of a 1N aqueous sodium hydroxide solution and then with 2 ml of a 1N aqueous hydrochloric acid solution. It is dried by filtration through a hydrophobie cartridge and evaporated to dryness. The product is purified by chromatography on silica gel, elution being carried out with a gradient of 15:85 to 45:55 ethyl acetate and cyclohexane, in 15 minutes, in order to obtain 0.06 g (0.14 mmol) of product in the form of a white powder.
Melting point (°C): 101-102
LC/MS (method D): Rt 1.2 min, m/z 428 (MH+)
IR (KBr, cm’1): 3353, 1738, 1643 1H NMR (DMSO, δ ppm, 400 MHz): 7.4 (m, 2H), 7.25 (m, 3H), 6.45 (sept., 1H), 6.0 (t, 1H), 4.1 (m, 2H), 3.75 (m, 2H), 3.15 (s, 3H), 3.0 (m, 2H), 2.65 (m, 1H), 1.7 (m, 2H).
Example 11 (compound No. 113)
2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 3-[(naphthalene-1-sulphonylamino)methyl]- pyrrolidine-1-carboxylate
11.1. 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 3-(aminomethyl)pyrrolidine-1-carboxylate hydrochloride
The procedure is the same as described in Example 10.1. using 1.56 g (7.83 mmol) of tert-butyl (pyrrolidin-3-ylmethyl)carbamate (in place of tert-butyl (2-(azetidin-3yl)ethyl)carbamate), in order to obtain 1.51 g (4.56 mmol) of product in the form of an oil, used as is in the following stage. A solid sample is obtained by triturating from ethyl acetate.
Melting point (°C): 190°C (décomposition)
IR (KBr, cm’1): 1732 1H NMR (DMSO, δ ppm, 200 MHz): 7.90 (m, 3H), 6.55 (sept., 1H), 3.65 (m, 1H), 3.55 (m,
1H), 3.40 (m, 1H), 3.15 (m, 1H), 2.95 (m, 2H), 2.50 (m, 1H), 2.10 (m, 1H), 1.75 (m, 1H).
11.2. 2,2,2-Trifluoro-1 -(trifluoromethyl)ethyl 3-[(naphthalene-1 -sulphonylamino)methyl]pyrrolidine-1-carboxylate
The procedure is the same as described in Example 10.2. using 0.10 g (0.30 mmol) of
2,2,2-trifluoro-1 -(trifluoromethyl)ethyl 3-(aminomethyl)pyrrolidine-1 -carboxylate hydrochloride obtained in stage 11.2., 0.066 g (0.29 mmol) of naphthalene-1-sulphonyl chloride and 0.13 ml (0.76 mmol) of diisopropylethylamine, in order to obtain, after purification by chromatography on silica gel, 0.096 g (0.20 mmol) of product in the form of a white powder.
Melting point (°C): 135-136
LC/MS (method C): Rt 4.88 min, m/z 485 (MH+)
IR (KBr, cm’1): 1732 1H NMR (DMSO, δ ppm, 400 MHz): 8.65 (d, 1H), 8.25 (d, 1H), 8.15 (m, 3H), 7.75-7.60 (m, 3H), 6.45 (sept., 1H), 3.45-3.20 (m, 3H), 3.05 (m, 1H), 2.85 (m, 2H), 2.30 (m, 1H), 1.85 (m, 1H), 1.55 (m, 1H).
Example 12 (compound No. 220)
2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 3-[1-(4-chlorobenzenesulphonylamino)cyclopropyl]- azetidine-1 -carboxylate
12.1. ferf-Butyl 3-(1-aminocyclopropyl)azetidine-1-carboxylate
10.5 ml (35 mmol) of titanium tetraisopropoxide (Ti(OiPr)4) and then, dropwise, 21 ml (63 mmol) of a 3M solution of ethylmagnesium bromide in diethyl ether are added, under a nitrogen atmosphère, to a solution of 4.8 g (26.34 mmol) of terf-butyl 4-cyanoazetidine1-carboxylate in 150 ml of diethyl ether. The mixture is stirred for 40 minutes and then 9 ml (71 mmol) of the boron trifluoride etherate complex (BF3.Et2O) are added dropwise. The reaction mixture is stirred for 5 hours. 100 ml of a 2M aqueous sodium hydroxide solution and 150 ml of dichloromethane are added. The mixture is filtered through celite. The organic phase is separated by settling. It is dried over sodium sulphate and evaporated to dryness. The product is purified by chromatography on silica gel, elution being carried out with a 90:10 mixture of dichloromethane and methanol, in order to obtain 1.91 g (9.0 mmol) of product in the form of a colourless oil which slowly solidifies. 1H NMR (CDCIa, δ ppm, 200 MHz): 3.65 (t, 2H), 3.35 (m, 2H), 2.30-2.20 (m, 1H), 1.45 (s, 2H), 1.15 (s, 9H), 0.35 (m, 2H), 0.20 (m, 2H).
12.2. tert-Butyl 3-[1-(4-chlorobenzenesulphonylamino)cyclopropyl]azetidine-1-carboxylate 0.35 g (1.65 mmol) of terf-butyl 3-(1-aminocyclopropyl)azetidine-1 -carboxylate, obtained in stage 12.1., 0.6 ml (3.44 mmol) of diisopropylethylamine and 0.34 g (1.61 mmol) of 4-chlorobenzenesulphonyl chloride are dissolved in 4 ml of dichloromethane. The mixture is stirred at ambient température for 20 hours. 20 ml of dichloromethane are added and washing is carried out with 10 ml of a 1N aqueous hydrochloric acid solution, then 10 ml of a 1N aqueous sodium hydroxide solution and 10 ml of a saturated aqueous sodium chloride solution. The organic phase is filtered through a hydrophobie cartridge and evaporated to dryness. The residue is purified by chromatography on silica gel, elution being carried out with a 95:5 mixture of dichloromethane and methanol, in order to obtain 0.30 g (0.77 mmol) of product in the form of a white solid.
1H NMR (CDCI3j δ ppm, 200 MHz): 7.85 (m, 2H), 7.55 (m, 2H), 5.55 (s, 1H), 3.90 (t, 2H), 3.50 (m, 2H), 3.15-3.00 (m, 1H), 1.50 (s, 9H), 0.80 (s, 4H).
12.3. N-(1 -(Azetidin-3-yl)cyclopropyl)-4-chlorobenzenesulphonamide hydrochloride
0.30 g (0.78 mmol) of terf-butyl 3-[1-(4-chlorobenzenesulphonylamino)cyclopropyl]azetidine-1-carboxylate, obtained in stage 12.2., is dissolved in 10 ml of methanol. 0,2 ml (1.58 mmol) of trimethylsilyl chloride is added. The mixture is stirred at ambient température overnight. A further 0.2 ml of trimethylsilyl chloride is added and stirring is continued for 4 hours. The mixture is concentrated under vacuum and then the residue is taken up in ethyl acetate and evaporated to dryness in order to obtain 0.28 g of product in the form of a white solid used as is.
12.4. 2,2,2-Trifluoro-1 -(trifluoromethyl)ethyl 3-[1 -(4-chlorobenzenesulphonylamino)cyclopropyl]azetidine-1 -carboxylate
A solution of 2.0 g (9.9 mmol) of 4-nitrophenyl chloroformate in 10 ml of dichloromethane is added dropwise to a solution of 2.50 g (14.9 mmol) of 1,1,1,3,3,3-hexafluoro-2propanol and 1.90 ml (23.5 mmol) of pyridine in 40 ml of dichloromethane. The mixture is left to react at ambient température overnight.
ml of this solution are withdrawn and 0.28 g (0.87 mmol) of N-(1-azetidin-3-ylcyclopropyl)-4-chlorobenzenesulphonamide hydrochloride, obtained in stage 12.3., and 1.3 ml (7.46 mmol) of diisopropylethylamine are added. The mixture is stirred for 8 hours. Washing is carried out with 2 times 10 ml of a 0.5N aqueous hydrochloric acid solution and then 3 times 10 ml of a saturated aqueous sodium carbonate solution. The organic phase is filtered through a hydrophobie cartridge and evaporated to dryness. The residue is purified by chromatography on silica gel, elution being carried out with a 95:5 mixture of dichloromethane and methanol, in order to obtain 0.32 g (0.66 mmol) of product in the form of a white powder.
Melting point (°C): 108-109
LC/MS (method C): Rt 4.97 min, m/z 481 (MH+)
IR(KBr, cm’1): 1761,1736 1H NMR (DMSO, δ ppm, 400 MHz): 8.55 (s, 1H), 7.80 (d, 2H), 7.70 (d, 2H), 6.45 (septet, 1H), 3.90 (m, 2H), 3.70 (m, 2H), 2.85 (m, 1H), 0.65 (m, 2H), 0.60 (m, 2H).
Example 13 (compound No. 231)
2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-(4-carbamoylpyrazol-1-ylmethyl)piperidine-1carboxylate h2n
13.1. tert-Butyl 4-(4-carbamoylpyrazol-1 -ylmethyl)piperidine-1 -carboxylate
2.15 g (10 mmol) of terf-butyl 4-(hydroxymethyl)piperidine-1-carboxylate, 2.11 ml (15 mmol) of triethylamine and 0.06 g (0.5 mmol) of 4-dimethylaminopyridine are dissolved in 15 ml of dichloromethane under an argon atmosphère. The solution is cooled with an ice bath and a solution of 1.60 g (14 mmol) of methanesulphonyl chloride in 5 ml of dichloromethane is added dropwise. The mixture is stirred at the température of the ice bath for one hour and then at ambient température for 2 hours. 20 ml of water and 20 ml of dichloromethane are added. The organic phase is separated by settling and washed with 20 ml of a 0.5N aqueous hydrochloric acid solution, then twice with 20 ml of water and 20 ml of a saturated aqueous sodium chloride solution. The organic phase is dried over sodium sulphate and evaporated to dryness in order to obtain 2.96 g (10 mmol) of mesylate in the form of an orange oil.
1.76 g (6 mmol) of this product are redissolved in 6 ml of N,N-dimethylformamide. 0.76 g (6.9 mmol) of 1 H-pyrazole-4-carboxamide and 1.24 g (9 mmol) of potassium carbonate are added with stirring and the mixture is heated at 70°C overnight. 30 ml of ethyl acetate are added and the solid is filtered off and washed with 6 ml of a 1:5 mixture of N,Ndimethylformamide and ethyl acetate and then 6 ml of ethyl acetate. The filtrâtes are evaporated to dryness. The residue is taken up in 50 ml of a 95:5 mixture of chloroform and methanol. The insoluble material is filtered off and washed twice with a 95:5 mixture of chloroform and methanol. The filtrâtes are evaporated to dryness and the residue is recrystallized under hot conditions from ethyl acetate in order to obtain 0.98 g (3.17 mmol) of product in the form of a white powder.
Melting point (°C): 190-192 1H NMR (CDCIa, δ ppm, 200 MHz): 7.80 (s, 1H), 7.70 (s, 1H), 5.55 (m, 2H), 4.05 (broad d,
2H), 3.95 (d, 2H), 2.60 (t, 2H), 2.00 (m, 1H), 1.45 (broad d, 2H), 1.80 (s, 9H), 1.20-1.00 (m, 2H).
13.2.1-(Piperidin-4-ylmethyl)-1 H-pyrazole-4-carboxamide hydrochloride
A suspension of 0.96 g (3.11 mmol) of tert-butyl 4-(4-carbamoylpyrazol-110 ylmethyl)piperidine-1 -carboxylate, obtained in stage 13.1., in 25 ml of a 5N solution of hydrochloric acid (124 mmol) in isopropanol is stirred overnight. It is evaporated to dryness and then coevaporated twice with 25 ml of ethyl acetate. The product is resuspended in 25 ml of ethyl acetate. It is filtered, washed twice with 10 ml of ethyl acetate and dried under vacuum in order to obtain 0.91 g (3.23 mmol) of product in the form of a white powder.
1H NMR (DMSO+D2O, δ ppm, 200 MHz): 8.15 (s, 1H), 7.85 (s, 1H), 4.05 (d, 2H), 3.25 (broad d, 2H), 2,80 (broad t, 2H), 2.10 (m, 1H), 1.60 (broad d, 2H), 1.45-1.25 (m, 2H).
13.3. 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-(4-carbamoylpyrazol-1-ylmethyl)piperidine20 1-carboxylate
A solution of 0.605 g (3 mmol) of 4-nitrophenyl chloroformate in 5 ml of dichloromethane is added dropwise to a solution of 1.00 g (6 mmol) of 1,1,1,3,3,3-hexafluoro-2-propanol, 0.49 ml (6 mmol) of pyridine and 0.036 g (0.3 mmol) of 4-dimethylaminopyridine in 5 ml of dichloromethane. The mixture is left to react at ambient température overnight.
This solution is added dropwise, under an argon atmosphère, to a solution, cooled with an ice bath, of 0.84 g (3 mmol) of 1-(piperidin-4-ylmethyl)-1H-pyrazole-4-carboxamide hydrochloride, obtained in stage 13.2., and 2.2 ml (13 mmol) of diisopropylethylamine in a mixture of 15 ml of Ν,Ν-dimethylformamide and 7 ml of dimethyl sulphoxide. The reaction mixture is subsequently stirred at ambient température for 2 hours and evaporated under vacuum. The residue is taken up in 50 ml of ethyl acetate and 2.8 g (20 mmol) of potassium carbonate are added thereto. The mixture is stirred vigorously for 2 hours. The solid is filtered off and washed twice with 25 ml of ethyl acetate. The filtrate is subsequently washed twice with 10 ml of a semisaturated aqueous sodium chloride solution and then twice with 10 ml of a saturated aqueous sodium chloride solution. The filtrate is dried over sodium sulphate and evaporated to dryness. The product is purified by chromatography on silica gel, elution being carried out with a 97:3, then 95:5 and 92:8 mixture of dichloromethane and methanol, in order to obtain 1.0 g of product in the form of a white solid, contaminated by approximately 3 mol% of 4-nitro-phenyl 4-(4carbamoylpyrazol-1-ylmethyl)piperidine-1-carboxylate.
0.80 g of this product is redissolved in 15 ml of ethyl acetate. 0.2 g of 10% palladium-oncharcoal is added thereto and the mixture is stirred under a hydrogen atmosphère of 2 bar for 3 hours. It is subsequently filtered through celite. Rinsing is carried out 4 times with 10 ml of ethyl acetate and the filtrate is evaporated to dryness. The product is purified by chromatography on silica gel, elution being carried out with a 97:3, then 95:5 and then 92:8 mixture of dichloromethane and methanol, in order to obtain 0.75 g of product in the form of a white solid. Recrystallization is carried out under hot conditions from a mixture of ethyl acetate and diisopropyl ether in order to obtain 0.68 g (1.69 mmol) of product in the form of a white powder.
Melting point (°C): 98-118
LC/MS (method D): Rt 0.97 min, m/z 403 (MH+)
IR(KBr, cm·1): 1722,1656 1H NMR (CDCIs, δ ppm, 400 MHz): 7.90 (s, 1H), 7.80 (s, 1H), 5.75 (septet 1H), 5.55 (m, 2H), 4.20 (broad t, 2H), 4.05 (d, 2H), 2.90 (m, 2H), 2.20 (m, 1H), 1.65 (m, 2H), 1.25 (m, 2H).
Example 14 (compound No. 234)
2,2,2-Trifluoro-1-(trifluoromethyl)ethyl 4-[2-(5-carbamoylpyrazin-2-ylamino)ethyl]piperidine1 -carboxylate
H
14.1. tert-Butyl 4-[2-(5-carbamoylpyrazin-2-ylamino)ethyl]piperidine-1 -carboxylate
A mixture of 1.12 g (7.15 mmol) of 5-chloropyrazine-2-carboxamide, 1.95 g (8.58 mmol) of tert-butyl 4-(2-aminoethyl)piperidine-1 -carboxylate and 1.18 g (8.58 mmol) of potassium carbonate in 1.4 ml of dimethyl sulphoxide is heated during 5 hours at 100°C under an argon atmosphère and with stirring. After cooling to ambient température, 25 ml of ethyl acetate and 25 ml of water are added. The organic phase is separated by settling and washed 3 times with 25 ml of water and then 25 ml of a saturated aqueous sodium chloride solution. It is dried over sodium sulphate and evaporated to dryness. The residue is purified by chromatography on silica gel, elution being carried out with a 97:3, then 95:5 and 93:7 mixture of dichloromethane and methanol, in order to obtain 1.99 g (5.69 mmol) of product in the form of a light-yellow paste.
1H NMR (CDCIs, δ ppm, 200 MHz): 8.65 (s, 1H), 8.10 (s, 1H), 7.55 (m, 1H), 5.75 (m, 1H),
4.85 (m, 1H), 4.15 (m, 2H), 3.45 (m, 2H), 2.75 (t, 2H), 1.80-1.60 (m, 5H), 1.50 (s, 9H), 1.35-1.10 (m, 2H).
14.2. 5-(2-(Piperidin-4-yl)ethylamino)pyrazine-2-carboxamide dihydrochloride
1,98 g (5.68 mmol) of terf-butyl 4-[2-(5-carbamoylpyrazin-2-ylamino)ethyl]piperidine-1carboxylate, obtained in stage 14.1., are dissolved in 20 ml of dichloromethane. 13 ml of a 5N solution of hydrochloric acid in isopropanol are added and the mixture is stirred overnight. It is evaporated to dryness and then coevaporated twice with 50 ml of ethyl acetate. The residue is taken up in 17 ml of ethyl acetate and stirred for one hour. The 10 solid is filtered off, washed with 2 times 5 ml of ethyl acetate and dried under vacuum in order to obtain 1.78 g (5.54 mmol) of product in the form of a yellow solid.
1H NMR (DMSO+D2O, δ ppm, 200 MHz): 8.20 (s, 1H), 8.10 (s, 1H), 3.40 (t, 2H), 3.25 (broad d, 2H), 2.80 (t, 2H), 1.90 (broad d, 2H), 1.70-1.15 (m, 5H).
14.3. 2,2,2-Trifluoro-1 -(trifluoromethyl)ethyl 4-[2-(5-carbamoylpyrazin-2ylamino)ethyl]piperidine-1-carboxylate
A solution of 1.01 g (5 mmol) of 4-nitrophenyl chloroformate in 8.5 ml of dichloromethane is added dropwise to a solution, cooled under argon with an ice bath, of 1.69 g (10 mmol) of 1,1,1,3,3,3-hexafluoro-2-propanol, 0.82 ml (10 mmol) of pyridine and 0.030 g 20 (0.25 mmol) of 4-dimethylaminopyridine in 8.5 ml of dichloromethane. The mixture is left to react at ambient température overnight.
This solution is added dropwise, under an argon atmosphère and with stirring, to a mixture, cooled with a bath of cold water, of 1.62 g (5.04 mmol) of 5-(2-(piperidin-4yl)ethylamino)pyrazine-2-carboxamide dihydrochloride, obtained in stage 14.2., and 3.75 25 ml (22 mmol) of diisopropylethylamine in 11 ml of dimethyl sulphoxide. The reaction mixture is subsequently stirred at ambient température for 4 hours and evaporated under vacuum. The residue is taken up in 110 ml of ethyl acetate and 4.7 g (34 mmol) of potassium carbonate are added thereto. The mixture is stirred vigorously for 4 hours. The solid is filtered off and washed twice with 30 ml of ethyl acetate. The filtrate is 30 subsequently washed 3 times with 16 ml of a semisaturated aqueous sodium chloride solution and then 3 times with 16 ml of a saturated aqueous sodium chloride solution. The filtrate is dried over sodium sulphate and evaporated to dryness. The product is purified by chromatography on silica gel, elution being carried out with a 90:10 mixture of ethyl acetate and cyclohexane and then with ethyl acetate, in order to obtain 1.6 g of 35 product. It is redissolved in 90 ml of ethyl acetate and washed 3 times with 7.5 ml of a 1M aqueous potassium carbonate solution and then twice with 7.5 ml of water. The organic phase is dried over sodium sulphate and evaporated in order to obtain 1.57 g of product.
.· J »
Recrystallization is carried out under hot conditions from a mixture of ethyl acetate and diisopropyl ether, in order to obtain 1.31 g (2.95 mmol) of product in the form of a lightyellow powder.
Melting point (°C): 156-158
LC/MS (method D): Rt 1.16 min, m/z 444 (MH+)
IR (KBr, cm'1): 1725, 1675 1H NMR (DMSO, δ ppm, 400 MHz): 8.65 (s, 1H), 8.10 (s, 1H), 7.45 (broad s, 1H), 5.75 (septet, 1H), 5.55 (broad s, 1H), 4,70 (broad s, 1H), 4.15 (broad t, 2H), 3.50 (broad s, 2H), 2.90 (m, 2H), 1.80-1.20 (m, 7H).
The chemical structures and the physical properties of a few examples of compounds according to the invention are illustrated in thefollowing Table 1. In this table:
M.p. (°C) represents the melting point of the compound in degrees Celsius;
- (m/z) represents the molecular ion observed in mass spectrometry (LC/MS); (MH+) represents a molecular ion with protonation;
((M-H)-) represents a molecular ion with loss of a proton;
- (M+) represents a molecular ion with loss of an électron;
- (MH+ACN) represents a molecular ion in the form of an adduct with acetonitrile;
(MNH4+) represents a molecular ion in the form of an adduct with ammonia;
- (MACO2-) represents a molecular ion in the form of an adduct with the acetate ion;
- in the Z and A columns, means that Z and/or A are absent;
in the Sait column, represents a compound in the form of the free base and HCl represents a compound in the hydrochlorideform;
NC represents a cyano group;
- -(c-prop) represents a cyclopropylenyl group;
- -NHC-(c-prop)- represents a group:
The compounds described in Table 1 were prepared according to the methods described above.
The rétention times (Rt) of several compounds of Table 1, measured by LC/MS analysis according to one of the methods A, B, C, D or E described above, are illustrated in Table 2.
The optical rotations ([a]D) obtained for the enantiomeric compounds 22, 23, 24 and 25 of Table 1 and the conditions for measuring [a]D are given in Table 3.
Table 1
No. | R | Z | A | m | n | Sait | M.p. (°C) | LC/MS (m/z) |
1. | 4-CI-phenyl | - | - | 1 | 1 | - | 60-62 | 390 (MH+) |
2. | 3-CH3-phenyl | - | - | 1 | 1 | oil | - | 411 (MH+ACN) |
3. | 2-CF3-phenyl | - | - | 1 | 1 | oil | - | 465 (MH+ACN) |
4. | 2-CH3Û-phenyl | - | - | 1 | 1 | oil | - | 427 (MH+ACN) |
5. | 4-NC-phenyl | - | - | 1 | 1 | - | 54-56 | 398 (MNH4+) |
6. | 4-CH3NHCO-phenyl | - | - | 1 | 1 | oil | 413 (MH+) | |
7. | naphth-1-yl | - | 1 | 1 | oii | - | 447 (MH+ACN) | |
8. | benzoxazol-2-yl | - | - | 1 | 1 | - | 71-73 | 397 (MH+) |
9. | 5-F-benz[d]isoxazol-3-yl | - | - | 1 | 1 | - | 127-129 | 415 (MH+) |
10. | 6-F-benz[d]isoxazol-3-yl | - | - | 1 | 1 | - | 91-93 | 415 (MH+) |
11. | 2-oxobenzimidazol-1-yl | - | 1 | 1 | - | 196-198 | 412 (MH+) | |
12. | 5-CI-2-oxobenzimidazol-1-yl | - | - | 1 | 1 | - | 231-233 | 446 (MH+) |
13. | 5-CF3-benzotriazol-1 -yl | - | 1 | 1 | - | 127-129 | 465 (MH+) | |
14. | 5-(4-F-phenyl)-1,3,4-oxadiazol-2-yl | - | - | 1 | 1 | - | 113-115 | 442 (MH+) |
15. | 6-F-indazol-3-yl | - | - | 1 | 1 | - | 137-141 | 414 (MH+) |
16. | phenyl | CHZ | - | 1 | 1 | oil | - | 411 (MH+ACN) |
17. | 3-(4-Cl-phenyl)isoxazol-5-yl | ch2 | 1 | 1 | - | 91-93 | 471 (MH+) | |
18. | 4-CI-phenyl | (CHz)2 | - | 1 | 1 | oil | - | 435 (MNH4+) |
19. | 4-CI-phenyl | c^c | - | 1 | 1 | oil | - | 414 (MH+) |
20. | 3-(4-F-phenyl)phenyl | - | O | 0 | 0 | - | 68-69 | 438 (MH+) |
21. | 3-(3-NC-phenyl)phenyl | - | O | 0 | 0 | oil | - | 444 (M+) |
22. | 3-(4-F-phenyl)phenyl | - | O | 0 | 1 | - | 72-73 | 452 (MH+) |
23. | 3-(4-F-phenyl)phenyl | - | O | 0 | 1 | - | 72-73 | 452 (MH+) |
24. | 3-(3-NC-phenyl)phenyl | - | O | 0 | 1 | oil | - | 476 (MNH4+) |
25. | 3-(3-NC-phenyl)phenyl | - | O | 0 | 1 | oil | - | 476 (MNH4+) |
26. | 4-F-phenyl | - | O | 1 | 1 | oil | - | 389 ((M-H)-) |
27. | 3-H2NCO-phenyl | - | O | 1 | 1 | - | 121-123 | 415 (MH+) |
28. | 4-H2NCO-phenyl | - | O | 1 | 1 | - | 153-155 | 415 (MH+) |
29. | 3-(3-F-phenyl)phenyl | - | O | 1 | 1 | oil | - | 466 (MH+) |
30. | 3-(4~F-phenyl)phenyl | - | O | 1 | 1 | - | 78-80 | 466 (MH+) |
31. | 3-(3-CI-phenyl)phenyl | - | O | 1 | 1 | - | 70-72 | 482 (MH+) |
32. | 3-(4-CI-phenyl)phenyl | - | O | 1 | 1 | - | 98-100 | 482 (MH+) |
33. | 3-(3-NC-phenyl)phenyl | O | 1 | 1 | - | 80-82 | 473 (MH+) | |
34. | 3-(4-NC-phenyl)phenyl | - | O | 1 | 1 | - | 73-77 | 473 (MH+) |
35. | 4-(3-NC-phenyl)phenyl | - | O | 1 | 1 | - | 87-89 | 473 (MH+) |
36. | 4-(4-NC-phenyl)phenyl | - | O | 1 | 1 | 141-143 | 473 (MH+) | |
37. | 3-(3-CH3O-phenyl)phenyl | - | O | 1 | 1 | oil | - | 478 (MH+) |
38. | 3-(4-CH3O-phenyl)phenyl | - | O | 1 | 1 | oil | - | 478 (MH+) |
39. | 4-CI-naphth-1-yl | - | O | 1 | 1 | - | 88-90 | 514 (MACO2-) |
40. | naphth-2-yl | - | O | 1 | 1 | - | 113-115 | 422 (MH+) |
41. | 6-NC-naphth-2-yl | - | O | 1 | 1 | - | 127-129 | 447 (MH+) |
42. | 6-CH3O-naphth-2-yl | - | O | 1 | 1 | - | 120-122 | 452 (MH+) |
43. | 7-CH3O-naphth-2-yl | - | O | 1 | 1 | - | 98-100 | 452 (MH+) |
44. | pyridin-4-yl | - | O | 1 | 1 | oil | - | 373 (MH+) |
45. | 6-(3-NC-phenyl)pyridin-2-yl | - | O | 1 | 1 | - | 124-126 | 474 (MH+) |
46. | 5-(3-NC-phenyl)pyridin-3-yl | - | O | 1 | 1 | - | 138-140 | 474 (MH+) |
47. | 6-(3-NC-phenyl)pyrimidin-4-yl | - | O | 1 | 1 | - | 129-133 | 475 (MH+) |
48. | 6-(4-F-phenyl)pyrazin-2-yl | - | O | 1 | 1 | - | 107-109 | 468 (MH+) |
49. | 6-(3-NC-phenyl)pyrazin-2-yl | - | O | 1 | 1 | - | 122-124 | 475 (MH+) |
50. | 3-H2NCO-phenyl | - | OCH2 | 1 | 1 | - | 109-111 | 429 (MH+) |
51. | 4-CI-naphth-1-yl | - | OCH2 | 1 | 1 | - | 141-143 | 470 (MH+) |
52. | 3-(3-NC-phenyl)phenyl | - | OCH2 | 1 | 1 | - | 83-85 | 487 (MH+) |
53. | 3-(4-NC-phenyl)phenyl | - | OCH2 | 1 | 1 | - | 109-111 | 487 (MH+) |
54. | 4-(3-NC-phenyl)phenyl | - | OCH2 | 1 | 1 | - | 109-111 | 487 (MH+) |
55. | 4-(4-NC-phenyl)phenyl | - | OCH2 | 1 | 1 | - | 133-135 | 487 (MH+) |
56. | naphth-2-yl | - | OCH2 | 1 | 1 | - | 71-73 | 436 (MH+) |
57. | 6-CH3O-naphth-2-yl | - | OCH2 | 1 | 1 | - | 107-109 | 466 (MH+) |
58. | 7-CH3O-naphth-2-yl | - | OCH2 | 1 | 1 | - | 120-122 | 466 (MH+) |
59. | 6-NC-naphth-2-yl | - | OCH2 | 1 | 1 | - | 106-108 | 461 (MH+) |
60. | 4-phenyl-phenyl | - | O(CH2)2 | 1 | 1 | - | 97-99 | 476 (MH+) |
61. | 4-C!-naphth-1-yl | - | O(CH2)2 | 1 | 1 | - | 86-88 | 483 (M+) |
62. | 6-Br-pyridin-2-yl | - | NH | 1 | 1 | HCl | 163-167 | 450 (MH+) |
63. | 5-NC-pyridin-2-yl | - | NH | 1 | 1 | - | 138-140 | 397 (MH+) |
64. | 5-H2NCO-pyridin-2-yl | - | NH | 1 | 1 | - | 193-195 | 415 (MH+) |
65. | 5-CF3-pyridin-2-yl | - | NH | 1 | 1 | HCl | 225-235 | 440 (MH+) |
66. | 4-CF3-pyrimidin-2-yl | - | NH | 1 | 1 | - | 111-115 | 441 (MH+) |
67. | 2-Br-pyrimidin-4-yl | NH | 1 | 1 | - | 147-149 | 451 (MH+) | |
68. | 6-(4-F-phenyl)pyridin-2-yl | - | NH | 1 | 1 | - | 91-93 | 466 (MH+) |
69. | 6-(3-NC-phenyl)pyridin-2-yl | - | NH | 1 | 1 | 113-115 | 473 (MH+) | |
70. | 2-(3-NC-phenyl)pyrimidin-4-yl | - | NH | 1 | 1 | - | 151-153 | 474 (MH+) |
71. | 6-CI-pyridin-2-yl | - | NHCH2 | 1 | 1 | - | 57-59 | 420 ((M-H)-) |
72. | pyridin-4-yl | - | S | 1 | 1 | oil | - | 389 (MH+) |
73. | phenyl | - | SO2 | 1 | 1 | oil | - | 437 (MNH4+) |
74. | 4-F-phenyl | - | CO | 1 | 1 | oil | - | 402 (MH+) |
75. | 4-CI-phenyI | - | CO | 1 | 1 | oil | - | 418 (MH+) |
76. | 4-CI-phenyl | - | CONH | 1 | 1 | - | 156-157 | 431 ((M-H)-) |
77. | 4-CH3-phenyl | - | CONH | 1 | 1 | - | 194-195 | 413 (MH+) |
78. | indol-1-yl | - | CONH | 1 | 1 | - | 158-160 | 436 ((M-H)-) |
79. | 3-CI-benzo[b]thiophen-2-yl | - | CONH | 1 | 1 | - | 146-147 | 487 ((M-H)-) |
80. | 4-CI-phenyl | och2 | CONH | 1 | 1 | - | 115-116 | 461 ((M-H)-) |
81. | phenyl | (E)-CH=CH | CONH | 0 | 0 | - | 134-135 | 397 (MH+) |
82. | phenyl | (E)-CH=CH | CONH | 1 | 1 | - | 143-145 | 425 (MH+) |
83. | 4-CI-phenyl | - | conhch2 | 1 | 1 | - | 149-151 | 447 (MH+) |
84. | indol-1-yl | - | conhch2 | 1 | 1 | - | 145-147 | 452 (MH+) |
85. | 3-CI-benzo[b]thiophen-2-yl | - | conhch2 | 1 | 1 | - | 126-127 | 503 (MH+) |
86. | 4-CI-phenyl | OCH2 | conhch2 | 1 | 1 | - | 81-82 | 477 (MH+) |
87. | 4-CI-phenyl | OC(CH3)2 | conhch2 | 1 | 1 | - | 77-78 | 505 (MH+) |
88. | phenyl | (£)-CH=CH | conhch2 | 0 | 1 | - | 125-126 | 425 (MH+) |
89. | phenyl | (E)-CH=CH | conhch2 | 1 | 1 | - | 137-138 | 439 (MH+) |
90. | 4-Cl-phenyl | och2 | conhch2 | 0 | 1 | oil | - | 463 (MH+) |
91. | indol-1-yl | - | CONH(CH2)2 | 1 | 1 | - | 113-115 | 466 (MH+) |
92. | phenyl | ch2 | CONH(CH2)2 | 0 | 0 | - | 78-79 | 413 (MH+) |
93. | 4-CI-phenyl | och2 | CONH(CH2)2 | 0 | 0 | oil | - | 463 (MH+) |
94. | phenyl | (E)-CH=CH | CONH(CH2)2 | 0 | 0 | - | 119-120 | 425 (MH+) |
95. | 2-CH3O-5-Br-phenyl | - | so2nh | 0 | 0 | - | 61 | 515 (MH+) |
96. | 2-F-4-Br-phenyl | so2nh | 0 | 0 | - | 96-97 | 502 ((M-H)-) | |
97. | indan-5-yl | so2nh | 0 | 0 | - | 88-89 | 445 ((M-H)-) | |
98. | 4-phenyl-phenyl | - | so2nh | 0 | 0 | - | 146-147 | 481 ((M-H)-) |
99. | 4-CH3-naphth-1-yl | - | so2nh | 0 | 0 | - | 163-164 | 471 (MH+) |
100. | 5-CI-thien-2-yl | - | so2nh | 0 | 0 | - | 151-152 | 445 ((M-H)-) |
101. | 5-Br-thien-2-yl | - | so2nh | 0 | 0 | - | 125-126 | 489 ((M-H)-) |
102. | benzo[b]thiophen-2-yl | - | so2nh | 0 | 0 | - | 189-190 | 427 (MH+) |
103. | 3-CI-phenyl | - | so2nh | 1 | 1 | - | 115-116 | 467 ((M-H)-) |
104. | 4-CI-phenyl | - | so2nh | 1 | 1 | - | 153-155 | 469 (MH+) |
105. | 2-CH3O-5-Br-phenyl | - | so2nh | 1 | 1 | - | 149-150 | 541 ((M-H)-) |
106. | naphth-1-yl | - | so2nh | 1 | 1 | - | 117-118 | 483 ((M-H)-) |
107. | naphth-2-yI | so2nh | 1 | 1 | - | 157-158 | 483 ((M-H)-) | |
108. | phenyl | ch2 | so2nh | 0 | 0 | - | 118-119 | 419 ((M-H)-) |
109. | phenyl | ch2 | so2nh | 1 | 1 | - | 143-145 | 449 (MH+) |
110. | 4-CI-phenyl | - | so2nhch2 | 0 | 0 | - | 98-99 | 455 (MH+) |
111. | 3-CI-phenyl | - | so2nhch2 | 0 | 1 | - | 61-62 | 469 (MH+) |
112. | 4-CI-phenyl | - | so2nhch2 | 0 | 1 | - | 117-118 | 469 (MH+) |
113. | naphth-1-yl | - | so2nhch2 | 0 | 1 | - | 135-136 | 485 (MH+) |
114. | naphth-2-yl | - | so2nhch2 | 0 | 1 | - | 134-135 | 485 (MH+) |
115. | phenyl | - | so2nhch2 | 1 | 1 | - | 82-84 | 449 (MH+) |
116. | 2-F-phenyl | so2nhch2 | 1 | 1 | - | 108-110 | 467 (MH+) | |
117. | 4-F-phenyl | - | so2nhch2 | 1 | 1 | - | 103-105 | 467 (MH+) |
118. | 2-CI-phenyl | - | so2nhch2 | 1 | 1 | - | 98-100 | 483 (MH+) |
119. | 3-CI-phenyl | SO2NHCH2 | 1 | 1 | - | 59-60 | 481 ((M-H)-) | |
120. | 4-CI-phenyl | SO2NHCH2 | 1 | 1 | - | 136-138 | 483 (MH+) | |
121. | 2-CH3-phenyl | SO2NHCH2 | 1 | 1 | - | 81-83 | 463 (MH+) | |
122. | 3-CH3-phenyl | SO2NHCH2 | 1 | 1 | 96-98 | 463 (MH+) | ||
123. | 4-CH3-phenyl | SO2NHCH2 | 1 | 1 | 115-117 | 463 (MH+) | ||
124. | 2-CF3-phenyl | SO2NHCH2 | 1 | 1 | - | 83-85 | 517 (MH+) | |
125. | 3-CF3-phenyl | SO2NHCH2 | 1 | 1 | - | 103-105 | 515 ((M-H)-) | |
126. | 4-CF3-phenyl | SO2NHCH2 | 1 | 1 | - | 115-117 | 517 (MH+) | |
127. | 2-CH3O-phenyl | SO2NHCH2 | 1 | 1 | - | 86-88 | 479 (MH+) | |
128. | 3-CH3O-phenyl | SO2NHCH2 | 1 | 1 | - | 98-100 | 477 ((M-H)-) | |
129. | 4-CH3O-phenyl | SO2NHCH2 | 1 | 1 | - | 131-133 | 479 (MH+) | |
130. | 3-CFsO-phenyl | SO2NHCH2 | 1 | 1 | oil | - | 533 (MH+) | |
131. | 4-CF3O-phenyl | SO2NHCH2 | 1 | 1 | - | 109-110 | 533 (MH+) | |
132. | 3-NC-phenyl | SO2NHCH2 | 1 | 1 | - | 118-120 | 474 (MH+) | |
133. | 4-NC-phenyl | SO2NHCH2 | 1 | 1 | - | 148-150 | 472 ((M-H)-) | |
134. | 2-F-3-CI-phenyl | SO2NHCH2 | 1 | 1 | - | 98-100 | 501 (MH+) | |
135. | 2-CI-3-CI-phenyI | SO2NHCH2 | 1 | 1 | - | 88-90 | 517 (MH+) | |
136. | 2-CF3-4-F-phenyl | SO2NHCH2 | 1 | 1 | - | 110-111 | 533 ((M-H)-) | |
137. | 3-F-4-F-phenyl | SO2NHCH2 | 1 | 1 | - | 118-119 | 483 ((M-H)-) | |
138. | 3-F-4-CH3-phenyl | SO2NHCH2 | 1 | 1 | - | 94-96 | 479 ((M-H)-) | |
139. | 3-CI-4-F-phenyl | SO2NHCH2 | 1 | 1 | - | 144-146 | 499 (MH+) | |
140. | 3-CI-4-CI-phenyl | SO2NHCH2 | 1 | 1 | - | 105-106 | 515 ((M-H)-) | |
141. | 3-CI-4-CH3-phenyl | SO2NHCH2 | 1 | 1 | - | 99-100 | 495 ((M-H)-) | |
142. | 3-CI-4-CF3O-phenyl | SO2NHCH2 | 1 | 1 | - | 101-103 | 565 ((M-H)-) | |
143. | 3-CH3-4-CH3-phenyl | SO2NHCH2 | 1 | 1 | - | 134-136 | 475 ((M-H)-) | |
144. | 3-F-4-CH3O-phenyl | SO2NHCH2 | 1 | 1 | - | 115-116 | 497 (MH+) | |
145. | 3-CH3-4-F-phenyl | SO2NHCH2 | 1 | 1 | - | 117-119 | 479 ((M-H)-) | |
146. | 3-CH3O-4-F-phenyl | SO2NHCH2 | 1 | 1 | - | 131-132 | 497 (MH+) | |
147. | 3-CF3-4-F-phenyl | SO2NHCH2 | 1 | 1 | - | 112-113 | 533 ((M-H)-) | |
148. | 3-CF3-4-CI-phenyl | SO2NHCH2 | 1 | 1 | - | 108-109 | 549 ((M-H)-) | |
149. | 4-CH3SO2-phenyl | SO2NHCH2 | 1 | 1 | - | 180-181 | 527 (MH+) | |
150. | 4-(pyrrolidin-1-yl)-SO2-phenyl | SO2NHCH2 | 1 | 1 | - | 198-199 | 582 (MH+) | |
151. | 4-phenylphenyl | SO2NHCH2 | 1 | 1 | - | 137-138 | 525 (MH+) | |
152. | naphth-1-yl | SO2NHCH2 | 1 | 1 | - | 155-156 | 499 (MH+) | |
153. | naphth-2-yl | SO2NHCH2 | 1 | 1 | - | 113-114 | 499 (MH+) | |
154. | benzo[ô]thiophen-3-yl | SO2NHCH2 | 1 | 1 | - | 128-130 | 505 (MH+) | |
155. | 3-CH3-5-CH3-isoxazol-4-yl | SO2NHCH2 | 1 | 1 | oii | 101-103 | 466 ((M-H)-) | |
156. | 4-(oxazol-5-yl)phenyl | SO2NHCH2 | 1 | 1 | - | 121-122 | 514 ((M-H)-) | |
157. | 4-CI-phenyl | ch2 | SO2NHCH2 | 1 | 1 | - | 100-102 | 495 ((M-H)-) |
158. | 4-CI-phenyl | S02NHC-(c-prop) | 1 | 1 | - | 150-152 | 509 (MH+) | |
159. | 4-CH3O-phenyl | SO2NHC-(c-prop) | 1 | 1 | - | 142-144 | 505 (MH+) | |
160. | 3-Cl-phenyl | SO2NH(CH2)2 | 0 | 0 | - | 71-72 | 469 (MH+) | |
161. | 4-CI-phenyl | SO2NH(CH2)2 | 0 | 0 | - | 112-113 | 469 (MH+) | |
162. | naphth-1-yl | SO2NH(CH2)2 | 0 | 0 | - | 124-125 | 485 (MH+) |
163. | naphth-2-yl | - | SO2NH(CH2)2 | 0 | 0 | - | 130-131 | 485 (MH+) |
164. | phenyl | - | OCONH | 1 | 1 | - | 146-148 | 413 ((M-H)-) |
165. | phenyl | - | NHCONH | 1 | 1 | - | 203-205 | 414 (MH+) |
166. | 3-CI-phenyl | - | NHCONH | 1 | 1 | - | 204-206 | 448 (MH+) |
167. | 4-CI-phenyl | - | NHCONH | 1 | 1 | - | 182-184 | 448 (MH+) |
168. | 3-NC-phenyl | - | NHCONH | 1 | 1 | - | 173-175 | 439 (MH+) |
169. | 4-NC-phenyl | - | NHCONH | 1 | 1 | 108-112 | 439 (MH+) | |
170. | 2-F-4-F-phenyl | NHCONH | 1 | 1 | - | 158-160 | 450 (MH+) | |
171. | 2-CI~4-CI-phenyl | - | NHCONH | 1 | 1 | - | 183-185 | 482 (MH+) |
172. | 2-CI-5-CI-phenyl | - | NHCONH | 1 | 1 | - | 179-181 | 482 (MH+) |
173. | 2-CH3O-5-CI-phenyl | - | NHCONH | 1 | 1 | - | 172-174 | 478 (MH+) |
174. | 3-CH3SC>2-phenyl | - | NHCONH | 1 | 1 | - | 170-174 | 492 (MH+) |
175. | 3-H2NCO-phenyl | - | NHCONH | 1 | 1 | - | 202-204 | 457 (MH+) |
176. | phenyl | ch2 | NHCONH | 1 | 1 | - | 163-165 | 428 (MH+) |
177. | 4-CI-phenyl | - | NHCONHCH2 | 0 | 0 | - | 150-151 | 434 (MH+) |
178. | 3-CI-phenyl | - | NHCONHCH2 | 0 | 1 | - | 130-131 | 448 (MH+) |
179. | 4-CI-phenyl | - | NHCONHCH2 | 0 | 1 | - | 183-184 | 448 (MH+) |
180. | 4-NC-phenyl | - | NHCONHCH2 | 0 | 1 | oïl | - | 439 (MH+) |
181. | 4-CI-phenyl | - | NHCONHCH2 | 1 | 1 | - | 155-157 | 462 (MH+) |
182. | benzimidazol-5-yl | - | NHCONHCH2 | 1 | 1 | 143-145 | 468 (MH+) | |
183. | indazol-6-yl | - | NHCONHCH2 | 1 | 1 | 83-85 | 468 (MH+) | |
184. | 2-(4-CF3-phenyl)thiazol-4-yl | NHCONHCH2 | 1 | 1 | - | 183-184 | 579 (MH+) | |
185. | phenyl | ch2 | NHCONHCH2 | 0 | 1 | - | 86-87 | 428 (MH+) |
186. | phenyl | ch2 | NHCONHCH2 | 1 | 1 | - | 162-164 | 442 (MH+) |
187. | phenyl | - | N(CH3)CONHCH2 | 0 | 1 | - | 101-102 | 428 (MH+) |
188. | 3-CI-phenyl | - | NHCONH(CHz)2 | 0 | 0 | - | 116-117 | 448 (MH+) |
189. | 4-CI-phenyl | - | NHCONH(CH2)2 | 0 | 0 | - | 119-120 | 448 (MH+) |
190. | 4-NC-phenyl | - | NHCONH(CH2)2 | 0 | 0 | oïl | - | 439 (MH+) |
191. | phenyl | - | N(CH3)CONH(CH2)2 | 0 | 0 | - | 101-102 | 428 (MH+) |
192. | 4-CI-phenyl | - | NHCONH(CH2)2 | 1 | 1 | - | 159-161 | 476 (MH+) |
193. | phenyl | ch2 | NHCONH(CH2)2 | 0 | 0 | - | 105-106 | 428 (MH+) |
194. | 4-CI-phenyl | - | SO2NHCO | 1 | 1 | - | 166-167 | 495 ((M-H)-) |
195. | 4-CI-phenyl | - | SO2NHCONH | 1 | 1 | - | 173-174 | 510 ((M-H)-) |
196. | 4-CI-phenyl | - | SO2NHCONHCH2 | 1 | 1 | - | 156-157 | 524 ((M-H)-) |
197. | 4-H2NCO-phenyl | - | OCH2 | 1 | 1 | - | 169-171 | 429 (MH+) |
198. | 3-H2NCO-phenyl | - | O(CH2)2 | 1 | 1 | - | 102-106 | 443 (MH+) |
199. | 4-H2NCO-phenyl | O(CH2)2 | 1 | 1 | - | 125-127 | 443 (MH+) | |
200. | 4-CH3SÛ2-phenyl | - | SO2NH | 1 | 1 | - | 173-175 | 511 ((M-H)-) |
201. | pyridin-3-yl | - | SO2NH | 1 | 1 | - | 162-164 | 436 (MH+) |
202. | 2-CF3O-phenyl | SO2NHCH2 | 1 | 1 | - | 72-74 | 533 (MH+) | |
203. | 2-CH3O-4-CH3-phenyl | - | SO2NHCH2 | 1 | 1 | - | 122-124 | 493 (MH+) |
204. | 2,4-(OCH3)2 -phenyl | - | SO2NHCH2 | 1 | 1 | - | 123-125 | 509 (MH+) |
205. | 2-CH3O-5-CH3O-phenyl | - | SO2NHCH2 | 1 | 1 | - | 81-83 | 509 (MH+) |
206. | 2-CH3O-5-F-phenyl | SO2NHCH2 | 1 | 1 | - | 138-140 | 497 (MH+) |
207. | 2-CH3O-5-CH3SOz-phenyl | - | SO2NHCH2 | 1 | 1 | - | 82-84 | 557 (MH+) |
208. | 2,5-(CH3)z-4-CI-phenyl | - | SO2NHCH2 | 1 | 1 | - | 122-124 | 509 ((M-H)-) |
209. | 3-(5-CH3-1,3,4-oxadiazol-2-yl)-phenyl | - | SO2NHCH2 | 1 | 1 | - | 138-140 | 531 (MH+) |
210. | 2,3-dihydrobenzo[1,4]dioxan-6-yl | - | SO2NHCH2 | 1 | 1 | - | 122-124 | 507 (MH+) |
211. | benzo[1,2,5]thiadiazol-4-yl | - | SO2NHCH2 | 1 | 1 | 146-148 | 507 (MH+) | |
212. | 4-CH3-3,4-dihydro-2H- benz[1,4]oxazin-7-yl | SO2NHCH2 | 1 | 1 | 118-120 | 520 (MH+) | ||
213. | 3-(2-CH3-pyrimidin-4-yl)phenyl | - | SO2NHCH2 | 1 | 1 | 135-137 | 541 (MH+) | |
214. | 1,3-(CH3)2-5-CI-pyrazol-4-yl | - | SO2NHCH2 | 1 | 1 | - | 86-88 | 501 (MH+) |
215. | pyridin-3-yl | - | SO2NHCH2 | 1 | 1 | - | 92-94 | 450 (MH+) |
216. | 6-CI-pyridin-3-yl | - | SO2NHCH2 | 1 | 1 | - | 144-146 | 482 ((M-H)-) |
217. | 4-CI-phenyl | - | SO2N(CH3)CH2 | 1 | 1 | oii | - | 497 (MH+) |
218. | 4-CH3SO2-phenyl | - | SO2NH(CH2)2 | 1 | 1 | - | 113-115 | 541 (MH+) |
219. | pyridin-3-yl | - | SO2NH(CH2)2 | 1 | 1 | - | 103-105 | 464 (MH+) |
220. | 4-Cl-phenyl | - | SO2NHC-(c-prop) | 0 | 0 | - | 108-109 | 481 (MH+) |
221. | 2-CH3O-5-CH3SOz-phenyl | - | SO2NHC-(c-prop) | 0 | 0 | - | 98-100 | 572 (MNH4+) |
222. | pyridin-3-yl | - | SC>2NHC-(c-prop) | 0 | 0 | - | 122-124 | 448 (MH+) |
223. | 4-CH3SC>2-phenyl | - | SO2NHC-(c-prop) | 0 | 0 | - | 198-200 | 525 (MH+) |
224. | 4-CH3SO2-phenyl | - | NHCH2 | 1 | 1 | - | 107-109 | 504 (MH+ACN) |
225. | 4-H2NSO2-phenyl | - | NHCH2 | 1 | 1 | - | 184-186 | 464 (MH+) |
226. | 2-H2NCO-pyridin-4-yl | - | NHCH2 | 1 | 1 | - | 160-163 | 429 (MH+) |
227. | 4-H2NCO-pyridin-2-yl | - | NHCH2 | 1 | 1 | - | 143-145 | 429 (MH+) |
228. | 5-H2NCO-pyridin-2-yl | - | NHCH2 | 1 | 1 | - | 146-148 | 429 (MH+) |
229. | 6-H2NCO-pyridin-2-yl | - | NHCHZ | 1 | 1 | - | 50-60 | 429 (MH+) |
230. | 5-H2NCO-pyrazin-2-yl | - | NHCH2 | 1 | 1 | - | 187-189 | 430 ((M-H)-) |
231. | 4-H2NCO-pyrazol-1 -yl | ch2 | - | 1 | 1 | - | 98-118 | 403 (MH+) |
232. | 5-H2NCO-pyridin-2-yl | - | NH(CH2)2 | 1 | 1 | - | 148-150 | 443 (MH+) |
233. | 4-H2NCO-pyrimidin-2-yi | - | NH(CH2)2 | 1 | 1 | - | 145-147 | 444 (MH+) |
234. | 5-H2NCO-pyrazin-2-yl | - | NH(CH2)2 | 1 | 1 | - | 156-158 | 444 (MH+) |
235. | 6-H2NCO-pyrazin-2-yl | - | NH(CH2)2 | 1 | 1 | - | 156-158 | 444 (MH+) |
236. | 2,3-dihydrobenz[1,4]oxazin-4-yl | - | CONH | 1 | 1 | - | 123-125 | 456 (MH+) |
237. | 2,3-dihydrobenz[1,4]oxazin-4-yl | - | CONHCH2 | 1 | 1 | - | 35-37 | 470 (MH+) |
238. | 3-CH3SO2-phenyl | - | CONH(CH2)2 | 1 | 1 | - | 115-117 | 505 (MH+) |
239. | 4-CH3SC>2-phenyl | CONH(CH2)2 | 1 | 1 | - | 112-114 | 505 (MH+) | |
240. | 4-H2NSO2-phenyl | - | CONH(CH2)2 | 1 | 1 | - | 176-178 | 506 (MH+) |
241. | 2,3-dihydrobenz[1,4]oxazin-4-yl | - | CONH(CH2)2 | 1 | 1 | oïl | - | 484 (MH+) |
242. | benzimidazol-5-yl | - | NHCONH | 1 | 1 | - | 172-174 | 454 (MH+) |
243. | 1-CH3SO2-indolin-5-yl | - | NHCONH | 1 | 1 | - | 103-105 | 533 (MH+) |
244. | indazol-6-yl | - | NHCONH | 1 | 1 | - | 118-120 | 454 (MH+) |
245. | 2-CH3O-5-CH3SO2-phenyl | - | NHCONHCH2 | 1 | 1 | - | 106-108 | 536 (MH+) |
246. | 2-CH3O-5-(pyrrolidin-1-yl-SO2)phenyl | - | NHCONHCH2 | 1 | 1 | - | 96-98 | 591 (MH+) |
247. | 1-CH3SO2-indolin-5-yl | NHCONHCH2 | 1 | 1 | - | 88-90 | 547 (MH+) |
Table 2
No. | Rt (min) | Method |
2 | 2.37 | E |
3 | 2.39 | E |
4 | 2.29 | E |
6 | 1.77 | E |
7 | 2.42 | E |
16 | 2.37 | E |
18 | 11.8 | B |
19 | 11.4 | B |
21 | 1.47 | D |
26 | 10.2 | B |
29 | 12.4 | B |
37 | 12.2 | B |
38 | 12.3 | B |
44 | 1.26 | E |
72 | 1.32 | E |
73 | 1.88 | E |
74 | 2.10 | E |
75 | 10.0 | B |
90 | 1.28 | D |
93 | 1.29 | D |
130 | 1.40 | D |
217 | 5.38 | C |
241 | 1.35 | D |
Table 3
No. | Enantiomer | [a]D | Conditions |
22 | (S) | +20° | DMSO, conc. 0.159 g/100 ml, 20°C |
23 | (R) | -15° | DMSO, conc. 0.145 g/100 ml, 20°C |
24 | (S) | +29° | MeOH, conc. 0.310 g/100 ml, 20°C |
25 | (R) | -30° | MeOH, conc. 0.484 g/100 ml, 20°C |
The compounds according to the invention surprisingly exhibit an inhibitory effect with regard to the enzyme MGL (monoacyl glycerol lipase). The enzyme MGL catalyses the hydrolysis of endogenous dérivatives of monoglyceride esters of various fatty acids (FEBS Letters, 1998, 429, 152-156) and in particular the hydrolysis of
2-arachidonoylglycerol (2-AG) and of 1(3)-arachidonoylglycerol (1(3)-AG) (J. Biol. Chem.,
1987, 272 (48), 27218-27223; Proc. Natl. Acad. Sci. USA, 2002, 99 (16), 10819-10824; Biochem. Pharmacol., 2004, 67, 1381-1387; Mol. Pharmacol., 2004, 66 (5), 1260-1264). The 2-AG and 1(3)-AG dérivatives in particular interact with cannabinoid receptors (J. Biol. Chem., 1999, 274 (5), 2794-2801; J. Biol. Chem., 2000, 275 (1), 605-612; British J. Pharmacol., 2001, 134, 664-672).
The compounds of the invention block this décomposition pathway and increase the tissue levels of these dérivatives, in particular of 2-AG and/or 1(3)-AG. They can therefore be used in the prévention and treatment of pathologies in which 2-AG and/or 1(3)-AG, in particular, and/or any other substrate metabolized with the enzyme MGL are implicated (Progress in Lipid Research, 2006, 45, 405-446; Nature Reviews Drug
Discovery, 2008, 7, 438-455).
The compounds according to the invention hâve formed the subject of pharmacological tests which make it possible to détermine their inhibitory effect on the enzyme MGL.
Tests hâve consisted in measuring the in vitro activity of the compounds of the invention with regard to the enzyme MGL.
The inhibitory activity with respect to MGL is given by the concentration which inhibits 50% of the activity of MGL.
The inhibitory activity was measured in a radioenzymatic assay based on measuring the product of hydrolysis of 2-oleoylglycerol ([3H]2-OG) by the enzyme MGL. The products of hydrolysis of [3H]2-OG, labelled on the glycerol, are oleic acid and [3H]glycerol. The source of enzyme MGL is a homogenate of mouse brain from which the 30 cerebellum and the medulla oblongata hâve been removed. The mouse brains are removed and stored at -80°C until they are used or homogenized immediately for 2 times 5 seconds using a Precellys device (Bertin) at 5000 rpm in a 10 mM Tris-HCI pH 8, 150 mM NaCI, 1 mM EDTA buffer at 4°C. The concentration of the homogenates is subsequently adjusted to 3.75 pg/pl.
The dilution sériés of the compounds is prepared from stock solutions at 20 mM in
100% DMSO. The first dilution of this sériés is prepared in 100% DMSO and then the second is prepared in the enzymatic reaction buffer (50 mM phosphate, 0.1% BSA), resulting in the préparation of a 10-times concentrated concentration range. The test compounds are preincubated at the chosen concentration for 20 minutes with the mouse brain homogenate préparation. The final concentration of DMSO in the enzymatic reaction does not exceed 0.1%.
Assaying of the MGL activity is carried out at ambient température in a 96-well microplate in a final reaction volume of 50 pl. Briefly, 37.5 pg of proteins are diluted in 50 mM of phosphate buffer comprising 0.1% of BSA. After 20 minutes of preincubation with the test compounds, the proteins are incubated for 20 minutes in the presence of 50 μΜ of 2-OG comprising an amount of [3H]2-OG of 0.027 pCi per well (spécifie activity 10 of 20 Ci/mmol). The reaction is stopped by the addition of 50 pl per well of a charcoal suspension (6% of Sigma activated charcoal, référencé C4386, in suspension in a 0.5M HCl, 1.5M NaCI solution). After stirring for 10 minutes, the [3H]glycerol, not retained by the charcoal, is collected by filtration in a microplate comprising 100 pl of scintillant (OptiPhase Supermix, Perkin-Elmer) per well. The radioactivity présent in each well is 15 counted for 5 minutes by liquid scintillation (Wallac 1450 MicroBeta).
Under these conditions, the most active compounds of the invention exhibit an IC5o (concentration which inhibits the control enzymatic activity of the MGL by 50%) of between 0.0001 and 0.1 μΜ.
For example, compounds Nos. 13, 33, 70, 120, 161, 188 and 211 showed an IC5o of 0.006, 0.0006, 0.005, 0.004, 0.0014, 0.0011 and 0.007 μΜ respectively.
It is thus apparent that the compounds according to the invention hâve an inhibitory 25 activity with respect to MGL.
The compounds according to the invention can thus be used in the préparation of médicaments, in particular of médicaments which are inhibitors of the enzyme MGL.
Thus, according to another of its aspects, a subject-matter of the invention is médicaments which comprise a compound of formula (I) or an addition sait of the latter with a pharmaceutically acceptable acid or also a hydrate or a solvaté of the compound of formula (I).
These médicaments are employed therapeutically, in particular in the treatment and the prévention of:
pain, in particular acute or chronic pain of neurogenic type: migraine, neuropathie ·»>
pain, including forms associated with the herpes virus and with diabètes;
acute or chronic pain associated with inflammatory diseases: arthritis, rheumatoid arthritis, osteoarthritis, spondylitis, goût, vasculitis, Crohn’s disease, irritable bowel syndrome;
acute or chronic peripheral pain;
dizziness, vomiting, nausea, in particular that resulting from chemotherapy; eating disorders, in particular anorexia and cachexia of various natures;
metabolic syndrome and its manifestations, including obesity;
dyslipidaemia and its manifestations, including atherosclerosis and coronary diseases;
neurological and psychiatrie pathologies: tremors, dyskinesias, dystonias, spasticity, obsessive-compulsive behaviour, Tourette’s syndrome, ali forms of dépréssion and of anxiety of any nature and origin, mood disorders, psychoses;
acute or chronic neurodegenerative diseases: Parkinson’s disease, Alzheimer’s disease, senile dementia, Huntington’s chorea, lésions related to cérébral ischaemia and to cranial and medullary trauma, amyotrophie latéral sclerosis;
epilepsy;
sleep disorders, including sleep apnoea;
cardiovascular diseases, in particular hypertension, cardiac arrhythmias, arteriosclerosis, heart attack, cardiac ischaemia;
rénal ischaemia;
cancers: benign skin tumours, brain tumours and papillomas, prostate tumours, cérébral tumours (glioblastomas, medulloepitheliomas, medulloblastomas, neuroblastomas, tumours of embryonic origin, astrocytomas, astroblastomas, ependymomas, oligodendrogliomas, plexus tumour, neuroepitheliomas, epiphyseal tumour, ependymoblastomas, malignant meningiomas, sarcomatosis, malignant melanomas, schwannomas);
disorders of the immune system, in particular autoimmune diseases: psoriasis, lupus erythematosus, diseases of the connective tissue or collagen diseases, Sjogren’s syndrome, ankylosing spondylitis, undifferentiated spondylitis, Behcet’s disease, autoimmune haemolytic anaemia, multiple sclerosis, amyotrophie latéral sclerosis, amyloidosis, graft rejection, diseases affecting the plasmocytic line;
allergie diseases: immédiate or delayed hypersensitivity, allergie rhinitis or conjunctivitis, contact dermatitis;
parasitic, viral or bacterial infectious diseases: AIDS, meningitis;
inflammatory diseases, in particular joint diseases: arthritis, rheumatoid arthritis, osteoarthritis, spondylitis, goût, vasculitis, Crohn’s disease, irritable bowel syndrome;
·») osteoporosis;
eye conditions: ocular hypertension, glaucoma, degeneration and apoptosis of retinal ganglion cells and neuroretinal cells;
pulmonary conditions: diseases of the respiratory tract, bronchospasm, coughing, asthma, chronic bronchitis, chronic obstruction of the respiratory tract, emphysema;
gastrointestinal diseases: irritable bowel syndrome, inflammatory intestinal disorders, ulcers, diarrhoea;
urinary incontinence and bladder inflammation.
According to another of its aspects, the présent invention relates to pharmaceutical compositions comprising, as active principle, a compound according to the invention. These pharmaceutical compositions comprise an effective dose of at least one compound according to the invention, or a pharmaceutically acceptable sait or a hydrate or a solvaté of the said compound, and also at least one pharmaceutically acceptable excipient.
The said excipients are chosen, depending on the pharmaceutical form and the method of administration desired, from the usual excipients which are known to a person skilled in the art.
In the pharmaceutical compositions of the présent invention for oral, sublingual, subcutaneous, intramuscular, intravenous, topical, local, intratracheal, intranasal, transdermal or rectal administration, the active principle of formula (I) above or its optional sait, solvaté or hydrate can be administered in a unit administration form, as a mixture with conventional pharmaceutical excipients, to animais and to man for the prophylaxis or the treatment of the above disorders or diseases.
Appropriate unit administration forms comprise oral forms, such as tablets, soft or hard gelatin capsules, powders, granules and oral solutions or suspensions, forms for sublingual, buccal, intratracheal, intraocular or intranasal administration or for administration by inhalation, forms for topical, transdermal, subcutaneous, intramuscular or intravenous administration, forms for rectal administration and implants. For topical application, the compounds according to the invention can be used in creams, gels, ointments or lotions.
By way of example, a unit administration form of a compound according to the invention in the form of a tablet can comprise the following components:
Compound according to the invention | 50.0 mg |
Mannitol | 223.75 mg |
Croscarmellose sodium | 6.0 mg |
Maize starch | 15.0 mg |
Hydroxypropylmethylcellulose | 2.25 mg |
Magnésium stéarate | 3.0 mg |
According to another of its aspects, the présent invention also relates to a method for the treatment of the pathologies indicated above which comprises the 10 administration, to a patient, of an effective dose of a compound according to the invention or one of its pharmaceutically acceptable salts or its hydrates or its solvatés.
Claims (17)
1. Compound corresponding to the formula (I):
(O in which:
R représente an R1 group optionally substituted by one or more R2 and/or R3 groups;
R1 représente an aryl or heteroaryl group;
R2 represents a halogen atom or a cyano, nitro, oxo, (C-i-C6)alkyl, (CrC6)alkoxy, hydroxyl, (CrC6)alkylthio, (CrC6)haloalkyl, (Ci-Ce)haloalkoxy, (CrC6)haloalkylthio, NR4R5, NR4COR5, NR4SO2R5, COR4, CO2R4, CONR4Rs, SO2R4, SO2NR4R5, phenyloxy or benzyloxy group;
R3 represents a monocyclic aryl or heteroaryl group which can be substituted by one or more R2 groups which are identical to or different from one another;
R4 and R5 represent, independently of one another, a hydrogen atom or a (C-rC6)alkyl group or form, with the nitrogen atom or the N-CO or N-SO2 fragment which carries them, a heterocycle optionally substituted by a (Ci-C6)alkyl or benzyl group;
Z represents a bond, a (CrC6)alkylene group, a (C2-C6)alkenylene group, a (C2-C6)alkynylene group, an O-(Ci-C6)alkylene group or an N(RA)-(Ci-C6)alkylene group;
A represents a bond, an oxygen atom, a sulphur atom, an N(RA) group, an N(RA)(Ci-C6)alkylene group, a CON(RA) group, a CON(RA)-(Ci-C6)alkylene group, an SO2N(RA) group, an SO2N(RA)-(Ci-C6)alkylene group, an OCON(RA) group, an OCON(RA)-(C1C6)alkylene group, an N(RB)CON(RA) group, an N(RB)CON(RA)-(Ci-C6)alkylene group, an N(Rb)SO2N(Ra) group, an N(RB)SO2N(RA)-(Ci-C6)alkylene group, an O-(Ci-C6)alkylene group, an N(RB)CO2 group, an N(RB)CO2-(Ci-C6)alkylene group, an S-(Ci-C6)alkylene group, an SO2 group, an SO2-(CrC6)alkylene group, an N(RB)SO2 group, an N(RB)SO2(C-i-C6)alkylene group, a CO group, a CO-(CrC6)alkylene group, an N(RB)CO group, an N(RB)CO-(Ci-C6)alkylene group, an SO2N(RB)CO group, an SO2N(RB)CO(Ci-C6)alkylene group, an SO2N(RB)CON(RA) group or an SO2N(RB)CON(RA)(CrC6)alkylene group;
Ra and Rb represent, independently of one another, a hydrogen atom or a (CrC6)alkyl group;
ô >
m and n represent, independently of one another, an integer equal to 0 or 1, in the form of the base or of an addition sait with an acid.
2. Compound of formula (I) according to Claim 1, characterized in that:
5 R1 represents a phenyl, naphthyl, indanyl, benzoxazole, benzisoxazole, benzimidazole, benzotriazole, oxadiazole, indazole, isoxazole, pyridine, pyrazine, pyrimidine, thienyl, thiazole, benzothiophene, indole, dihydrobenzodioxane, benzothiadiazole, pyrazole, dihydrobenzoxazine or indoline group;
R2 represents one or more groups chosen from a halogen atom or a methyl,
10 trifluoromethyl, methoxy, trifluoromethoxy, cyano, oxo, CH3NHCO, CH3SO2, NH2CO, NH2SO2 or pyrrolidine-SO2 group;
R3 represents a group chosen from a phenyl or an oxazole;
and also the compound 2,2,2-trifluoro-1-(trifluoromethyl)ethyl 4-{[3-(2-methylpyrimidin-4yl)benzenesulphonylamino]methyl}piperidine-1-carboxylate,
15 in the form of the base or of an addition sait with an acid.
3. Compound of formula (I) according to either of Claims 1 and 2, characterized in that:
Z represents a bond or a CH2, (CH2)2, CH=CH, CsC, OCH2 or OC(CH3)2 group,
20 in the form of the base or of an addition sait with an acid.
4. Compound of formula (l) according to one of Claims 1 to 3, characterized in that:
A represents a bond, an oxygen atom, a sulphur atom, an OCH2 group, an
25 O(CH2)2 group, an NH, NHCH2 or NH(CH2)2 group, an SO2or CO group, a CONH group, a CONHCH2 or CONH(CH2)2 group, an SO2NH group, an SO2NHCH2 or SO2NH(CH2)2 group, an SO2NHCO, SO2NHCONH or SO2NHCONHCH2 group, an OCONH group, an NHCONH group, an NHCONHCH2 group, an N(CH3)CONHCH2, NHCONH(CH2)2 or N(CH3)CONH(CH2)2 group or an SO2N(CH3)CH2 group,
30 in the form of the base or of an addition sait with an acid.
5. Compound of formula (I) according to one of Claims 1 to 4, characterized in that m and n represent 1, in the form of the base or of an addition sait with an acid.
35
6. Compound of formula (I) according to one of Claims 1 to 4, characterized in that m represents 1 and n represents 0, in the form of the base or of an addition sait with an acid.
t -?/ »
7. Compound of formula (I) according to one of Claims 1 to 4, characterized in that m and n represent 0, in the form of the base or of an addition sait with an acid.
8. Compound of formula (I) according to one of Claims 1 to 7, characterized in that:
R1 represents a phenyl, naphthyl, indanyl, benzoxazole, benzisoxazole, benzimidazole, benzotriazole, oxadiazole, indazole, isoxazole, pyridine, pyrazine, pyrimidine, thienyl, thiazole, benzothiophene, indole, dihydrobenzodioxane, benzothiadiazole, pyrazole, dihydrobenzoxazine or indoline group;
R2 représente one or more groups chosen from a halogen atom or a methyl, trifluoromethyl, methoxy, trifluoromethoxy, cyano, oxo, CH3NHCO, CH3SO2, NH2CO, NH2SO2 or pyrrolidine-SO2 group;
R3 représente a group chosen from a phenyl or an oxazole;
Z represents a bond or a CH2, (CH2)2, CH=CH, C=C, OCH2 or OC(CH3)2 group;
A represents a bond, an oxygen atom, a sulphur atom, an OCH2 group, an O(CH2)2 group, an NH, NHCH2 or NH(CH2)2 group, an SO2 or CO group, a CONH group, a CONHCH2 or CONH(CH2)2 group, an SO2NH group, an SO2NHCH2 or SO2NH(CH2)2 group, an SO2NHCO, SO2NHCONH or SO2NHCONHCH2 group, an OCONH group, an NHCONH group, an NHCONHCH2 group, an N(CH3)CONHCH2, NHCONH(CH2)2 or N(CH3)CONH(CH2)2 group or an SO2N(CH3)CH2 group;
m and n represent, independently of one another, an integer equal to 0 or 1, in the form of the base or of an addition sait with an acid.
9. Process for the préparation of a compound of formula (I) according to any one of Claims 1 to 8, characterized in that a compound of formula (II):
(H) in which A, Z, R, m and n are as defined in the general formula (I) according to
Claim 1, is reacted with a compound of the formula (III):
in which X représente a leaving group, such as a chlorine atom, a 4-nitrophenoxy group, an imidazole group, a 1,2,4-triazole group or an N-oxysuccinimide group.
10. Process for the préparation of a compound of formula (I) according to Claim 1, in which A represents a CON(RA), CON(RA)-(CrC6)alkylene, SO2N(RA), SO2N(RA)(Ci-C6)alkylene, N(RB)CON(RA), N(RB)CON(RA)-(CrC6)alkylene, OCON(RA) or OCON(RA)-(CrC6)alkylene group, characterized in that a compound of formula (IV):
R-Z-W ()v) in which R and Z are as defined in the general formula (I) according to Claim 1 and W represents a COCI, SO2CI, NCO, OCOCI or N(RB)COCI functional group, RA and Rb being as defined in the formula (I) of Claim 1, is reacted with a compound of
(V) in which m and n are as defined in the general formula (I) according to Claim 1 and V represents an amine HN(RA) or HN(RA)-(C-rC6)alkylene functional group.
11. Compound of formula (V):
in which m and n are as defined in the general formula (I) according to Claim 1 and V represents an amine HN(RA) or HN(RA)-(C-rC6)alkylene functional group, RA being as defined in the formula (I) of Claim 1.
12. Médicament, characterized in that it comprises a compound of formula (I) according to any one of Claims 1 to 8 or an addition sait of this compound with a pharmaceutically acceptable acid.
13. Pharmaceutical composition, characterized in that it comprises a compound of formula (I) according to any one of Claims 1 to 8 or a pharmaceutically acceptable sait and at least one pharmaceutically acceptable excipient.
14. Use of a compound of formula (I) according to any one of Claims 1 to 8 in the préparation of a médicament intended for the treatment and for the prévention of a pathology in which endogenous 2-arachidonoylglycerol (2-AG) and endogenous 1 (3)-arachidonoylglycerol and/or any other substrate metabolized by the enzyme MGL are implicated.
15. Use of a compound of formula (I) according to any one of Claims 1 to 8, in the form of the base or of a pharmaceutically acceptable sait, in the préparation of a médicament intended to prevent or treat acute or chronic pain, dizziness, vomiting, nausea, eating disorders, metabolic syndrome, dyslipidaemia, neurological and psychiatrie pathologies, acute or chronic neurodegenerative diseases, epilepsy, sleep disorders, cardiovascular diseases, rénal ischaemia, cancers, disorders of the immune System, allergie diseases, parasitic, viral or bacterial infectious diseases, inflammatory diseases, osteoporosis, eye conditions, pulmonary conditions, gastrointestinal diseases, urinary incontinence or bladder inflammation.
16. Compound of formula (I) according to any one of Claims 1 to 8 for the préparation of a médicament intended for the treatment and for the prévention of a pathology in which endogenous 2-arachidonoylglycerol (2-AG) and endogenous 1 (3)-arachidonoylglycerol and/or any other substrate metabolized by the enzyme MGL are implicated.
17. Compound of formula (I) according to any one of Claims 1 to 8, in the form of the base or of a pharmaceutically acceptable sait, for the préparation of a médicament intended to prevent or treat acute or chronic pain, dizziness, vomiting, nausea, eating disorders, metabolic syndrome, dyslipidaemia, neurological and psychiatrie pathologies, acute or chronic neurodegenerative diseases, epilepsy, sleep disorders, cardiovascular diseases, rénal ischaemia, cancers, disorders of the immune System, allergie diseases, parasitic, viral or bacterial infectious diseases, inflammatory diseases, osteoporosis, eye conditions, pulmonary conditions, gastrointestinal diseases, urinary incontinence or bladder inflammation.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1054411 | 2010-06-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA17933A true OA17933A (en) | 2018-03-12 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8835418B2 (en) | Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application | |
RU2376305C2 (en) | Derivatives of aryl- and heteroarylpiperidinecarboxylates, their production and their use as inhibitors of faah ferment | |
AU2010212235B2 (en) | Derivatives of azaspiranyl-alkylcarbamates of 5-member heterocyclic compounds, preparation thereof and therapeutic use thereof | |
RU2384569C2 (en) | Piperidine alkyl carbamate derivatives, production thereof and use thereof as faah enzyme inhibitors | |
ES2312471T3 (en) | 5 MEMBER RING COMPOUNDS CONTAINING NITROGEN. | |
JP4329291B2 (en) | Nitrogen-containing five-membered ring compounds | |
KR20170017792A (en) | 1,3,4-Oxadiazole Derivative Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the same | |
AU2009274355B2 (en) | Alkyl thiazole carbamate derivatives, preparation thereof, and use thereof as FAAH enzyme inhibitors | |
IL176769A (en) | Aryloxyalkylcarbamate-type derivatives, preparation method thereof and use of same in therapeutics | |
TWI794880B (en) | Novel compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same | |
OA17933A (en) | Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application | |
CA2653524A1 (en) | Pyrrolidine derivatives useful against diseases that depends on activity of renin | |
AU2005229666A1 (en) | Nitrogen-containing 5-membered ring compound | |
JP2005200427A (en) | Nitrogen-containing five-membered ring compound | |
KR20060099287A (en) | Compounds inhibiting peptide deformylase, method for the preparation thereof and pharmaceutical composition containing same |